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ABSTRACT
Chronic neuropathic pain, characterised by allodynia (perception of innocuous stimuli as
painful) and hyperalgesia (facilitated responses to painftil stimuli), is poorly understood and
is usually resistant to classical analgesics. Such abnormal pain phenomena can be associated
with human demyelinating conditions such as Charcot-Marie-Tooth disease. Using mouse
models of peripheral nerve demyelination, we have provided evidence for the consequent
establishment of neuropathic pain and investigated possible underlying mechanisms.
The first model investigated was the Prx-mi\\ mouse. The murine periaxin gene (Prx) is
expressed in Schwann cells and encodes L- and S-periaxin, two abundant PDZ-domain
proteins thought to have a role in stabilisation of myelin in the peripheral nervous system
(PNS). Prx-null mice show progressive demyelination in peripheral nerves and
electrophysiological investigations indicate the presence of spontaneous action potential
discharge; abnormal activity thought to be critical for the development of persistent pain
states. Consistent with the time course of demyelination, Rrx-null mice display an increased
behavioural reflex sensitivity to cutaneous mechanical and noxious thermal stimulation.
To further investigate the link between demyelination of peripheral nerves and neuropathic
pain, we have also characterised a novel model of focal peripheral nerve demyelinating
neuropathy. Focal demyelination of the sciatic or saphenous nerve was induced with
lysolecithin (lysophosphatidylcholine) and resulted in an increased behavioural reflex
sensitivity to both thermal and mechanical tests, peaking at 9-14 days following treatment.
Nerve morphology was investigated using light and electron microscopy, which revealed 30-
40% demyelination of the treated nerve, (without lysolecithin-treated axon loss) coinciding
with peak behavioural changes. Changes in the excitability of saphenous nerves were
revealed, with spontaneous action potential discharge of 2-3 impulses per second present at
peak behavioural change. No associated change in peripheral activation thresholds or
conduction velocity was observed.
In both models, immunohistochemical investigations revealed no cell loss in the dorsal root
ganglia (DRG) and no evidence for axonal damage. Similar methods revealed changes in the
expression of neuropeptide Y, and the sodium channels Nav1.3 and Nav1.8 in DRG
neurones. Such changes may account for increased nerve excitability and are known to
occur in other models of nerve injury. However, these changes in the demyelinating models
occur in a more restricted manner, specifically in the cells of formerly myelinated fibres.
Intrathecal injections of the selective NMDA receptor antagonist, [R]-CPP, indicated that
NMDA receptor-dependent changes are crucial for the development of a neuropathic pain-
xii
like state following peripheral nerve demyelination. Intrathecal administration of
pharmacological agents indicated a role for the transcription factor NFkB in the production
of the behavioural reflex sensitivity of lysolecithin-treated mice, as well as identifying the
endogenous cannabinoid system as an effective inhibitory regulator and potential analgesic
target.
This study describes the first mouse models of peripheral nerve demyelination designed for
the study of neuropathic pain and reveals phenotypic changes in DRG, which may contribute
to the development of a neuropathic pain-like state. Therefore, these models may be useful
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Pain is defined by the International Association for the Study of Pain (IASP) as:
" An unpleasant sensory and emotional experience associated with actual or potential tissue
damage...".
(IASP Press 1994).
The sensation of pain is an extremely complex physiological phenomenon. It initially
involves nociceptive processes, which lead to the transduction of information regarding
potentially damaging stimuli from the point of stimulation to the brain. This information is
then combined with cognitive, emotional and situational processing, producing the
subjective individual experience of pain.
The capacity to experience pain serves a protective role to warn the animal or human of
imminent or actual tissue damage and elicits co-ordinated reflex and behavioural responses
to keep such damage to a minimum. Acute pain is therefore, a self-limiting normal
sensation, which subsides upon cessation of the damaging stimulus.
Following tissue damage, excitability changes occur in the peripheral nervous system (PNS)
and central nervous system (CNS) which establish a profound, but reversible pain
hypersensitivity in the inflamed and surrounding tissue (Woolf and Mannion, 1999). This
process assists wound repair as it promotes avoidance of the damaged area, and the pain
experienced generally subsides once healing is complete.
However, persistent pain syndromes, in which the pain experienced outlasts the damaging
stimulus and any associated healing processes, offer no such biological advantage. Such
maladaptive, chronic pain can persist for weeks, months or even years, and typically results
from damage to part of the nervous system resulting in hyperexcitability that produces
spontaneous and hypersensitive pain syndromes. A major cause of chronic pain results from
damage to a peripheral nerve. This is termed neuropathic pain, which is the main focus of
this study. However, an understanding of the mechanisms of hyperexcitability requires first
the consideration of the basic mechanisms of nociception leading to pain perception.
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1.2 Introduction to Basic Mechanisms of Nociception
Somatosensory systems consist of highly specialised somatosensory nerve fibres, which
provide information to the CNS regarding the external environment. Afferent axons run
uninterrupted from their sensory endings in the peripheral target tissue to their central
synaptic terminals in the CNS. The cell bodies lie in the dorsal root ganglia (DRG) near the
spine or in the cranial nerve ganglia at the base of the skull.
Sensory impulse generation typically begins when a stimulus causes an increase in the
permeability of the membrane of the sensory endings to various ions, particularly sodium
ions (Na+), depolarising the cell membrane. If the change in membrane depolarisation is
sufficient, voltage-dependent ion channels open, resulting in the generation of an action
potential and impulse propagation along the nerve to the CNS.
1.3 Peripheral Aspects of Nociception
Glabrous and hairy skin contain a complex array of sensory fibres, which arc selectively
sensitive to stimuli such as temperature and touch. Stimulation of the skin, evoking
sensations such as vibration, stretch, touch, itch, pressure and pain, is detected by specialised
receptors of primary afferent sensory axons, which transmit the information to the dorsal
horn of the spinal cord in which afferents have highly structured termination patterns (Brown
and Fuchs, 1975). There are three main types of cutaneous sensory afferent fibre, classified
by their axonal diameter, conduction velocity and the specific modalities of sensory stimuli
that evoke a response. They are broadly categorised as Ap. A5 and C-fibres. Ap fibres are
large diameter (> 1 Oprm), myelinated fibres and therefore have fast conduction velocities, in
the range of 30-100m/s. A5-fibres are also myelinated, but have smaller axonal diameters
(2-6p.m) and therefore have a slower conduction velocity ranging from 12-30m/s. C-fibres
are unmyelinated, small diameter (0.4-1.2|im) fibres with the slowest conduction velocities
in the range of 0.5-2.0 m/s.
Mechanoreceptors and nociceptors relay information regarding mechanical stimuli (such as
light touch, vibration and pressure) and painful stimuli (noxious pressure, pinch or low or
high temperature), respectively (Lynn, 1994). They are associated with particular primary
afferent axon types and have distinct activation thresholds, which must be achieved by a
particular stimulus before activation occurs.
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1.3.1 Non-nociceptive mechanoreceptors
Cutaneous mechanoreceptors, usually associated with myelinated primary afferent fibres,
respond to a variety of innocuous tactile sensations. This diverse group of sensory receptors
includes rapidly adapting ('RA') Meissner and Pacinian corpuscle receptors responding to
light touch, pressure and vibration; slowly adapting ('SA') type I and type II
mechanoreceptors associated with Merkel cells and Ruffini corpuscles respectively, which
are involved in stretch perception and shape discrimination, (Willis and Coggeshall, 1991);
and D. G and T-hair receptors which innervate hair follicles and respond to hair movement
(Brown and Iggo, 1967;Lynn and Carpenter, 1982). Unmyelinated C-fibre
mechanoreceptors have also been identified, which respond to gentle mechanical stimulation
and cooling of the skin (Bessou et al., 1971).
1.3.2 Non-nociceptive thermoreceptors
Warm thermoreceptors are generally thought to be associated with unmyelinated axons (Iggo
A, 1959) and respond only to slight wanning of the skin in the non-noxious range (30-37°C).
Non-nociceptive cold specific receptors respond to small variations in cold sensations and
exist mainly associated with AS-fibres, although some may be associated with C-fibres
(Iggo, 1959;Iggo. 1969).
1.3.3 Nociceptors
Nociceptors respond preferentially to stimuli that are potentially or actually injurious
(Sherrington, 1906) (noxious) and are the least differentiated of the sensory receptors in the
skin, where they terminate as free nerve endings. Nociceptors are functionally divided into
two groups, comprising A5-fibre associated mechanical nociceptors or C-fibre associated
polymodal nociceptors.
A8 fibre nociceptors are primarily high threshold mechanoreceptors responding to high
threshold mechanical (HTM) stimulation of the skin, such as pressure and pinch; however,
they may also show weak responses to high intensity heat, cold (0 to -10°C) (Simone and
Kajander, 1996;Simone and Kajander, 1997) and chemical stimuli. Their activation results
in rapid, pricking or sharp sensations referred to as 'first pain', and perhaps aching.
C-polymodal nociceptors respond to multiple high threshold stimuli including heat (>45°C),
high threshold mechanical and chemical stimulation (Bessou and Perl, 1969) and in some
cases intense cold (Cervero and Iggo, 1980;Simone and Kajander, 1996;Willis and
Coggeshall, 1991). Activity sufficient to activate C-fibre afferents results in a dull, diffuse
or burning pain referred to as 'second pain'.
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Other types of nociceptors have been identified including chemical nociceptors, which
respond specifically to changes in extracellular pH and acidosis; and 'silent' nociceptors,
which may be completely inactive until sensitised, for example, by the onset of inflammation
(Besson and Chaouch, 1987;Bessou and Perl, 1969;Schmidt et al., 1995).
1.3.4 Sensory neurons: cell identification
The cell bodies of the sensory primary afferents lie in the DRG. They are characterised by
their responsiveness to growth factors such as nerve growth factor (NGF) glial cell-derived-
neurotrophic factor (GDNF) and by their expression of various substances, which can be
used to identify and categorise them. For example, neuropeptides including calcitonin gene
related peptide (CGRP) and substance P (SP) are normally expressed in a restricted pattern
and will be dealt with in detail below (see section 1.7.4). Further markers expressed in a cell
type restricted pattern include neurofilament (NF) protein, which can be composed of three
subunits; the heavy chain, NFH (200 kDa), the medium chain NFM (155 kDa) and the light
chain, NFL (68 kDa); nitric oxide synthase (NOS), the growth associated protein GAP-43,
fluoride-resistant acid phosphatase (FRAP) as well as binding for the isolectin B4 (1B4)
(Bergman et al., 1999; Da Silva et al., 1986; Petmska et al., 2000).
The primary sensory neurons of rats and mice have been classified into type 1/A, large light
cells (LLC); type 2/B, small dark cells (SDC); and type 3/C cells on the basis of size and
ultrastuctural and immunocytochemical characteristics. The LLC subpopulation is identified
by immunostaining with the antibody to the phosphorylatcd form of NFH, RT97 (Kitao et
al., 1996;Lawson et al., 1984;Perry et al., 1991) and accounts for approximately 35% of cells
(Bergman et al., 1999). These cells do not express SP (Petruska et al., 2000) and are likely
to be associated with Ap-fibres. The SDC subpopulation can be defined by the binding of
IB4, a lectin from plant Griffonia simplicifolia, which has been found to recognise a-D-
galactose carbohydrate residues on the surface of a subset of small DRG neurons accounting
for approximately 50% of cells (Bergman et al., 1999). The neurons labelled by 1B4 binding
in rat and mouse sensory ganglia are often regarded as non- NGF-dependent and non-
peptidergic. However, a considerable number of lB4-positive neurons in the DRG are also
shown to be immunoreactive to SP and CGRP (Petruska et al., 2000), which are synthesized
by NGF-dependent neurons and are likely to be associated with C-fibres. Furthermore, in
situ hybridization histochemistry of DRG neurons demonstrated that 29% of NGF receptor
expressing neurons and 66% of GDNF receptor expressing neurons were intensely labelled
by IB4 binding. This suggests 1B4 labelled neurons are peptidergic and growth factor
dependent (Kashiba et al., 2001). The remaining subpopulation (approximately 15% of cells)
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express RT97 and bind IB4. do not express SP (Petruska et al., 2000) and are likely to be
associated with A5-fibres. All three subpopulations, especially type 1, express CGRP many
of which are also capable of synthesising galanin (Bergman et al., 1999). NOS is present in
the RT97- subpopulations and frequently colocalize with CGRP (92%). GAP-43 is expressed
in all three DRG subpopulations and colocalize with CGRP (88%), and/or NOS (22%)
(Bergman et al., 1999). In contrast. FRAP appears to mark a subpopulation of DRG small
cells which are non-peptidergic nociceptors demonstrated by studies of afferent terminal
immunoreactivity (Da Silva et al., 1986).
1.4 Central Aspects of Nociception
The dorsal horn of the spinal cord, the first stage of processing of sensory information in the
somatosensory system, plays an important role in transmitting information from nociceptive
primary afferent neurons to the brain; however, our knowledge of its neuronal and synaptic
organisation is still limited. Essentially, the dorsal horn consists of the central terminals of
primary afferent fibres, intrinsic dorsal horn neurons and outputs and inputs to, and from, the
rest of the CNS making it a complex, multisynaptic structure (Doubell and Mannion, 1999).
1.4.1 The dorsal horn of the spinal cord
The current view of the spinal cord is based on the work of Rexed (Rexed. 1952) who
classified the 'butterfly' shape of the spinal cord grey matter, containing the neuronal cell
bodies, into nine laminae that make up the dorsal and ventral horns of the spinal cord and a
tenth lamina that surrounds the central canal. The central terminals of primary afferents in
the dorsal horn occupy highly ordered spatial locations divided into five broadly parallel
laminae in several mammalian species (Molander et al.. 1984;Rexed. 1952) (see Figure la).
Therefore only these five laminae will be considered for the purposes of the present
investigation.
Dorsal horn organisation
Lamina I (LI), also known as the 'marginal zone' is the thin outermost layer of the dorsal
horn and extends medially and laterally. It contains sparsely distributed small (5x5 pm) and
large cells (15x15pm), many of which are projection neurons and cells of origin of the
spinothalamic tract (STT) (Giesler et al., 1976;Todd, 2002). LI cells send axons to various
parts of the brain, including the caudal ventrolateral medulla (CVLM), parabrachial area,
periaqueductal grey (PAG) and thalamus. A group of giant neurons named Waldeyer cells
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can be identified in LI by the presence of high levels of the glycine receptor-associated
protein gephyrin on their cell bodies and proximal dendrites (Puskar et al., 2001). Unlike
many lamina I projection neurons which respond to excitatory input, Waldeyer cells either
lack the neurokinin 1 (NKj) receptor, or express it at a very low level and lie adjacent to y-
aminobutyric acid (GABA) containing terminals (Puskar et al., 2001), suggesting that they
are influenced in an inhibitory manner. Lamina II (LII) also called the 'substantia
gelatinosa', lies ventral to LI and consists of an outer zone (LII0), which contains densely
packed small cells (5x5 pm) and a less compact inner zone (Llf). LII contains mostly
intrinsic interneurons with extensive local integration. Only a few (~1%) LII neurons project
axons to the brainstem (Giesler et al., 1976;Willis et al., 1979), whilst some neurons project
into LI. Together, LI and LII are known as the 'superficial dorsal horn'.
Nociceptive afferents, many of which contain SP, terminate mainly in laminae 1 and II of the
spinal dorsal horn. Correspondingly, up to 80 % of lamina I projection neurons express the
SP, receptor NK, (Todd, 2002).
Lamina III (LII1) lies ventral to LII and contains generally larger and less tightly packed
cells. Primary afferents of large hair follicles, Pacinian corpuscles and RA mechanoreceptors
terminate in LIII and cell dendrites project to LI and IV. LI1I also contains cells of origin of
the spinocervical tract (SCT) and the postsynaptic dorsal column (PSDC) tract (see Section
1.9) (Brown and Fyffe, 1981). Lamina IV (LIV) is a thicker layer, ventral to LIII and
contains large, scattered cells (10x15pm) many of which project dendrites into LI -III and
are therefore able to receive a direct primary afferent input from fibres that enter the
superficial layers. A significant number of the larger LIV cells are also cells of origin of the
SCT and the PSDC (Brown and Fyffe, 1981).
Within laminae III and IV, a population of large neurons express the NK! receptor, (Nairn et
al., 1997), project to the CVLM and parabrachial area (Todd. 2002) and may also target
lamina I projection neurons (Sakamoto et al., 1999). These observations indicate that there
are specific patterns of synaptic connectivity within the spinal dorsal horn.
Lamina V (LV) forms the neck of the dorsal horn and contains a heterogeneous neuropil
including the largest cells of the dorsal horn laminae (15x20pm), many of which constitute
the ascending projection to the thalamus as the STT (Giesler et al., 1976). Together, LIII. IV
and the dorsal part of LV make up the 'nucleus proprius' (Brown and Fyffe, 1981). For
schematic diagram of laminar organisation see Figure 1.1a.
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1.4.2 Dorsal horn neurons
Nociceptive primary afferents terminate primarily in the superficial dorsal horn (LI and LII).
C-fibres terminate predominantly in LII (Woolf and Doubell, 1994) while A8-afferents
terminate in both the superficial laminae and send some projections deeper to lamina V
(lessell and Dodd, 1985). Ap-fibres normally terminate only in the deeper laminae (III-1V)
(Willis and Coggeshall, 1991) whilst many fine afferent fibres from muscle and viscera
project directly in LV (Brown et al., 1981). The rostrocaudal and mediolateral location of
the central terminals generate a sonratotopic map of the body surface in the horizontal plane
of the dorsal horn (Doubell and Mannion, 1999). For a schematic diagram of cutaneous
afferent input into the dorsal horn see Figure 1. lb.
The neurons of the dorsal horn can therefore be categorised by their response characteristics
to primary afferent fibre sensory input. They have been classified into three major groups;
Class 1, non-nociceptive neurons, involved in innocuous information processing (Iggo and
Ramsey, 1974); Class 2, multireceptive neurons, sensitive to cutaneous mechanoreceptive
and nociceptive input; and Class 3, noci-specific neurons responding only to noxious
stimulation of the skin (Cervero et al ., 1976;Iggo and Ramsey, 1974). There is also a fourth
class of dorsal horn neuron which are proprioceptive in nature, responding to joint
movement and pressure on deep tissues and, as such, are beyond the scope of this work.
Dorsal horn neurons can also be broadly divided into three categories based on the
destination of their axon projections. These are; projecting neurons, which relay their input
to higher brain centres, local circuit neurons and local interneurons. The vast majority of
dorsal horn neurons are interneurons and can be excitatory, containing glutamate as a
neurotransmitter, thereby relaying excitatory afferent inputs to projection neurons, or
inhibitory, containing the neurotransmitters GABA and/or glycine. Inhibitory interneurons
synapse both presynaptically on primary afferents and postsynaptically on dorsal horn
neurons so that the majority of primary afferent input into the dorsal horn occurs via
polysynaptic pathways involving interneurons. For example, neurons in lamina III/IV
receive numerous synapses from axons of local inhibitory interneurons which contain GABA
and neuropeptide Y (NPY) (Todd, 2002) and some lamina I projection neurons receive a
selective and dense input from GABAergic cells suggesting that these cells, which convey
noxious information to the brain, are under powerful inhibitory control (Puskar et al., 2001).
This leads to modulation of incoming somatosensory information before it is relayed to
higher centres and is thought to inhibit much of the sensory input, implicating dorsal horn
interneurons in several theories of pain and analgesia (Basbaum and Fields, 1984;Bennett,
1994;Jessell and Iversen, 1977;Melzack and Wall, 1965). Dorsal horn neurons also receive
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inputs from descending neurons from the brain, which can exert further modulatory
influences on spinal sensory processing. For example, descending serotonergic axons from
the medullary raphe nuclei innervate LI and LIII/IV projection neurons (Todd, 2002).
However, the present study has not addressed of the role of these descending inhibitory
































Figure 1.1. Laminar organisation of the dorsal horn of the spinal cord and cutaneous
afferent input to the spinal cord
a) Schematic representation of the laminar divisions of Rexed (Rexed. 1952) in the L5
segment of the rat spinal cord. (Molander et al., 1984) Liss- Lissauer's tract IM- intermedio-
medial nucleus Pyr- pyramidal tract VM- ventro-medial nucleus LSN- lateral spinal nucleus
I-X- Rexed's ten laminae, b) A hypothetical cross-section of the spinal dorsal horn
illustrating the afferent fibres and neuronal endings in LI-IV. Rexed's (Rexed, 1952) laminar
divisions are indicated on the right, with the afferent fibre types terminating in each region of
the dorsal horn indicated on the left. Some neuron types are illustrated; a LI marginal cell, a
LII limiting cell and two neurons of the nucleus proprius where dendrites of the LIII neuron
illustrated projects into (Cervero and Iggo, 1980).
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1.5 Sensory Projection Pathways
The projection cells of the spinal dorsal horn send their axons, via ascending tracts, to
brainstem and midbrain regions, including thalamic nuclei and medullary structures.
Reciprocally, these and other areas exert modulatory influences upon information processing
in the spinal cord via descending control systems. Such inhibitory pathways contribute to
endogenous analgesia systems, which will be briefly described below.
1.5.1 Ascending tracts
Spinothalamic Tract (STT)
STT cells of origin are located in LI, LII, LIV and LV from which information is carried to
the contralateral side of dorsal horn and up the STT to the thalamic nuclei. In the rat. STT
cells usually respond to noxious mechanical stimulation of the cutaneous receptive field, but
they can also respond to innocuous mechanical stimulation and temperature (Giesler et af,
1976).
Spinomesencephalic Tract (SMT)
The SMT projects from cells located predominantly in LI, LV and LVI (Menetrey et al.,
1982) to the mesencephalic tegmentum region including the PAG. A significant proportion
of lamina I neurons contribute to the SMT many of which are likely to be nociceptive
neurons (Menetrey et al., 1982).
Dorsal Column pathways
a) Postsynaptic Dorsal Column System (PSDC)
Axons of the PSDC originate in LIII/IV and project ipsilaterallv through the dorsal funiculus
to the nucleus gracilis and nucleus cuneatus of the medulla (Giesler et al., 1984). These cells
are excited by innocuous hair movement, pressure, pinching and cooling as well as
nociceptive stimuli (Angaut-Petit, 1975).
b) Spinocervical Tract (SCT):
SCT cells of origin are mostly located in the deeper laminae (LIV-LVII) and project
ipsilaterally to the lateral funiculus (Cao et al., 1993). The SCT projects into the PSDC and
horseradish peroxidase intracellular tracing has shown that a proportion of SCT cells also
give rise to collaterals which project either to deeper regions in the grey matter, medially
towards the central canal, across the mid-line in the ventral white commissure or in to the
contralateral ascending ventral funiculus (Cao et al., 1993). The majority of SCT neurons
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respond to tactile stimuli from hair follicles, however, many are multireceptive (Fleetwood-
Walker et al., 1988) responding to innocuous stimuli as well as intense cutaneous pressure,
pinch and thermal nociceptive stimulation (Cervero et al., 1979;Brown et al., 1983).
1.6 Endogenous Inhibitory Modulation
Endogenous systems involved in the modulation of pain were initially suggested by Melzack
and Wall (Melzack and Wall, 1965) who proposed the 'Gate Control' theory of pain, in
which spinal nociceptive transmission could be inhibited by non-nociceptive inputs. It is now
clear that nociceptive processing is modulated not only via segmental control from inhibitory
interneurons and activity in large diameter Ap-fibres, but also by influences of descending
pathways from supraspinal areas and endogenous analgesic compounds such as the
cannabinoids. Together, these pathways influence activity in primary afferents, neurons of
origin of ascending pathways and interneurons, providing a feedback system onto the dorsal
horn.
1.6.1 Segmental control
Segmental control of spinal neurons to nociceptive stimulation is characteristically produced
by cutaneous stimulation of large A-fibres, which can selectively inhibit C-fibre- and
noxious stimulation-evoked excitation of dorsal horn neurons (Besson and Chaouch
1987;Woolf and Wall, 1982). Such inhibitory influences can be exerted on multireceptive
and noci-specific dorsal horn neurons via the activation of spinal interneurons by primary
afferent fibres, or indirectly by the activation of pathways descending from the brain
involving the release of inhibitory transmitters such as the amino acids GABA and glycine
and/or endogenous opioid peptides. In addition, monoamines such as serotonin and
noradrenaline, are directly released by descending control systems to exert inhibitory effects
(Besson and Chaouch, 1987).
GABA
GABA-like-immunoreactivity is shown by interneurons located predominately in LI-LIII
(Barber et al., 1982;Todd and Sullivan, 1990). Ionophoretic application of GABA can inhibit
dorsal horn neuron activity implicating GABA as a postsynaptic inhibitory neurotransmitter
(Curtis et al., 1970;Zieglgansberger and Sutor, 1983).
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Glycine
Glycine expression is found in LI-III of the spinal cord where it is often colocalised with
GABA (Todd and Sullivan, 1990). Although thought of as an inhibitory neurotransmitter
acting via the strychnine-sensitive glycine receptor (Budai et al., 1992), glycine can also
exert an excitatory action via the A'-methyl-D-aspartatc (NMDA) receptor. However,
ionophoretic application of glycine results in strong depression of dorsal horn neuron activity
(Zieglgansberger and Sutor, 1983).
1.6.2 Endogenous opioids
Endogenous opioid peptides mimic narcotic analgesics in producing prolonged analgesic
effects in animals. Opioid peptides such as enkephalin and dynorphin are present within
synaptic terminals of the spinal dorsal horn (Cruz and Basbaum, 1985;Glazer and Basbaum,
1981 ;Willis and Coggeshall, 1991), such that they are highly associated with areas receiving
small diameter afferent primary fibres (Cruz and Basbaum, 1985;Glazer and Basbaum,
1981), interneurons and in terminals synapsing with STT neurons, presumably providing the
basis for an important inhibition of spinal nociceptive transmission (Ruda et al., 1984). The
functional importance of this spinal modulatory system is well supported by the long-lasting
analgesic effects seen in animals following the intrathecal administration of morphine
(Yaksh and Reddy, 1981), which is further supported by studies in which ionophoretic
application of opioids in the substantia gelatinosa produces strong inhibition of dorsal horn
neuron responses to noxious stimulation (Fleetwood-Walker et al., 1988). Three members of
the opioid receptor family were cloned in the 1990s, including the mouse delta-opioid
receptor (DOR) (Evans et al., 1992;Kieffer et al., 1992), the mu-opioid receptor (MOR)
(Chen et al., 1993;Thompson et al., 1993) and the kappa-opioid receptor (KOR) (Meng et al.,
1993;Nishi et al., 1993). These receptors have been identified in the superficial dorsal horn
of the spinal cord (Atweh and Kuhar, 1977) as well as on primary afferent terminals
implying that their inhibitory action may occur via presynaptic sites or as an indirect action
following activation of interneurons. All three receptors belong to the family of seven
transmembrane G-protein coupled receptors, and share extensive structural homologies
(Przewlocki and Przewlocka, 2001).
Various agonist and antagonist studies (Fleetwood-Walker et al., 1988;Gouarderes et al.,
1996;Kalso et al., 1993;Sullivan et al., 1994) and more recently gene knockout models (for
review see Kieffer and Gaveriaux-Ruff, 2002) have demonstrated a role for all three opioid
receptors in the modulation of nociceptive processing in specific, yet distinct, areas of the
spinal cord. Extracellular recordings made of the cutaneous sensory responses of SCT
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neurons in the lumbar dorsal horn demonstrate that KOR agonists cause a selective reduction
of the nociceptive responses of the neurons without effect on responses to innocuous stimuli
(Fleetwood-Walker et al., 1988). When applied to the substantia gelatinosa, only MOR
agonists showed a selective antinociceptive effect. Therefore, MORs and KORs can
participate in the selective antinociceptive influence that opioids can exert over
somatosensory information ascending to supraspinal levels, but at anatomically distinct sites.
The MOR 1 subunit is present on primary afferent axons and in a population of neurons in
the superficial dorsal horn of the rat spinal cord, the majority of which are restricted to LII
(Spike et al., 2002), where it is thought to play a role in opiate-induced analgesia via local
inhibitory actions. 94% of MORI expressing cells do not express GABA or glycine, (Kemp
et al., 1996) implying that most of the cells in the superficial dorsal horn which possess
MORI are excitatory interneurons. Therefore, part of the action of MOR agonists, such as
morphine, involves the inhibition of these excitatory interneurons interrupting the flow of
nociceptive information through polysynaptic pathways in the spinal cord. Intrathecal
administration of the morphine analogue DAMGO stimulates MOR internalization in LII
neurons correlating precisely with the extent of analgesia produced (Trafton et al., 2000).
However, it has been suggested that endogenous opioids do not initiate such MOR
internalisation suggesting they may not act on interneurons but perhaps via presynaptic
MORs or delta-opioid receptors (Trafton et al., 2000). However, this finding could be due to
difficulties in detecting low levels of internalisation at such sites. Furthermore, noxious
thermal stimulation of the hind paw induces c-Fos expression, indicative of activation, in
approximately 15% of MOR-1 cells in the medial third of the ipsilateral dorsal horn at mid-
lumbar level indicating postsynaptic activation of opioid responsive cells due to activation
by nociceptive afferents (Spike et al., 2002). LII MOR expressing cells do not express NKi
but receive many inputs from SP-containing afferents, the majority ofwhich contain the mu-
selective opioid peptide, endomorphin-2. Therefore, endomorphin-2 released from primary
afferents is an endogenous ligand for pre- and postsynaptic MORs opposing the excitatory
actions of co-localised SP, thereby serving as a major modulator of pain perception (Martin-
Schild et al., 1998). This is supported by the fact that endomorphin-1 and -2 produce short
acting, naloxone-sensitive antinociception in the tail flick test and inhibited the behaviour
elicited by intrathecally injected substance P (Stone et al., 1997).
In general, the antinociceptive potency of opioids is greater against various noxious stimuli
in animals with peripheral inflammation. Inflammation-induced enhancement of opioid
antinociceptive potency is characteristic predominantly for MORs, since morphine elicits a
greater increase in spinal potency of MORs than of DOR and KOR agonists (Hylden et al.,
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1991). However, the reason for this is still relatively unknown as there are no apparent
changes in receptor affinity or number (Cesselin et ah, 1980;Stanfa and Dickenson, 1993).
1.6.3 Tonic descending modulation
Spinal nociceptive processing can also be modulated by descending pathways from
supraspinal sites. Such systems can specifically modulate dorsal hom neuron responses to
noxious input with little effect on innocuous input (Morton et ah, 1983). Lesion studies have
implicated the lateral reticular nuclei in the brainstem as sources of descending pathways
(Foong and Duggan, 1986;Morton et ah, 1983) and it is known that neurons in the medullary
nucleus Raphe magnus (NRM) and adjacent structures of the rostral ventromedial medulla
(RVM) are involved in descending control of nociceptive transmission. However, the exact
origin of tonic descending inhibition is unclear. The NRM provides a major serotonergic
input to the dorsal horn LI/II and V cells (Basbaum and Fields. 1978), electrical stimulation
of which can produce analgesia to noxious stimuli (Guilbaud et ah, 1977; Willis, 1977;
Oliveras et ah, 1974; Duggan and Griersmith, 1979). Electrical stimulation in the RVM
produces a biphasic modulatory effect, showing facilitation at low intensities and inhibition
at higher intensities (Calejesan et ah, 2000). Fields and Heinricher (Fields and Heinricher,
1985) demonstrated two main classes of cell in the RVM namely; 'on-cells', which are
constantly activated by noxious heat stimulation of almost anywhere on the body surface and
'off-cells', which are inhibited by the same stimulus (Hernandez and Vanegas, 2001).
Under mild noxious stimulation, RVM cells with inhibitory projections to the dorsal hom are
not subject to strong GABAergic influence (Gilbert and Franklin, 2001) and are therefore
capable of inhibiting spinal dorsal hom relay neurons. However, intense noxious peripheral
stimulation may stimulate the release of GABA onto RVM cells, which in turn shuts off
descending inhibitory fibres to allow transmission of nociceptor input through the dorsal
hom (Gilbert and Franklin, 2001). The modulatory circuitry of the RVM may also be
engaged physiologically in behaving animals via opioid-mediated activation of the RVM
from higher brain centres such as the amygdala (McGaraughty and Heinricher. 2002),
anterior cingulate cortex (Calejesan et ah, 2000) synapsing via the periaqueductal gray
(PAG). Such analgesia due to activation of 'off-cell' firing and depression of 'on-cells' has
been demonstrated to involve the activation of both the DOR2 (Harasawa et ah, 2000) and
MORs (Wang and Wessendorf, 2002).
A similar division of cell type has been demonstrated in the parafascicular neurons (PF) of
the thalamus (Zhang et ah, 1997), which is modulated by ascending and descending
influences of the locus coeruleus (LC) which provides noradrenergic input to the forebrain,
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cerebellum, brainstem and spinal cord (Nygren, 1977). The LC exerts two different effects
on nociceptive transmission via the PF; a predominantly inhibitory role on the nociceptive
transmission at the spinal cord level by descending noradrenergic fibres, and a facilitatory
role on the responsiveness of PF to noxious inputs by ascending fibres (Zhang et al., 1997).
Therefore, descending modulation of nociceptive transmission in the spinal cord involves
complex integration between various brain structures.
1.6.4 The endogenous cannabinoid system
An alternative spinal modulatory system that can exert selective antinociceptive effects is the
endogenous cannabinoid system (Fox et al., 2001;Herzberg et al., 1997a;Richardson et al.,
1998a). This is of particular interest to this study due to evidence that they may exert
beneficial analgesic effects in chronic pain states including neuropathic pain and
demyelinating diseases such as multiple sclerosis (Consroe et al., 1997;Robson, 2001).
Endocannabionaids
The endogenous cannabinoid receptor agonists, anandamide (arachidonylethanolamide) and
2-arachidonyl glycerol, were discovered in the 1990's. Both of these can act as
neuromodulators or neurotransmitters, and are correspondingly synthesised by neurons and
rapidly removed from the intercellular space following release (Di, V and Deutsch, 1998).
Two types of cannabinoid receptor have been identified so far; CB) and CB2 (Pertwee,
1997:Pertwee, 1998), both of which are coupled negatively to adenylate cyclase (AC) and
positively to MAP kinase via Gl/o proteins. These receptors have been shown to be present in
the PNS and CNS. particularly in areas associated with nociceptive processing such as the
superficial laminae of the spinal cord (Farquhar-Smith et al., 2000;Herkenham et al., 1991).
CB2 receptors are thought to be located mainly on peripheral immune cells whereas CB,
receptors are found in particularly high concentrations within the CNS, on some peripheral
neurons (Ahluwalia et al., 2000;Hohmann and Herkenham, 1999) and certain non-neuronal
tissues. CB) receptors have also been reported to be located predominantly on spinal
interneurons in the outer part of lamina II (Farquhar-Smith et al., 2000;Salio et al., 2002) and
are also located on dorsal horn neurons of the spinal cord where they are likely to have an
excitatory effect on neurotransmission due to closure of M-type potassium channels
(Schweitzer, 2000). As well as this post-synaptic location, CB, receptors appear to be
located both pre-synaptically on C-fibre and A-fibre primary afferent terminals where they
probably modulate release of excitatory and inhibitory neurotransmitters. Autoradiographic
studies of dorsal horn CB receptor binding in rats treated neonatally with capsaicin suggests
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that only 16% of spinal CB receptors are located on C-fibre afferent endings (Hohmann and
Herkenham, 1999) and in situ hybridisation studies have demonstrated the capability of
predominantly medium and large sized neurons in the DRG to svnthesise CB, receptors and
insert them on primary afferent terminals (Hohmann and Herkenham, 1999).
A number of behavioural (Lichtman and Martin, 1997;Smith and Martin, 1992) and
electrophysiological studies (Drew et al., 2000;Hohmann et al., 1998) have now
demonstrated the ability of cannabinoids to inhibit acute nociception. It has been shown that
under normal conditions, spinal CB receptors modulate C-fibre transmission and particularly
facilitate post-discharge responses of dorsal horn neurons (Drew et al., 2000). Anandamide
has been shown to inhibit capsaicin-evoked CGRP release into the dorsal horn of the spinal
cord (Rarner et al., 1998) indicating a functional role for CB1 receptors located on C-fibre
afferents presynaptically.
Understanding the role cannabinoids play in the modulation of nociceptive processing has
been remarkably improved by the development of a variety of CB receptor agonists and
antagonists. The mixed CBi/CB2 agonist, WIN55,212-2 has been shown to presynaptically
inhibit GABAergic and glycinergic synaptic transmission in the superficial medullary DH
(Jennings et al., 2001). Furthermore, putative selective CB] receptive antagonists such as
SR141716A, at least partly block anti-nociceptive effects of spinally administered
cannabinoid agonists (Drew et al., 2000) suggesting that they act predominantly via CB]
receptors to modulate nociceptive processing.
Interactions of cannabinoids with other receptors
CB1 receptors are strongly colocalised with the vanilloid receptor. VR1. in sensory DRG
(Ahluwalia et al., 2000). VRl's are pro-nociceptive receptors restricted to nociceptive
afferents and mediate pain responses to noxious heat or changes in pH and are activated by
the chilli pepper component, capsaicin. It is thought that the colocalisation of VR1 with CB1
may suggest VR1 is an endogenous target of anadamide (Di, V et al., 2000) and high
concentrations of anadamide have been shown to excite central terminals of DRG afferent
neurons via VR1 receptor activation (Tognetto et al., 2001). It has been suggested that such
activation leads to desensitisation of the excitatory VR1 receptor producing antinociception
(Iversen and Chapman, 2002). The relationship between the CB1 and VR1 receptors is an
intriguing one, which is yet to be fully understood.
It is also possible that cannabinoids and opioids may interact in the control of nociception at
the spinal level due to co-localization of CB1 and MORs in L1I interneurons (Salio et al.,
2001).
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1.7 Neurotransmission from Primary Afferents
Stimulation of primary afferent fibres results in the release of a variety of neurotransmitters
and neuropeptides from their nerve terminals in the spinal dorsal horn. These
neurotransmitters and neuropeptides act upon dorsal horn neurons via their postsynaptic
receptors. The major excitatory amino acid neurotransmitter from primary afferents is
thought to be glutamate.
1.7.1 Glutamate
The excitatory amino acid, L-glutamate, appears to be the main neurotransmitter involved in
primary afferent-mediated transmission. Electrical nerve stimulation causes glutamate
release by terminals of both myelinated and unmyelinated axons (Davies et al.. 1979:Duggan
and Johnston, 1970) and correspondingly, activation of nociceptors causes glutamate release
from nociceptive central terminals. Glutamate acts via a number of glutamate receptors
which are divided into two main subtypes; ionotropic glutamate receptors, which are ligand-
gated ion channels and metabotropic, G-protein linked glutamate receptor (mGluRs).
1.7.2 lonotropic glutamate receptors
Based on their pharmacological response characteristics, the ionotropic receptors are
subdivided into two main groups; N-methyl-D-aspartate (NMDA) receptors and non-NMDA
receptors. The non-NMDA class of ligand-gated receptors are further subdivided into a-
amino-3-hydroxy-5-methyl-4-isoxazole proprionic acid (AMPA) and kainate receptor
subtypes. Glutamate produces a fast excitatory potential when acting at the AMPA receptor
site and a long synaptic potential when acting at the NMDA receptor site.
High concentrations of AMPA receptor subunits have been demonstrated in neurons of the
superficial laminae of the dorsal horn (Furuyama et ah, 1993; Henley, Jenkins and Hunt.
1993; Tolle et ah, 1993; Popratiloff, Weinberg and Rustioni, 1996) and NMDA receptors
have been shown to be located throughout the brain and spinal cord particularly in the
superficial dorsal horn (Greenamyre et ah. 1985;Monaghan and Cotman. 1985). There is
extensive evidence indicating a critical role of AMPA and NMDA receptors in spinal
nociceptive processing, and in plastic changes in the spinal cord, which lead to persistent
nociception (Coderre, 1993;Wilcox, 1991;Woolf and Thompson, 1991), such as in
neuropathic pain. There is also compelling evidence to suggest that the NMDA receptor
plays a crucial role in excitability changes such as long term potentiation (LTP)(Collingridge
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et al., 1983;Morris et al., 1986) which is necessary for "spatial" learning and memory to
occur in the hippocampus. Therefore, NMDA receptor dependent LTP is considered to be a
possible parallel mechanism to that occurring in sensitisation of the spinal cord (Jia et al.,
2001) and consequently the involvement of such mechanisms have been demonstrated in the
generation of hyperalgesia (Dougherty et al., 1992;Zhou et al., 1996). Therefore, activation
of the NMDA receptor is of particular relevance to this study and will be dealt with in more
detail below (see 1.7.4).
1.7.3 Metabotropic glutamate receptors
The mGluRs are members of the super-family of seven transmembrane domain G protein-
coupled receptors. Group I metabotropic receptors are concentrated in the superficial dorsal
horn of the spinal cord (Berthele et al., 1999;Jia et al., 1999) and are of particular importance
to nociception. This group includes mGluRl and mGluR5. the activation of which leads to
phosphoinositide hydrolysis, intracellular calcium (Ca2+) mobilisation and possibly, to a
lesser extent, increases in cyclic adenosine 3',5'-monophosphate (cAMP) accumulation (Abe
et al., 1992;Aramori and Nakanishi, 1992), which all contribute to cell excitability.
Various roles for mGluRs in the induction of synaptic plasticity have been indicated. For
example, activation of group I mGluRs in hippocampal slices of the CA1 region induces a
form of long-term depression (LTD) of excitatory synaptic transmission which is thought to
be via Ca 2+ independent presynaptic mechanisms (Fitzjohn et al., 2001). There is also much
evidence to suggest that group I mGluRs are involved in LTP at CA1 synapses within the
hippocampus. Activation of class I-mGluRs can link them with intracellular kinases such as
protein kinase C (PKC) and sre which can phosphorylate and enhance the open probability
of the NMDA receptor channel (Jia et al., 2001). This may lead to LTP involving the
NMDAR, but not the AMPA receptor. However, evidence suggests that mGlu receptor-
mediated potentiation ofNMDA responses is not essential for the induction of LTP (Doherty
et al., 2000) and that the role of mGluRs in the induction of LTP is fundamentally different
from that of NMDA receptors (Bortolotto et al., 1994). NMDA receptors are ionotropic, and
therefore, need to be activated each time a stimulus is delivered to initiate a linked molecular
event involved in potentiation of the cells responsiveness. In contrast, mGluRs are coupled to
G-proteins and therefore, a single activation can be sufficient activate a molecular switch
negating the need for mGluR stimulation during the induction of LTP. This mGluR-activated
switch is input-specific and can be turned off by a train of low-frequency stimulation
(Bortolotto et al., 1994). Such a molecular switch has fundamental consequences for our
understanding of synaptic plastic mechanisms such as those occurring in the spinal cord.
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1.7.4 Neuropeptides
Various neuropeptides are synthesised in DRG neurons and are often co-released with
glutamate from peripheral afferent terminals exerting a variety of synergistic effects on
postsynaptic dorsal horn cells.
Substance P (SP)
SP is a member of the tachykinin family and is expressed by -20% of DRG neurons which
are mainly of small diameter (Hokfelt et al., 1975;Ju et al., 1987) When released. SP
activates the NKi receptor located in the superficial dorsal horn of the spinal cord implicating
it as a transmitter in primary sensory neurons.
In the rat, most SP-containing cells also contain CGRP and some also contain galanin
(Battaglia and Rustioni, 1988;Ju et al., 1987). Functionally, SP and CGRP appear to
facilitate transmission in the dorsal horn (Henry, 1978;Wiesenfeld-Hallin et al.. 1991b) and it
would appear that SP represents the main excitatory sensory peptide with a role in
nociceptive transmission. Intrathecal injection of SP or an NKi receptor-selective agonist
elicits biting and scratching behaviours in mice that may be indicative of pain sensation
(Courteix et al., 1993;Hylden and Wilcox, 1981). However. NKi receptor antagonists are
generally not effective at reducing dorsal horn neuron responses to brief noxious stimuli
(Fleetwood-Walker et al., 1990;Yamamoto and Yaksh. 1991) and NKi receptor antagonists
have not proved to be efficacious in clinical trials of chronic pain states (Hill, 2001) although
this finding and the use of NKj receptor antagonists may be dependent upon the model of
pain used.
Calcitonin gene-related peptide (CGRP)
CGRP is normally expressed by approximately 50% of DRG neurons with unmyelinated
axons, as well as one-fifth of A5 DRG neurons with myelinated axons (McCarthy and
Lawson, 1990;Rosenfeld et al., 1983). Noxious thermal and mechanical stimulation of
primary afferents causes CGRP release into LI. LII and LV of the spinal cord (Lee et al.,
1985;Morton and Hutchison, 1989) where it plays an excitatory role. This is supported by
reports that intrathecal application of CGRP decreases the nociceptive threshold for acute
mechanical stimulation (Oku et al., 1987). Furthermore, CGRP plays a modulatory role in
excitatory transmission to the spinal cord by inhibiting SP endopeptidase, potentiating the
effect of co-released SP (Mao et al., 1992).
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Vasoactive intestinal polypeptide (VIP)
Under normal conditions, VIP expression is seen only at very low levels in DRG neurons
and in LI and LII neurons of the spinal dorsal hom (Gibson et al., 1981;Knyihar-Csillik et
al., 1991). VIP activates the receptors VPACi, VPAC2 and to a lesser extent PAC) (Hosoya
et al., 1997;Ishihara et al., 1992). VIP generally appears to become more important
following nerve injury and therefore will be discussed further below (see 1.12.1).
Pituitary adenylate cyclase-activating polypeptide (PACAP)
PACAP is a peptide similar in action to VIP as it is also normally present in low abundance
in the DRG (Nahin et al., 1994;Zhang et al., 1995) and is a further agonist at VPACt, VPAC2
and PACi, the latter of which displays a much higher affinity for PACAP as compared to
VIP (Hashimoto et al., 1993;Shivers et al., 1991). Furthermore, PACAP is also thought to
play a more significant role in somatosensory transmission following peripheral nerve injury,
following which it is upregulated in the DRG cells (Noguchi et al., 1989;Zhang et al., 1996).
Galanin
Galanin is a peptide normally expressed at very low levels in sensory and sympathetic
neurons and co-exists with several other neurotransmitters including CGRP and SP (Ju et al.,
1987;Ma and Bisby, 1997). Galanin has widespread CNS distribution and can be found
concentrated in LI-III of the dorsal horn, with moderate expression in IV-V and primary
afferent terminals (Kar and Quirion, 1995). Galanin may act centrally as a modulator of
excitatory peptides supported by evidence that intrathecal pre-administration of galanin
antagonises the excitatory effects of SP and CGRP on the flexor withdrawal reflex
(Wiesenfeld-Hallin et al., 1991b;Xu et al., 1990) and inhibits the analgesic effect of
morphine on noxious thermal and mechanical stimuli (Wiesenfeld-Hallin et al., 1991a),
whilst producing no effect alone on nociceptive inputs. As with VIP. the main actions of
galanin in the PNS sensory transmission seem to occur following peripheral nerve injury and
therefore will be discussed further below (see 1.12.2).
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Neuropeptide Y (NPY)
NPY is not normally expressed by DRG neurons in normal animals (Lundberg et al., 1983).
However, there is a high density of NPY-positive nerve fibres present in the superficial
laminae of the dorsal horn arising from local cell populations or supraspinal sites (Wakisaka
et al., 1991) where NPY may co-exist with galanin or GABA (Laing et al., 1994;Zhang et
al., 1993). The functional role of NPY in the spinal cord is unclear, as at low doses
intrathecal administration ofNPY appears to be excitatory whereas at high doses, it produces
inhibitory actions (Scherer et al., 1994). Again, the main actions of NPY of interest to this
study occur following peripheral nerve injury and will therefore be dealt with further below.
Somatostatin (SOM)
SOM is a peptide expressed by small diameter primary afferent neurons which do not
express SP (Hokfelt et al., 1976;Nagy and Hunt. 1982) and is thought to act, at least in part,
by opposing the action of (SP) in neurogenic inflammation. In situ hybridisation has
demonstrated SOM expression to be restricted to approximately 10% of lumbar DRG
neurons of the rat all of which are intensely IB4-labeled neurons and express the GNDF
receptor (Kashiba et al., 2001). Application of GDNF to the rat dorsal horn of the spinal
cord promotes activity-induced release of SOM from central terminals of sensory neurons
(Lever and Malcangio, 2002) and GDNF induced inhibition of intrathecal SP-induced
thermal hypersensitivity was reversed by the SOM antagonist (Lever and Malcangio, 2002).
SOM expression in the spinal cord is restricted to LII (Hokfelt et al., 1976), however, its role
in nociceptive processing is unclear with reports of both inhibitory and excitatory actions on
dorsal horn neurons (Salt and Hill, 1983;Murase et al.. 1982;Randic and Miletic, 1978).
Intrathecal SOM application has been reported to increase the excitability of the spinal cord
neurons following mechanical and thermal stimuli (Wiesenfeld-Hallin, 1985). In contrast,
administration of somatostatin to the spinal cord or brain areas involved in nociception has
been shown to result in analgesia and somatostatin sst2(a) receptors have been shown to be
expressed by neurons closely associated with brain areas involved in analgesia and the
modulation of nociception (Schindler et al., 1998). This inhibitory action of SOM especially
in inflammatory pain, is supported by the fact that SOM receptor (SSTR) agonists produce
analgesia following intrathecal or epidural administration in humans and that activation of
peripheral SSTRs in the rat reduces both inflammatory pain and the activity of sensitized
nociceptors (Carlton et al., 2001).
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1.8 Chronic Pain
Chronic pain is currently a major health care problem throughout the world with reports of
14% of the UK population (Munglani et al., 1999) and 15-20% the USA population (Rudin,
2001) experiencing significant chronic pain. Common sources of chronic pain are cancer,
inflammatory disorders, headache, low back pain, arthritic pain and neurogenic pain, which
is defined as pain that arises from the nervous system (IASP press, 1994). Unfortunately,
effective long-term therapies to treat chronic pain syndromes are limited in efficacy, making
it a huge socio-economic problem.
1.9 Neuropathic Pain
Neuropathic pain is a common form of chronic pain resulting from a primary lesion or
dysfunction in the nervous system (IASP Press 1994). Whether of central or peripheral
origin, neuropathic pain is characterised by a neuronal hyperexcitability in damaged areas of
the nervous system.
Peripheral neuropathic pain results from damage to the peripheral nerves, which may arise
from polyneuropathy, entrapment neuropathy, or as a result of disease such as herpes zoster
(Mohamed, Carr. 1994) or systemic illnesses such as diabetes, infection with human
immunodeficiency virus (HIV) (Hewitt et al., 1997) or nutritional deficiencies. Although the
causes of peripheral neuropathy are diverse, associated symptoms are consistent and include
weakness, numbness, paraesthesias (abnormal sensations such as burning, tickling, pricking
or tingling) and pain (Scadding, 1981). Such pain typically manifests as spontaneous,
stimulus-independent pain and/or stimulus-evoked pain, which is typically characterised by
the abnormal pain states of tactile allodynia; pain due to a stimulus which does not normally
provoke pain (IASP Press 1994), and hyperalgesia; the increased response to a stimulus
which is normally painful (IASP Press 1994) (Woolf et al., 1998).
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1.10 Animal Models of Neuropathic Pain
Unravelling the mechanisms involved in neuropathic pain requires the use of laboratory
animal models that replicate as far as possible, the different pathophysiological changes
present in patients. For reasons of reproducibility and simplicity, most studies of neuropathic
pain are based upon animal models of traumatic nerve injury, usually in the rat sciatic nerve
(Boucher and McMahon, 2001). It is unlikely that any single animal model will include the
full range of neuropathic pain mechanisms and therefore, several such models exist,
employing a variety of nerve injury-inducing techniques. In the most frequently used
models, a mixture of intact and injured fibres is created by loose ligation of either the whole
sciatic nerve, known as a chronic constriction injury (CCI) (Bennett and Xie, 1988) or a tight
ligation of a part of the sciatic nerve, known as partial sciatic nerve ligation injury (PSNL)
(Seltzer et ah, 1990). More recently a variant of partial denervation has been developed
called the spared nerve injury model (Decosterd and Woolf. 2000). involving a lesion of two
of the three terminal branches of the sciatic nerve (tibial and common peroneal nerves)
leaving the remaining sural nerve intact. Therefore, in this model the co-mingling of distal
intact axons with degenerating axons is restricted, permitting behavioural testing of the non-
injured skin territories adjacent to the denervated areas. Probably the most commonly used
model today involves the tight ligation of one or two spinal nerves just distal to the DRG,
known as spinal nerve ligation (SNL) (Kim and Chung, 1992). This results in an all or none
axotomy of DRG neurons within relevant ganglia. In all these animal models pronounced
sensory changes are seen which are similar to those observed in many patients with
neuropathic pain. Such changes are paralleled in the animal by behaviour indicative of such
pain including guarding and avoidance of weight bearing on the appropriate paw, and escape
behaviour to very light tactile stimuli, consistent with the development of allodynia.
However, all of these models share the common feature of damage to, and degeneration of,
some sensory fibres in a major somatosensory nerve.
23
1.11 Introduction to Mechanisms Underlying Neuropathic Pain
In peripheral neuropathic pain, damaged nerves exhibit abnormal spontaneous and/or
increased evoked activity. Such hyperexcitability is thought to occur as a result of a series of
molecular changes at the level of the peripheral nociceptor and in the DRG, which are
thought to lead to similar molecular changes in the dorsal horn of the spinal cord. These
changes include abnormal expression of Na+ channel subtypes, changes in neuropeptide
complement, increased activity in glutamate receptor sites, changes in GABA-ergic
inhibition, and an alteration of calcium influx into cells. The next section will discuss some
of these changes in more detail.
1.12 Changes in the Peripheral Nervous System
Sensory communication depends on sustained, yet controlled firing in afferents and
subsequent pathways. Following injury to the nerve, primary afferent fibres may become
sensitised to peripheral sensory stimulation, decreasing their threshold for activation and
thereby producing an increased rate of firing to previously subthreshold stimuli. Perhaps
more importantly for the generation of neuropathic pain is the generation of impulses at
abnormal locations along the axon of sensory neurons (Devor and Seltzer, 1999). Such
'ectopic' activity can emerge due to various components of the injury, such as an area of
demyelination (Baker and Bostock. 1992;Calvin et al., 1982;Rasminsky, 1978) or afferent
sprouting and neuroma formation (Devor and Dubner, 1988). As a result, the damaged
peripheral nerve acquires an ongoing, 'spontaneous' discharge. In addition to firing
spontaneously, such ectopic pacemaker sites are often excited by mechanical forces applied
to them during movement, resulting in spontaneous and movement-evoked pain (Devor and
Seltzer, 1999). Spontaneous discharge can also occur in the DRG neurons, causing
transmission not only to the central nervous system, but also antidromically towards the
peripheral terminal, which can lead to further excitation of the peripheral axon (Kim et al.,
1998;Xie et al., 1995).
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1.12.1 Membrane remodelling
Repetitive firing capability depends on the distribution and gating properties of specific
transmembrane ion channels (Devor and Seltzer, 1999). Nerve injury leads to the
remodelling of the neuronal membrane including changes in expression and location of
voltage-gated Na+ and potassium ion (K+) channels, which are responsible for afferent
hyperexcitability.
Na+ channels
High-density clusters of voltage-gated Na+ channels are expressed at the nodes of Ranvier in
myelinated fibres of the PNS where they are essential for saltatory propagation of action
potentials. Following injury to the nerve, Na+ channels are known to accumulate along the
axon injury site (Devor and Seltzer, 1999), in aborted and regenerating sprouts and along
regions of demyelination (Devor et al., 1989;Novakovic et ah, 1998), rendering these sites as
hyperexcitable (Matzner and Devor, 1992;Matzner and Devor, 1994;Omana-Zapata et ah,
1997). Furthermore, expression of Na+ channels in neurons of the DRG is highly dynamic,
changing in various disease states, including some that are accompanied by pain (Waxman,
1999), making them important targets for the study of the molecular pathophysiology of
pain.
In the normal state, DRG neurons express a complex repertoire of Na" channel transcripts
(Waxman et ah. 1999b), which are distinguished by their sensitivity to tetrodotoxin (TTX)
(Black and Waxman, 1996). Some of these transcripts, such as TTX-resistant Na+ channels
SNS 1/Nav1.8 (Akopian et ah, 1996) and SNS 2/Nav1.9 (Tate et ah, 1998) are known to be
specifically expressed by sensory neurons and are therefore implicated in pain states
(Akopian et ah, 1996;Novakovic et ah, 1998). SNS 1/Nav1.8, which is of particular interest
to this study, has been shown to be expressed in approximately 50% of small diameter
unmyelinated (Amaya et ah, 2000) and in approximately 20% of medium to large diameter
myelinated cells of the DRG, whereas SNS 2/Nav1.9 is expressed only in neurons with
unmyelinated axons (Amaya et ah, 2000). Another Na+ channel of interest to this study is
the brain type III Na+ channel/Nav1.3, which is normally only found in DRG during
development. However, following axotomy (Waxman et ah, 1994b) and CCI (Dib-Hajj et
ah, 1999), changes are seen in the expression of such Na+ channels resulting in changes in
the properties of the Na+ current. Specifically, the expression of type III/Navl .3 is
upregulated in sensory neurons (Black et ah, 1999) whereas, the two known TTX-resistant
25
channels in DRG neurons, SNS 1/Nav1.8 and SNS 2/Nav1.9 are downregulated (Decosterd et
al.. 2002;Waxman et al., 1999a).
The SNS class of Na+ channel produce slowly inactivating currents (Akopian et al.,
1996;Waxman et al., 2000a), therefore their decreased expression in DRG neurons may lead
to a hyperpolarizing shift in resting potential, increasing the fraction of TTX-sensitive
channels available for activation (Dib-Hajj et al., 1999;Waxman et al., 2000). Upregulation
of the type III/Nav1.3 Na+ channel results in a switch in the properties of the TTX-sensitive
currents in DRG neurons, with the emergence of a rapidly repriming current (Waxman et al.,
1999c), which could sustain frequent ectopic discharges (Cummins and Waxman, 1997).
Therefore, DRG neurons that express type III/Nav 1.3 should be able to sustain higher firing
frequencies, which may lead to hyperexcitability in the cell. The involvement of SNS
1/Nav1.8 in the production of neuropathic pain is controversial. Partial knock down of the
SNS 1/Nav1.8 protein following spinal nerve injury via intrathecal administration of specific
antisense oligodeoxynucleotides has been shown to reduce the slow-inactivating, TTX-
resistant Na current in DRG cells of animals and reverse neuropathic pain without effect on
non-noxious sensation or response to acute pain (Lai et al., 2002). However, studies in SNS
1/Nav1.8 knockout mice reveal that neuropathic pain behaviours are unchanged (Kerr et al.,
2001), whereas earlier work suggests that the mutant demonstrates a pronounced analgesia to
noxious mechanical stimulation with little deficit in thermoreception (Akopian et al., 1999).
Studies have also argued against a role for the TTX-resistant Na+ channels in the generation
ectopic activity in injured primary sensory neurons (Dib-Hajj et al.. 1999;Sleeper et al.,
2000). Following partial nerve injuries, ectopic discharges are found in intact as well as
injured neurons (Chan et al., 2001;Hanus et al.. 1999;Liu et al., 2000a). However, it would
appear that changes in TTX-resistant Na+ channels are restricted to cells with injured
afferents (Decosterd ct al., 2002) making it unlikely that they contribute to ectopic activity
recorded in uninjured afferents. However, activation of intracellular kinase pathways
following inflammation lead to changes in the phosphorylation state of the SNS 1/Nav1.8
channel which have been shown to alter the threshold and kinetic properties of the channel
altering excitability contributing to sensitisation of the periphery (Gold et al., 1998;Khasar et
al., 1999). This implies a mechanism by which the channel could lead to hyperexcitability
following nerve injury in the neurons in which expression remains. Unfortunately, due to
the lack of specific antagonists to the individual Na+ channel subtypes (Wood and Baker,
2001), the significance of the role each plays has been hard to determine.
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Ephaptic crosstalk
Cross-excitation, allowing excitatory interactions between afferents and among neurons can
result in heightened activity following damage to the peripheral nerve. Normally, a single
primary sensory neuron constitutes an independent signal conduction pathway. However, in
the event of neuronal injury, an important form of cross-excitation in the PNS can occur,
resulting in ephaptic (electrical) crosstalk between axons. Ephapsis can occur in neuromas,
regenerating nerve and at patches of demyelination (Rasminsky, 1978) and is thought to
result from the close apposition of adjacent axons in the absence of their normal insulation
provided by Schwann cell myelination (Rasminsky, 1978). Electrically-coupled fibres are
frequently of different types, thereby ephaptic crosstalk may cause normally nociceptive
afferent neurons to be driven by electrical activity in low threshold afferents or even
efferents (Devor and Seltzer. 1999) allowing innocuous stimuli or even movement to result
in activity in the nociceptive pathway. This sort of cross excitation may account for changes
in excitability of uninjured afferents that cannot be explained by ion channel changes alone.
As well as the changes in the peripheral nerve itself, a number of changes occur in the DRG
and the spinal cord, which are thought to contribute to the initial development and then the
maintenance of neuropathic pain (for reviews see Woolf, 1993;Woolf and Costigan, 1999).
1.12.2 Neuropeptide plasticity
Following traumatic injury to the peripheral nerve, a number of neurochemical and
morphological changes may occur in peripheral nerve fibres, as well as centrally within the
spinal cord (Dray et al., 1994;Hokfelt et ah, 1994; Ma & Bisby, 1998). These are thought to
contribute to altered sensory transmission, such as that associated with chronic pain states.
A key event is the characteristic phenotypic changes that occur in many primary afferent
neurons, reflected in the altered expression of neuropeptides in their cell bodies in the DRG
(Hokfelt et ah, 1994;Villar et ah, 1991) and in their terminals and relevant receptors within
the spinal dorsal horn (Dickinson and Fleetwood-Walker, 1999). For example, it is known
that the expression of CGRP is downregulated following peripheral nerve injuries such as
axotomy and CC1 (Dumoulin et ah, 1992;Noguchi et ah, 1990) with a similar change
observed in the expression of SP (Jesscll et ah, 1979;Nielsch et ah. 1987). although there is
evidence to suggest that SP may be upregulated in larger Ap-fibre cell bodies (Malcangio et
ah, 2000), however the significance of such a change is controversial due to doubts regarding
techniques identifying termination patterns of primary afferents in the dorsal horn following
nerve injury (Bao et ah, 2002) (see 1.13.3). In contrast, galanin is strongly upregulated
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mainly in small and medium diameter neurons (Hokfelt et al., 1987;Villar et al., 1989),
especially those that normally contain substance P and CGRP (Doughty et al., 1991;Kashiba
et al ., 1992), the majority of which are unmyelinated. Studies of galanin knockout mice have
suggested that this upregulation may be important for the development of central
sensitisation (Wynick et al., 2001) and intrathecal application of galanin has been shown to
increase behavioural reflex sensitivity in naive animals (Kerr et al., 2000). Similarly in large
diameter primary sensory neurons, distinguished by the presence of the 200kDa subunit of
neurofilament protein (NF-200) (Kashiba et al., 1994;Marchand et al., 1999), there is a
marked increase in the expression of NPY after axotomy (Kashiba et al., 1994;Wakisaka et
al., 1991), partial sciatic injury (Ma and Bisby, 1998b), CCI of the sciatic nerve (Munglani et
al., 1995;Nahin et al., 1994) and following streptozocin-induced diabetic neuropathy
(Rittenhouse et al., 1996). Levels of VIP and PACAP are also markedly increased
predominantly in small to medium- sized neurons, especially those that normally contain SP
and CGRP (Kashiba et al., 1992;Xu et al., 1990;Zhang et al., 1995) and it is thought that
perhaps the upregulation of these latter peptides could reflect their capacity as mediators of
sensory transmission in neuropathic pain states. Due to the timing of their changes in
expression, it is thought that PACAP may be important in the regulation of the onset of the
neuropathic pain state within the first 1-4 days, before pain behaviours have developed,
whereas the more slowly rising levels of VIP. which peak at around 14 days following injury
when pain behaviours have fully developed, may be more important in the maintenance of
more prolonged pain states.
This phenotypic change may be primarily protective and restorative in the sense of
attenuating the input and therefore the pro-nociceptive influence of SP and CGRP, in dorsal
horn and by the trophic actions ofVIP following injury (Hokfelt et al., 1994). However, VIP
also causes enhanced transmission to the dorsal horn of the spinal cord (Wiesenfeld-Hallin et
al., 1990) and is therefore likely to contribute to the induction of a sensitised state, which
may underlie the development of chronic pain.
1.13 Changes in the Central Nervous System
1.13.1 Introduction to central sensitisation
Spontaneous discharge arising in some primary afferents following nerve injury provide
constant input to the CNS, and thus may induce functional changes in the sensory processing
mechanisms within the dorsal horn creating a phenomenon referred to as 'central
sensitisation'. Central sensitisation can manifest in three ways: enlargement of the peripheral
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receptive field of a neuron; increased response to a subthreshold input; and action potential
discharge initiated by previously subthreshold inputs. These changes manifest as
hypersensitivity to pain that spreads from the site of injury causing primary and secondary
hyperalgesia, which can include tactile Ap-fibre-mediated mechanical allodynia (Gracely et
al., 1992;Woolf CJ, 1997).
When induced in response to tissue damage or peripheral sensitisation, central sensitisation
can have a survival value as it helps to protect injured areas from further injury whilst
healing proceeds. However, when occurring as a result of nerve injury, the pain endured
persists even once healing processes are complete and therefore offers no such protective
advantage. The persistence of neuropathic pain is thought to be due to structural
reorganisation of the synaptic circuitry in the nervous system, which may include cell death
(Coggeshall et al., 1997;Coggeshall et al., 2001), degeneration or atrophy of axon terminals
(Castro-Lopes et al., 1990;Knyihar-Csillik and Rakic, 1987), appearance of new axon
terminals (Okamoto et al., 2001) and structural modification of synapses (Doubell and
Mannion, 1999). These structural changes within the dorsal horn may relate to a persistent
change in sensory processing long after healing of the initial injury.
Underlying this functional plasticity are activity-dependent changes in synaptic efficacy
within the spinal dorsal horn. In a variety of models of chronic pain, it is thought that
mechanical allodynia and thermal hyperalgesia are characteristically underpinned by changes
in NMDA receptor activation in the spinal dorsal horn, which, in a similar fashion to its
involvement in LTP (Collingridge et al., 1983;Morris et al.. 1986), is considered to be one of
the key factors underlying central sensitisation (Chaplan et al., 1997;Dickenson and Sullivan,
1987;Woolf and Costigan, 1999).
1.13.2 NMDA-receptor dependent central sensitisation
There is extensive evidence indicating that ionotropic glutamate receptors such as the AMPA
receptor (Nozaki-Taguchi and Yaksh, 2002) and especially the NMDA receptor, play a
critical role in plastic changes underlying spinal nociceptive processing, which can lead to
persistent nociception (Quartaroli et al., 2001;Wilcox, 1991;Woolf and Thompson, 1991)
and much work has gone into developing NMDA receptor blocking drugs for the treatment
of persistent pain states (Chizh et al., 2001;Parsons, 2001;Weinbroum and Ben Abraham,
2001).
At normal resting membrane potential, the NMDA receptor contributes relatively little to
primary afferent-evoked synaptic currents in dorsal horn neurons due to voltage-dependent
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block of the receptor ion channel by a magnesium ion. However, increased primary afferent
input in response to injury or ectopic pacemaker activity, results in the increased release of
glutamate and colocalised neuropeptides such as SP and neurokinin A. Via the activation of
their various G-protein coupled metabotropic receptors, these neurotransmitters induce
stimulation of intracellular PKC (Bleakman et al., 1992;Bond and Lodge, 1995) and
potentially other kinases such as tyrosine kinases (Chen and Huang, 1992), which may
mediate the phosphorylation of the NMDA receptor and facilitation of its activity. Such
phosphorylation leads to changes in the receptor binding kinetics for the magnesium ion
causing it to dissociate from the receptor at resting membrane potential. Consequently, pre-
synaptically released glutamate activates the NMDA receptor, inducing an influx of calcium
into the cell. Calcium entering the cell leads to many intracellular changes which may be
amplified by depolarisation-induced voltage-sensitive calcium channel activation and
calcium-induced release of calcium from intracellular stores. This increase in intracellular
calcium causes the activation of kinases, such as PKC (Malmberg et al., 1997;Munro FE et
al., 1994) and Ca2+/calmodulin-dependent protein kinase II (CaMIIK) (Bortolotto and
Collingridge, 1998;Silva et al., 1992), which have been shown to play significant roles in
LTP and persistent pain states. Inputs from other receptors (and to a lesser extent Ca3
elevation) may increase production of the intracellular second messenger; cyclic AMP
(cAMP), a pathway capable of activating protein kinase A (PKA), which is also implicated
in LTP and in spinal sensitisation (Cerne et al., 1992).
1.13.3 The importance of myelinated primary afferents in central sensitisation
The abnormal pain states of hyperalgesia and allodynia are thought to arise due to a
combination of changes in different cell types; hyperalgesia is thought to arise due to
abnormal processing of nociceptor input into the spinal cord, whereas, allodynia may be
produced by the action of low threshold Ap-afferents on an altered nervous system
(Koltzenburg, 1998;Torebjork et al., 1992;Woolf, 1997) and/or by the reduction in the
threshold of nociceptor terminals in the periphery.
In many circumstances, it is clear that abnormal activity in nociceptors, particularly C-fibre
nociceptors, is capable of inducing central sensitisation (Coderre, 1993). However, evidence
has begun to highlight the importance of activity in myelinated primary afferents in the
induction of central changes underlying persistent pain states, which is of particular
relevance to this study and has until recently been poorly explored in the context of
neuropathic pain. For example, following L5 SNL, spontaneous activity arises almost
exclusively in myelinated afferents for the time in which neuropathic pain develops and
30
becomes established (two weeks) (Bennett et al., 2000;Liu et al., 2000a), suggesting that
ectopic activity in myelinated A-fibres may be sufficient to trigger tactile allodynia in some
models of peripheral neuropathy (Liu et al., 2000a). This is further supported by evidence
that infusion of local anaesthetic onto the L5 DRG after SNL blocks ectopic discharges and
findings have indicated this reverses the hyperalgesia (Liu et al., 2000a), suggesting that
activity in damaged Ap fibres may maintain central sensitisation.
Activity in Ap-fibres may also be capable of activating nociceptive primary afferents in
areas of allodynia in a manner consistent with a pre-synaptic interaction (Garcia-Anoveros et
al., 2001). Such dorsal root reflexes produced by a central pre-synaptic interaction of Afl-
fibres may conduct centrally, evoking allodynia, and peripherally, evoking neurogenic
vasodilatation which may contribute to hyperalgesia as confirmed by studies of cutaneous
blood flow following electrical stimulation of the sural nerve in a range that excites AP-
fibres (Garcia-Nicas et al., 2001). Furthermore, input from non-noxious inputs via Ap-fibres
has been shown to enhance and extend the duration of previously developed secondary
hyperalgesia via stimulation of undamaged areas of peripheral tissue (Kim et al., 2001b).
This provides further support for the capability of large myelinated fibres to powerfully
modulate central sensitisation in the dorsal horn.
Although in some clinical situations, Ap-fibre mediated mechanical allodynia requires
continual input to maintain central hyperexcitability, the involvement of proposed
mechanisms such as phenotypic alterations and Ap-fibre sprouting (see below) may result in
Ap-fibre mediated pain that is independent of a constant nociceptive drive (Woolf and
Mannion, 1999).
Structural reorganisation: A-fibre sprouting and cell death
Central terminals of A-fibres occur in all laminae of the dorsal horn apart from lamina II of
the superficial dorsal horn, which receives input exclusively from C-fibre nociceptors.
However, following peripheral nerve injury, there may be induction of sprouting of Ap-fibre
central terminals into Lamina II (Lekan et al., 1996;Woolf et al., 1992). This may allow
activity in innocuous mechanoreceptors to activate nociceptive second order neurons, which
may lead to misinterpretation of the information by the nervous system. Therefore, A-fibre
sprouting may be an anatomical substrate for mechanical allodynia (Woolf and Mannion,
1999). However, strong doubts have now emerged with regard to the degree of sprouting as
assessed by the anterograde labelling technique using the cholera toxin B subunit (Tong et
al., 1999) which has been used extensively in studies of A-fibre sprouting (Woolf et al.,
1992). A recent study has demonstrated that that the cholera toxin B subunit also labels
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unmyelinated, C-fibre afferents in LII and that there is little sprouting of Ap-fibres into
superficial laminae (Bao et al.. 2002). Nonetheless, irrespective of the suitability of this
method, it appears that Ap-fibres gain the ability to excite monosynaptic neurons in
superficial laminae after peripheral nerve damage (Kohama et al., 2000). Whole cell
electrophysiological investigations have also demonstrated that following sciatic nerve
transection, large myelinated A-afferent fibres establish synaptic contact with interneurons
and transmit innocuous information to the substantia gelatinosa, representing a functional
reorganization of the sensory circuitry which may constitute an underlying mechanism for
associated sensory abnormalities (Okamoto et al., 2001).
Increased afferent drive may also lead to excitotoxicity due to excessive synaptic glutamate
release, which is a feature of many neurological conditions in which neuronal death occurs.
Primary afferent A-fibre activity, releasing glutamate into the dorsal horn, can induce
neuronal cell death especially in areas of Ap-fibre termination, the anatomical distribution of
which depends on whether intact or injured fibres are activated (Coggeshall et al., 2001).
Such stimulation-induced cell death may potentially contribute to the development of
persistent pain. For example, it is known that peripheral nerve injury can lead to GABAergic
cell loss, which coincides with the development of behavioural sensitivities (Ibuki et al.,
1997). A role for such loss in enhanced sensitivity associated with neuropathic pain has
been demonstrated with intrathecal injections of the glycine receptor antagonist, strychnine,
and the GABA A receptor antagonist, bicuculline, both of which enhance thermal
hyperalgesia following CCI (Yamamoto and Yaksh, 1993), reduce the cutaneous mechanical
threshold, and increase the response to Ap-inputs (Sivilotti and Woolf, 1994). This indicates
that a decrease in the efficacy of spinal inhibitory circuits may contribute to the touch-
evoked allodynia that occurs in pain hypersensitive states, where Ap-inputs begin to produce
pain.
Although sciatic nerve lesions do not actually result in detectable neuron loss in the dorsal
horn, activation of Ap-fibres in a previously sectioned sciatic nerve can cause substantial cell
death not only in lamina III but also in laminae I and II, areas in which Ap-fibre afferents do
not normally terminate (Coggeshall et al., 2001). The expansion of the territory of Ap-fibre
afferent-evoked cell death is likely to reflect the sprouting of the fibres into these laminae
after peripheral nerve injury.
Phenotypic changes
A-fibres may also contribute to central sensitisation following injury due to phenotypic
changes including the upregulation of potential neuromodulators such as SP, brain-derived
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neurotrophic factor (BDNF) and galanin. SP and CGRP are peptides normally expressed by
nociceptor primary afferents and are strongly implicated in nociceptive transmission to the
central nervous system. As mentioned above, following peripheral nerve injury the
expression of these peptides in small afferents appears to be downregulated. However,
following L5 SNL, large myelinated Ap-fibres begin to express these neuropeptides (Miki et
al., 1998) and stimulation of Ap-fibres releases SP from primary afferent terminals
(Malcangio et al., 2000). In inflammatory states, SP is thought to contribute to allodynic-
like responses (Ma and Woolf, 1997), therefore this release may be involved in the
generation of a central hyperexcitable state (Woolf and Mannion, 1999). Furthermore,
following injury Ap-fibres express BDNF (Michael et al., 1999;Zhou et al., 1999), which has
also been shown to modulate dorsal horn excitability, playing a significant role in
inflammation-induced hyperalgesia (Akopian et al., 1999;Mannion et al., 1999). Therefore, it
is feasible that injury-induced phenotype changes in these fast conducting myelinated fibres
render them capable of sensitising the CNS.
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1.13.4 Spinal pathways in neuropathic pain
Although changes in local inhibitory spinal activity, such as the loss of spinal activity of
GABA, have been shown to contribute to spinal nerve ligation-induced allodvnia and
hyperalgesia which is reversed by exogenous administration of GABA agonists (Malan et
al., 2002), it is likely that tactile allodynia and thermal hyperalgesia involve separate spinal
pathways. Complete and partial spinal cord lesions block allodynia, but not hyperalgesia,
after SNL (Ossipov et al., 2000;Sun et al., 2001). Furthermore, lidocaine microinjected into
dorsal column nuclei block only tactile allodynia (Sun et al., 2001). Therefore, tactile
allodynia after peripheral nerve injury may be more dependent upon inputs to supraspinal
sites whereas, thermal hyperalgesia is likely mediated predominantly through local spinal
circuitry (Ossipov et al., 2000). This indicates that the interpretation that tactile allodynia
following peripheral nerve injury is transmitted to the central nervous system by means of
large diameter, myelinated fibres, which run on the ascending tracts further supporting the
role for myelinated fibres in the transmission of neuropathic pain phenomena.
Abnormal activity in descending somatosensory pathways may also represent a mechanism
of chronic pain (Kovelowski et al., 2000). For example loss of specific RVM cells, which
project to spinal loci to inhibit or facilitate pain transmission, both prevents and reverses
experimental neuropathic pain respectively (Porreca et al.. 2001).
1.13.5 Opioids in neuropathic pain
A role for opioid peptides in the maintenance of persistent pain is supported by many clinical
case reports which suggest that sustained opioid exposure can elicit unexpected, paradoxical
pain and by the fact that subcutaneous delivery of morphine in the rat induces tactile
allodynia and thermal hyperalgesia (i.e. 'opioid-induced pain') (Vanderah et al., 2001). Such
opioid-induced pain may occur via interactions of descending pathways such as via tonic
activation of bulbospinal facilitation from the RVM (Vanderah et al., 2001) or via local
spinal opioid release. For example, abnormal, spontaneous afferent drive may also activate
spinal dynorphin (Tang et al., 2000) which may play a role in the induction of abnormal pain
states. Studies in prodynorphin knock-out mice suggest an early, dynorphin-independent
phase of neuropathic pain followed by a later dynorphin-dependent stage (Wang et al.,
2001). Correspondingly, antiserum to dynorplun given spinally blocks thermal hyperalgesia,
after SNL, and also restores diminished morphine antinociception (Vanderah et al., 2000).
This suggests that spinal dynorphin promotes abnormal pain and acts to reduce the
antinociceptive efficacy of spinal opioids (i.e. tolerance). The data also identify a possible
mechanism for previously unexplained clinical observations of the actions of administered
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opioids and offer a novel approach for the development of strategies that could improve the
long-term use of opioids for pain which have so far produced controversial results, especially
in the treatment of neuropathic pain (Rowbotham, 2001).
1.14 Additional Factors that may Contribute to the Development of Neuropathic Pain
1.14.1 Neurotrophic factors: friend or foe?
Neurotrophic factors are molecules that promote survival, growth and maintenance of
discrete populations of neurons. Some of these factors, such as the neurotrophins. are
absolutely essential for normal neuronal development. The neurotrophin family includes
NGF, BDNF, NT-3 and NT-4/5 which support the survival and growth of a distinct group of
sensory neurons (Patel et al., 2000;Snider and Wright, 1996), determined by the specific
expression of their relevant receptors, which include trkA (NGF), trkB (BDNF and NT4/5)
and trkC (NT-3) and the p75 receptor, which is a low affinity receptor capable of binding all
neuroptrophins. The neurotrophins also appear to regulate the development of normal
functional properties of sensory neurons, such as their ability to respond to peripheral stimuli
(Carroll et al., 1998).
A second family of neurotrophic factors important for survival of and normal function in
sensory neurons, are the glial cell line-derived neurotrophic factor (GDNF) family of
secreted proteins. These proteins are structurally related to GDNF and currently include
GDNF, neurturin, artemin and persephin. They have particularly important effects on
primary sensory neurons and all signal through ret, a transmembrane tyrosine kinase which
forms complexes with one of four known binding proteins of the GDNF family receptor
(GFR)al-4 which confers specificity of action of the different GDNF family members.
Due to the expression of the relevant receptors, nociceptive afferents are likely to be
sensitive to either NGF of GDNF, whilst large diameter mechanosensitive afferents are
likely to be sensitive in particular to NT-3 and GDNF (Boucher and McMahon, 2001).
As discussed above, the nerve damage that precipitates neuropathic pain leads to many
changes in sensory neurons, including alterations in putative neurotransmitters/modulators,
receptors, ion channels, structural proteins and anatomical terminations. The relative
contribution of each of these to neuropathic pain is currently unknown, however,
neurotrophic factors have been shown to prevent several of these axotomy-induced changes
(Bennett et al., 1998;Verge et al., 1995). Experimental evidence has implicated GDNF as
playing a particularly important role as continuous intrathecal infusion with GDNF during
partial sciatic nerve ligation or L5 SNL prevents the development of pam-associated
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behaviours with no effect of NGF or NT-3 infusion (Bennett et al., 2000). Furthermore,
following L5 SNL, spontaneous activity arising almost exclusively in myelinated afferents in
the period of development and establishment of the neuropathic pain state (two weeks), is
reduced following GDNF treatment (Bennett et al., 2000). In line with this, GDNF treatment
reverses changes in Na+ channel expression such that expression of type III/Nav1.3 is
completely suppressed paralleled by partial rescue of expression levels of SNS 1/Nav1.8 and
SNS 2/Nav1.9 (Bennett et al., 2000). This suggests that perhaps a decrease in production of
GDNF following nerve damage could contribute to the development of such
hyperexcitability leading to central sensitisation and that increasing the local supply of
GDNF may help to minimise the neuropathic pain.
However, the upregulation of various other neurotrophic factors following nerve injury may
contribute to changes underlying increased excitability, enhancing the development of a
neuropathic pain state. For example, synthesis of the leukemia inhibitory factor neurotrophic
factor (LIF), is increased in lesioned peripheral nerves and has been shown to increase the
expression ofgalanin in axotomized DRG neurons (Ozturk and Tonge, 2001). BDNF, which
modulates dorsal horn excitability, playing a significant role in inflammation-induced
hyperalgesia, has also been shown to increase in the uninjured L4 DRG neurons following
SNL (Fukuoka et al., 2001) and in Ap afferents following nerve injury (Michael et al., 1999)
(Akopian et al., 1999;Mannion et al., 1999). NGF has also been shown to increase after SNL
and evidence supports a role for both BDNF and NGF in the development of thermal
hyperalgesia (Fukuoka et al., 2001). However, evidence also suggests that the reduction in
levels of target-derived NGF in sympathetic and sensory neurons after axotomv is partly
responsible for the subsequent changes in neuropeptide expression associated with nerve
injury such as the decrease in SP and CGRP and upregulation of galanin and VIP (Shadiack
et al., 2001). These apparently conflicting data suggest that a precise balance of neurotrophic
factors is required for normal function in the nervous system. Therefore, dynamic alterations
in the expression and content of BDNF, NGF and LIF in the injured and uninjured DRG
neurons might be involved in the pathomechanisms of neuropathic pain.
The effects of growth factors in persistent pain states will be discussed further in relation to
Schwann cell changes in Section C.
1.14.2 The sympathetic nervous system
There is little evidence for electrical communication between postganglionic sympathetic
neurons and primary afferent neurons in the normal peripheral nervous system. However, in
many cases of clinically severe and intractable neuropathic pain, the symptoms are
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sympathetically maintained. Following nerve injury, such as in the CCI and SNL models of
neuropathic pain, sympathetic axons sprout into the DRG from the injured nerve (Chung and
Chung, 2001) with a time course that parallels the development of behavioural sensitivity
changes (Ramer and Bisby, 1997). This may be an anatomical substrate for the sympathetic
maintenance of pain, which may lead to sensitisation of neurons involved in chronic pain
states (Janig, 1995;Ramer and Bisby, 1997). In support of this, guanethidine sympathectomy
following CCI can reduce the heightened sensitivity, which develops in response to cold and
heat (45°C). However, there is no modulation of any spontaneous activity or of increased
sensitivity to mechanical stimulation (Attal et al., 1990;Perrot et al., 1993) implying that the
sympathetic nervous system may only play a restricted role in the development and
maintenance neuropathic pain. In recent years, there have been various mechanisms
hypothesised to underlie the anatomical nature of nerve injury-induced sympathetic-sensory
coupling. Several studies have been undertaken to determine what factor or factors are
responsible for the sprouting, and for the formation of abnormal sympathetic terminal
arborizations or 'baskets' around some DRG neurons (for review see) (Rarncr et ah, 1999).
The details of such factors are beyond the scope of this study but include roles of NGF,
BDNF (Deng et ah, 2000;Zhang et ah, 1998). and the cytokines; leukemia inhibitory factor
(LIF) (Thompson and Majithia, 1998) and interleukin-6 (IL-6) (Ramer and Bisby, 1998),
which may all be derived from the periphery as a result of Wallerian degeneration. A role of
such factors and satellite cells (Shinder et ah, 1999) within axotomized DRG, has also been
suggested in which LIF or IL-6 may activate satellite cells in the DRG to bind neurotrophins
to surface receptors for NGF which can then act as a sympathetic axon-guiding gradient by
encouraging them to sprout into the DRG (Ramer et ah, 1999).
1.14.3 A possible role of NFkB in neuropathic pain
Nuclear factor kappa B (NFkB) is a sequence-specific DNA binding protein/ transcription
factor, which serves as a transducer between extracellular signals and gene expression.
NFkB is known to exist in an inducible form in a wide range of eukaryotic cells, including
neurons and glia throughout the PNS and CNS (Kaltschmidt et ah, 1993) and is known to be
a crucial signal for glial and neuronal cell function during inflammation injury and neural
plasticity (see review) (O'Neill and Kaltschmidt, 1997). In unstimulated cells, NFkB exists
in a latent form in the cell cytoplasm as a heterodimer most commonly composed of the
subunits p50 and p65, which form a complex with an endogenous inhibitory protein of the
IkB family. Extracellular signals such as cytokines and neurotrophins can activate NFkB via
their receptors on the cell surface, phosphorylating IkB and releasing the bound NFkB,
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thereby allowing translocation of the active form of NFkB to the nucleus. NFkB becomes
able to specifically bind to consensus target sequences leading to the modulation of
expression of the NFicB-regulated array of genes. Immunohistochemical studies have
demonstrated the expression ofNFkB in 30-45% of neurons of all sizes, particularly those of
medium to large diameter, in L4 and L5 ganglia in the rat (Doyle and Flunt, 1997);(Ma and
Bisby, 1998a), suggesting that NFkB is involved in intracellular signalling in sensory
neurons under physiological conditions. Peripheral nerve injuries, especially those with the
involvement of demyelination or Wallerian degeneration, can lead to production of
inflammatory mediators by local Schwann cells and invading macrophages including
cytokines, such as tumour necrosis factor (TNF) (Wagner and Myers, 1996), interleukin-1
(IL-1) (Lindholm et al., 1987) and neurotrophins such as NGF (Herzberg et ah, 1997a).
These factors have all have been shown to activate NFkB in various cell types in the PNS
and CNS (Carter et ah, 1996;Moynagh et ah, 1994;Wood, 1995) and could therefore initiate
the induction of multiple gene expression in DRG and spinal cord cells which may lead to
events involved in the development of chronic pain. There are also various ways in which
NFkB could be activated as a downstream event of cellular changes involved in neuropathic
pain. A role for NMDA and non-NMDA ionotropic glutamate receptors has been
demonstrated in the activation of NFkB in striatal and cerebellar neurons in the mammalian
brain (Guerrini et ah, 1997;Kaltschmidt et ah, 1995;Nakai et ah, 2000) and could therefore
provide a further mechanism for the activation of NFkB in the spinal cord in which the
NMDA receptor is known to play a crucial role in neuropathic pain, as discussed previously
(see 1.13.2). Furthermore, it has been suggested that protein kinases such as PKA (Mosialos
and Gilmore, 1993;Neumann et ah, 1995) and PKCy (Leitges et ah, 2001;Shirakawa and
Mizel, 1989) are capable of activating NFkB both of which have been implicated in
persistent pain states (Cerne et ah, 1993;Malmberg et ah, 1997).
1.15 Clinical Treatments
The treatment of neuropathic pain conditions is currently extremely poor. The effectiveness
of classical analgesics such as the opioids is controversial and have been reported to be
poorly efficacious in many neuropathic circumstances (Bennett, 1994). However, opiods are
currently used to treat many neuropathic conditions in the clinic and produce varying degrees
of analgesia (for review see Rowbotham, 2001). However, they also produce a large number
of detrimental side effects. A number of other recognised medications used in the
management of chronic pain, such as the cyclo-oxygenase-targeting non-steroidal anti-
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inflammatory drugs (NSAIDs) also have a relatively minor and highly variable effect on
neuropathic pain.
The main problem experienced with current pharmacological agents used to combat
neuropathic pain is associated side effects. For example, NMDA receptor antagonists, such
as dextromethorphan or ketamine, initially appeared promising as therapeutic agents,
however, toxicity, low safety margins and psychotropic side effects have limited the use of
such drugs.
Anticonvulsant drugs such as carbamazepine and phenytoin have been investigated for the
treatment of neuropathic pain due to the similarity of some aspects of the neuronal
hyperexcitability with the electrical changes in certain forms of epilepsy (Backonja,
2000;Sindrup and Jensen. 2002). Studies have shown these agents can relieve painfi.il
diabetic neuropathy and paroxysmal attacks in trigeminal neuralgia (Charlton,
1993;McCleane, 1999;Zakrzewska., 1992). Furthermore, lamotrigine, a new anticonvulsant,
probably acting by stabilising a slow inactivated conformation of a Na" channel and
suppressing release of glutamate from presynaptic neurons (McNamara et al., 1996), is also
effective in trigeminal neuralgia (Lunardi et al., 1997;Solaro et al., 2000) as well as painful
peripheral neuropathy, and post-stoke pain (for review see Backonja, 2002). However,
anticonvulsants have adverse effects including sedation and cerebellar symptoms, such as
nystagmus, tremor and un-coordination and less commonly, haematological changes, and
cardiac arrhythmias (Jensen, 2002).
Gabapentin, developed as a structural analogue for the GABA system has also been
extensively studied for the treatment of pain conditions. The exact mechanism of gabapentin
action is unknown as it has no actual effect on GABA receptors (Jensen et al.. 2002;Lanneau
et al., 2001) or any influence on GABA uptake. Several randomised pain studies in humans
with postherpetic neuralgia (PHN) (Rice and Maton, 2001;Rowbotham et al., 1998) and
painfi.il diabetic neuropathy (Backonja, 2000;Morello et al.. 1999) have indicated a potential
for gabapentin in pain relief. Furthermore, a role for gabapentin in pain relief has been
demonstrated when administered intrathecally in animal models of PHN (Takasaki et al.,
2002) and following SNL (Cho et al., 2002). However, due to the difficulties associated
with human studies (varied population size, patient age, and differential diagnoses) the
results have been contradictory with some finding gabapentin to be no more useful than
placebo (Gorson et al., 1999;Hemstreet and Lapointe, 2001). A recent study has suggested a
facilitatory role for gabapentin in the efficacy of morphine in reducing signs of neuropathic
pain following SNL (Matthews and Dickenson, 2002) suggesting that perhaps combined
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regimes of drug therapy are likely to be a lot more efficacious. However, as with many other
tried and tested drugs for pain relief, gabapentin does produce side effects such as dizziness,
headache, peripheral oedema and sedation (Bosnjak et al., 2002;Rowbotham et al., 1998) and
therefore, is still not the ideal drug therapy.
1.15.1 An endogenous analgesia target: the cannabinoid system
As mentioned previously, the endogenous cannabinoid system has received much attention
of late due to its capacity to exert selective antinociceptive effects in both neuropathic and
inflammatory hyperalgesia (Fox et al., 2001;Herzberg et al., 1997;Richardson et al., 1998b).
Camiabinoids may exert beneficial analgesic effects in demyelinating diseases, such as
multiple sclerosis (Consroe et al., 1997;Robson, 2001) and are currently under assessment as
clinical therapeutic agents for this disorder (Robson, 2001). There is considerable evidence
supporting a role for cannabinoids in the modulation of nociception and they have been
shown to be effective in reversing hyperalgesia and touch evoked pain behaviour in animal
models of inflammatory (Martin et al., 1999;Richardson et al., 1998a) and neuropathic pain
(Bridges et al., 2001;Fox et al., 2001;Herzberg et al., 1997;Kim and Chung 1992). The
majority of these effects appear to be mediated by the CBi cannabinoid receptors
(Richardson et al., 1998c). However, a possible role of the CB2 receptors as targets for the
treatment of chronic pain conditions has recently been indicated (Malan, Jr. et al., 2001) and
due to the peripheral location of these receptors, such treatment may avoid CNS
complications associated with CBi receptor targeting.
The discovery of the involvement of the 'endogenous cannabinoid system' in relieving pain
phenomena associated with chronic pain disorders, has led to the development of selective
CB, and CB2 receptor ligands, which may represent a valuable alternative strategy for the
relief of chronic pain. However, the search for adequate analgesics to treat all types of
neuropathic pain continues.
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1.16. Peripheral Nerve Myelin
The myelin sheath is a multilamellar structure with a high lipid to protein ratio (80:20) which
serves as an insulator of nerve fibres, reducing current flow across the internodal axonal
membrane and permitting saltatory conduction of nerve impulses at the nodes (Scherer,
1999). Myelin is present in the CNS where it is produced by oligodendrocytes and in the
PNS, where it is produced by Schwann cells. For the purpose of this study, only the latter
will be considered.
1.16.1 Peripheral nerve myelination
The Schwann cell is the major glial cell of the vertebrate PNS, where it not only myelinates
nerve fibres promoting rapid nerve impulse transmission but also has significant secondary
roles providing trophic support for spinal motoneurons and DRG neurons (Riethmacher et
al., 1997) and in promoting nerve regeneration in the PNS (Bunge, 1993;Zhang et al., 2002).
During the development of the PNS, Schwann cell precursors arise from the neural crest,
migrate and contact peripheral axons. These 'immature' Schwann cells invade and ensheath
bundles of developing axons, at which stage they further differentiate into myelinating or
non-myelinating Schwann cells (Webster, 1993). During this time, some Schwann cells
establish a one-to-one association with an axon (promyelination stage), which is necessary
for myelination to proceed. The thickness of the myelin sheath (Aguayo et al., 1977;Yin et
al., 1998) appears to be directly related to the axon (Friede and Miyagishi, 1972) such that
large diameter axons possess thicker myelin sheaths and thus a greater number of membrane
turns of the sheath, implying that axons may regulate the action of Schwann cells and
influence the process of myelination (Bunge et al., 1986).
To myelinate the axon, cytoplasm-filled processes extending from the myelinating Schwann
cell align along and rotate around axons forming the internodal segments of the myelin
sheath. These segments are divided by the nodes of Ranvier, which are relatively small (<1
pm in length), regularly spaced, unmyelinated regions of the axon (Morell et al., 1994). The
myelin sheath can be divided into two domains; compact myelin, which forms the bulk of
the myelin sheath and non-compact myelin (see Figure 2.1). Compact myelin is formed as
the cytoplasm of the Schwann cell process is extruded, bringing adjacent cytoplasmic and
extracellular membrane surfaces into apposition, resulting in the formation of a mature,
compact myelin sheath. This sheath is largely composed of lipids, mainly cholesterol and
sphingolipids (Arroyo and Scherer, 2000), but also contains a unique set of proteins
including protein zero (P0), myelin basic protein (MBP) and peripheral myelin protein-22
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kDa (PMP22) (Lemke, 1992;Lemke, 1993) which appear to be essential for normal
myelination (see Figure 2.1). Non-compact myelin is found at the nodes of Ranvier and in
Schmidt-Lanternman incisures, which form cytoplasmic channels through the myelin sheath
(see Figure 2.2).
Adjacent to the node is the paranodal region at which the lateral edge of the compact myelin
opens along the major dense line (MDL) -forming cytoplasm-filled lateral loops (paranodal
loops), which spirals round the axon, forming the axo-glial junction (Ichimura and Ellisman,
1991). Here, structures known as transverse bands span the periaxonal space, apparently
attaching the glial cell membrane to the axolemma allowing a close axo-glial association




























Figure 2.1. A) The organisation of the myelinated axon. An 'unrolled' Scwann cell,
revealing the regions that form compact and non-compact myelin. The nodal, paranodal and
juxtaparanodal regions are coloured red, green and blue respectively. B) The proteins of





Figure 2.2. Schematic depiction of the node, paranode and juxtaparanode in the PNS
myelin sheath. Na+ channels are clustered in the nodal area, whereas K+ channels
accumulate at the juxtraparanodal region. This distribution allows saltatory conduction of
action potentials to occur (Arroyo and Scherer, 2002).
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1.17 The Role of Peripheral Myelination in Primary Afferent Function
1.17.1 Axon-glial iteractions
There are many ways in which the axon is thought to directly influence the process of
myelination by interactions with the Schwann cell and myelin sheath. For example,
Schwann cell proliferation and differentiation into ensheathing or myelinating type (Poduslo
and Jang, 1984;Weinberg and Spencer, 1975), determination of myelin segment length,
myelin thickness and basal lamina production (Bunge et al., 1986) are all important aspects
of Schwann cell function known to be directly dependent upon axonal contact. Once
completed, the maintenance of myelination depends on continued Schwann cell-axon
interactions (Kamholz et ah, 2000) as does the integrity, function and survival of the both
myelinated and unmyelinated axons (Haney et ah, 1999). It is this relationship, which is of
particular interest to this study.
It is only in recent years that some of the molecules involved in the mediation of axonal-glial
interactions have been identified. For example, myelin-associated glycoprotein (MAG), a
member of the immunoglobulin gene super-family of cell adhesion molecules, and myelin
galactolipids are both glial components implicated in mediating axo-glial interactions during
the myelination process (Salzer et ah, 1990), supported by various mutant mouse studies
(Bosio et ah, 1996;Coetzee et ah, 1996;Dupree et ah, 1998;Marcus et ah, 2002). Various
other molecules, such as ankyrinG, neurofascin 155, Casprl and Caspr2, have recently been
localised to the nodal and paranodal region, implicating them in axon-glial interactions
especially in the regulation of ion channel localisation. The details of such proteins are
beyond the scope of this study, however, a brief summary of their role in axo-glial
interactions will be summarised below.
Voltage-gated sodium channel localisation
Myelinated nerves of the PNS express high-density clusters of voltage-gated Na+ channels
(1000's per pm2) at the node, where their focal positioning allows for rapid, saltatory
propagation of the action potential (Salzer, 1997). The nodal localisation of these channels
is thought to be dependent on myelination (Dugandzija-Novakovic et al., 1995;Novakovic et
al., 1996).
In the CNS and PNS, nodal microvilli contain molecules such as F-actin and cell adhesion
molecules (CAMs), which may form complexes with axonal proteins to govern the
clustering of voltage-gated Na+ channels at the node. AnkyrinG. located in the axolemma, is
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known to interact with voltage-gated Na+ channels, anchoring them to the nodal cytoskeleton
(Davis et ah. 1993; Kordeli et ah, 1990). Also localised to the paranodal axolemma is the
intrinsic membrane glycoprotein, contactin-associated protein (Casprl), also known as
paranodin (Dupree et ah, 1999;Einheber et ah, 1997;Peles et ah, 1997). Casprl can bind to
the actin cytoskeleton, indicating it may play a role in assembling signalling pathways within
the axon (Arroyo and Scherer, 2000). In the Schwann cell paranodal glial loops, Neurofascin
155 interacts with contactin and Casprl/paranodin to form septate-like junctions (Charles et
ah, 2002). As clusters of these proteins appear before ankyrinc, and Na+ channel clusters at
the node in the development of the PNS (Lambert et ah, 1997), it would seem likely that they
may play a role in the mediation of their nodal localisation which is thought to be intricately
related to the structure of the overlying myelin sheath (Arroyo and Scherer, 2000).
Voltage-gated potassium channel localisation
The Shaker-related potassium channels; Kvl.l, Kv1.2 and their associated P>2 subunit, are
concentrated in the region on the internodal side of the paranode; the juxtaparanode
(Rasband et ah, 1998;Vabnick and Shrager, 1998). These channels have been shown to
contribute to rapid axonal membrane repolarisation during development (Vabnick et ah,
1999) and are therefore thought to have an important physiological function in dampening
the excitability of myelinated fibres, preventing repetitive firing due to re-excitation of
myelinated fibres (Chiu et ah, 1999;Zhou et ah, 1998). The juxtaparanodal axonal membrane
contains a second member of the Caspr family of proteins, Caspr2 with which KV1.1, KV1.2
are precisely colocalised (Menichella et ah, 2001;Poliak et ah, 1999). Therefore, it would
appear that the Caspr family members differentiate myelinated axons distinct functional
subdomains.
Therefore, an important symbiotic relationship exists between the myelin sheath and the
axon, ensuring the restricted localisation of specific proteins that are essential for co¬
ordinated and controlled activity in the peripheral nerve axon and therefore the normal
function of the peripheral nerves.
However, when this crucial relationship is disrupted (such as in peripheral nerve
demyelinating disorders, which involve areas of damaged or dysfunctional myelin sheath,
leading to demyelinated segments), abnormalities can develop which can lead to a
dysfunctional neural function.
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1.18. Peripheral Nerve Demyelination and Neuropathic Pain
Abnormal sensory phenomena including spontaneous pain, hyperalgesia and allodynia may
be associated with human demyelinating neuropathies such as Multiple Sclerosis (MS),
Charcot-Marie-Tooth types I and 4 (CMT1 & CMT4) and Guillain-Barre Syndrome (GBS)
(see 1.22). MS is a chronic autoimmune demyelinating disease of the CNS (Pender, 2000),
which involves central pain in approximately two-thirds of patients at some time during the
course of their disease (Moulin, 1998;Nurmikko, 2000), the further discussion of which is
beyond the scope of this study. CMT 1 is a slowly progressive, autosomal dominant,
peripheral nerve demyelinating disorder characterised by diffuse muscle weakness and
severe motor deficit as well as sensory deficits which, although usually less severe, may
include pain (Carter et al., 1998). Similarly, GBS, often regarded as a predominantly motor
neuropathy with fewer sensory features, can also have painful symptoms (Asbury, 1990).
The next section will discuss possible mechanisms occurring following demyelination of the
peripheral nerve that may lead to the development of neuropathic pain.
1.19 Proposed Mechanisms of Neuropathic Pain Following Demyelination
It is likely that pain and excessive sensitivity to touch in diseases characterised by segmental
demyelination (particularly where there is no evidence for axonopathic changes) originate
due to the presence of ectopic repetitive firing (Rasminsky, 1981 ;Tal and Eliav, 1996).
Demyelinated segments can serve as foci for spontaneous multiple action potential
generation (Baker and Bostock, 1992;Smith and McDonald, 1980) and the fact that there is
good evidence that tactile allodynia is mediated by myelinated A-fibres (Bennett et al.,
1998;Coggeshall et al., 1997) suggests that demyelination of A-fibres could lead directly to
such abnormal phenomena. Nevertheless, the origin of tactile allodynia and neuropathic pain
in human demyelinating disorders is still poorly understood (Carter et al., 1998;Rasminsky,
1981).
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1.20 Changes to The Nerve Following Demyelination
1.20.1 Membrane remodelling
Demyelination of axons may initially result in partial or complete conduction block,
decreasing or abolishing the capacity of the nerve to transmit action potentials to and from
the CNS. This is thought to account for the negative sensory symptoms experienced, such as
motor dysfunction and sensory loss (Rasminsky, 1981). However, secondary reorganisation
of membrane electrical properties involving reorganisation of ion channels to allow action
potential generation across the demyelinated region may occur to overcome this conduction
block.
Voltage-gated Na+ channels
Following peripheral nerve demyelination, Na+ channel clusters lose their normal nodal
localisation and appear throughout the internodal segments of demyelinated axons. It
appears that that these channels are being newly recruited to these locations (England et al.,
1990;Novakovic et al., 1996) and are not simply uncovered or relocated from the node
(England et al., 1991). This would imply an increase in their synthesis within the cell body
with subsequent transport down the axon to these new locations. Although this change in
location is primarily a response of the nerve to recover conduction, areas of ectopic impulse
generation are likely to form, leading to hyperexcitability in the demyelinated nerve.
Voltage-gated if channels
Demyelination of the peripheral nerve also results in the delocalisation of K+ channels to
both nodal and paranodal regions (Rasband et al., 1998). Therefore, it is likely that their





The molecular abnormalities underlying heritable demyelinating neuropathies are generally
intrinsic to proteins expressed by Schwann cells. However, most clinical manifestations are
likely to result from changes in the properties of the axon (Griffin and Sheikh, 1999).
Therefore, interactions between Schwann cells and axons appear to be crucial for the normal
functioning of axons. A number of studies indicate that such Schwann cell-axonal
interactions are disrupted in peripheral demyelinating neuropathies, such as CMT 1, causing
significant changes to the nerve (Kamholz et al.. 2000). Various studies utilising mouse
models of PNS hypomyelination, have also demonstrated significant changes in axonal
structure and function following disruption of the myelin sheath including decreased
neurofilament and microtubule protein phosphorylation (de Waegh et al., 1992;Kirkpatrick
and Brady, 1994) with resulting increased neurofilament density (de Waegh et al., 1992) and
decreased axonal transport (de Waegh and Brady, 1990). These results indicate that the
presence of a myelinated internode has important effects on the neurofilamentous
cytoskeleton. Similar changes have been found in patients with CMT 1 (Watson et al., 1994)
and grafting experiments show that this change is induced by abnormal Schwann cell contact
(Aguayo et al., 1977). Furthermore, it is thought that the same principles of Schwann cell-
axon contact may apply to the CNS (Brady et al., 1999), resulting in similar axonal changes
in MS, which in later stages displays axonal interruption in areas of demyelination (Griffin
and Sheikh, 1999). Unfortunately, as yet, the nature of the glial cell-derived signal
influencing neurofilament phosphorylation, packing density, and axonal transport is not
known.
Changes to the cytoskeleton of axons may have consequences significant for the
development of neuropathic pain states. For example, targeting of axonal proteins such as
voltage-gated ion channels (Brady, 1993;de Waegh et al., 1992) to their correct location may
be dependent on an intact cytoskeleton. Furthermore, neurotrophic factors such as NGF
often reach the afferent cell bodies in the DRG via retrograde axonal transport from
peripheral target tissues which, when disrupted, as occurs following axonal damage, is
thought to play a role in the changing expression of neuropeptides in the DRG such as VIP
and NPY(McMahon and Priestley, 1995) (Verge et al., 1995). It seems plausible that
changes in axonal transport due to demyelination may have similar effects.
48
1.21.2 Schwann cell-derived neurotrophic factors
Following injury to the peripheral nerve, Schwann cells often assist the axonal regeneration
and restoration of function by secreting various factors, including neurotrophic factors
(Ramer et al., 1999), in a manner often mimicking development. Flowever, many of these
factors may have additional negative functional consequences when upregulated and may
contribute to mechanisms involved in the production of pain, such as influencing the
phenotype of DRG neurons (Jongsma et al., 2001;McMahon and Priestley, 1995), sprouting
of sympathetic afferents into the DRG (Ramer et al., 1999) and sprouting of regenerating
afferent axons in to abnormal locations or neuromas (Kryger et al., 2001). Furthermore, any
undamaged afferents are subsequently exposed to abnormal levels of neurotrophic factors,
which may influence their function.
Neurotrophic factors produced by Schwann cells following injury include NGF (Taniuchi et
al., 1988), GDNF (Bennett et al., 1999;Hoke et al., 2002). BDNF (Boyd and Gordon. 2002)
and basic fibroblast growth factor (bFGF) (Grothc and Nikkhah. 2001).
GDNF is thought to play a protective role, thereby reducing symptoms of neuropathic pain
(Bennett et al., 2000) and promoting axonal regeneration (Chen et al., 2001).
Correspondingly, GDNF expression is rapidly upregulated in Schwann cells as early as 48 h
after denervation of rat sciatic nerves (Hoke et al., 2002) however, levels decline a week
after denervation, when pain behaviours are developing significantly. Therefore, a decrease
or failure to maintain the upregulated expression of GDNF could contribute to the
development of neuropathic pain.
Axotomy of sciatic nerve fibres in adult rats also induces expression of NGF receptors in the
entire population of Schwann cells located distal to the injury (Taniuchi et al.. 1988). The
expression of Schwann cell NGF receptors is negatively regulated by axonal contact, being
induced when axons degenerate and suppressed when axons regenerate. It is likely that NGF
receptors bind NGF molecules upon the Schwann cell surface providing a substratum laden
with trophic support and chemotactic guidance for regenerating neurons. However, altered
input of NGF may cause phenotypic changes which may lead to induction of pain states
(Jongsma et al., 2001;McMahon and Priestley, 1995) and has been associated with axon
sprouting and neuroma formation (Kryger et al., 2001) (see 1.14.1).
In the DRG, molecules such as bFGF show a mainly neuronal expression, whereas following
nerve injury, Schwann cells and invading macrophages have been shown to become the main
cellular sources of bFGF with increasing levels of expression within a few hours of injury
(Grothe et al., 2000;Scarlato et al., 2001). bFGF mediates rescuing effects on injured
sensory neurons and supports neurite outgrowth of transected nerves (for review see)
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(Grothe and Nikkhah, 2001) and therefore over-expression may lead to axonal sprouting, a
mechanism implicated in abnormal pain phenomena (see 1.13.3). Additionally, BDNF, up-
regulated in denervated Schwann cells following chronic axotomy, has been shown to inhibit
axonal regeneration (Boyd and Gordon, 2002) and has previously been implicated in the
induction of hyperalgesia (Miletic and Miletic, 2002;Ramer et ah, 1999) therefore, increased
release from Schwann cells may enhance such actions.
Together with changes in expression in neurons (see 1.14.1), neurotrophic factors produced
by Schwann cells in response to nerve injury and associated demyelination seems likely to
play a significant role in mechanisms leading to the development of persistent pain states.
1,22 Human Peripheral Demyelinating Disorders
1.22.1 Charcot-Marie-Tooth (CMT) disease
Charcot-Mane-Tooth (CMT) is one of the most common degenerative neurological disorders
with a prevalence of 1 in 2500 (Skre, 1974). It is an hereditary motor and sensory
neuropathy (HMSN) disease comprising a heterogeneous group of inherited peripheral
neuropathies (Kamholz et ah, 2000), the inheritance of which can be autosomal dominant,
autosomal recessive (ARCMT) or X-linked. There are several different forms of HMSN. of
which Type I (demyelinating form), Type II (neuronal form), Type IV (autosomal recessive
demyelinating form) and the X-linked CMTX represent the CMT syndrome.
CMT Type 1
CMT 1, the most common form of CMT (Young and Suter, 2001) and the most common
autosomal dominant neuropathy (Lynch and Chance, 1997), is associated with peripheral
demyelination and is caused by mutations in one of several Schwann cell genes. CMT 1 is
characterised by markedly reduced conduction velocities in peripheral sensory and motor
nerves, segmental demyelination and Schwann cell hypertrophy with onion bulb formation
in peripheral nerves (Calore et ah, 1994).
There are at least three forms of CMT 1 based on their molecular genetics. The majority of
CMT 1 patients, designated CMT 1A, have a duplication in the gene encoding the major
PNS myelin proteins peripheral myelin protein 22 (PMP22) (Chance et ah, 1993;Chance and
Pleasure, 1993). CMT IB is less common and is caused by mutations in the gene encoding
the major myelin structural protein zero (P0) (Hayasaka et ah, 1993;Kulkens et ah, 1993).
Several other gene mutations have also been associated with less common forms of CMT1
(Warner et ah, 1998).
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These mutations disrupt myelination and Schwann cell function in a number of ways
producing a wide variety of clinical phenotypes. They may also produce secondary axonal
damage, a major cause of weakness in CMT 1 (Kamholz et al., 2000).
Neuropathic pain is reportedly a significant problem for many CMT patients and impairment
of nerve function in CMT1 is thought to be mediated mainly by changes in myelinated axons
(Ericson and Borg, 1999).
CMTX
CMTX is associated with mutations in the gene for the gap junction protein, connexin-32,
(Anzini et al., 1997) and is characterised by late onset peripheral demyelination.
CMT type 2
CMT 2, in which axonal neuropathy predominates, is often a less severe disease than CMT1
exhibiting axon loss and resultant Wallerian degeneration. Although motor and sensory
action potential amplitudes are diminished, relatively normal conduction velocities remain
(Carter et al., 1998), suggesting myelinated fibres are mildly affected and that nerve function
impairment due to axonal damage to unmyelinated fibres dominates. Pain is not generally
reported to be associated with CMT2 (Ericson and Borg, 1999), however, reports of
incidence and severity differ and the fact that CMT1 and CMT2 are often clinically hard to
distinguish makes the distinction between sensory problems associated with particular
pathologies difficult to determine (Carter et al., 1998).
CMT type 4
CMT4. the autosomal recessive form of demyelinating CMT is also caused by mutations in
various genes encoding myelin proteins, many of which are yet unidentified, but are known
to include P0 and PMP-22. More recently and of particular interest to this study is the
discovery of a mutation in the human Periaxin gene, PRX, underlying CMT in a large
consanguineous Lebanese family (Guilbot et al., 2001). The PRX gene encodes L- and S-
periaxin, which are proteins of myelinating Schwann cells and will be dealt with in more
detail below (see 1.23.6). This mutation leads to an autosomal recessive demyelinating form
of CMT, named CMT4F. Histopathological and immunohistochemical analysis of the sural
nerve reveals supernumerary Schwann cells surrounding thinly myelinated or naked axons
forming so-called 'onion bulb' structures and hypermyelinated regions of nerve. This
morphology is very similar to the peripheral nerves in the mutant Prx-null mouse (Gillespie
et al., 2000) which will be discussed further below (see 1.24). Of interest to this study is the
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fact that patients with CMT4F display a variety of distal abnormalities including pain in both
upper and lower extremities (Delague et al., 2000).
1.22.2 Guillain-Barre Syndrome (GBS)
GBS, or acute inflammatory polyneuropathy, is often regarded as being a predominantly
motor neuropathy with few sensory features. However, pain is a common symptom
(Asbury, 1990) with the incidence ranging from 54%-84%. Pathologically, there is
inflammation of the peripheral nerve and spinal nerve root with lymphocytic and
macrophage infiltration and demyelination (Moulin, 1998). Various types of pain are
described in GBS patients, with dysaesthetic extremity pain, especially of the legs being
common during the course of the illness and persisting indefinitely in 5-10% of patients
(Moulin et al., 1997). It is thought that neuropathic pain of this type may be due to ectopic
impulse formation at sites of demyelination, as well as axonal degeneration and regeneration
along the peripheral nerve (Devor and Seltzer, 1999).
It has been generally argued that pain associated with demyelinating conditions results from
axonal damage. The consequences of the lack of myelin alone have been largely ignored.
However, demyelination is the common symptom of all these disorders, only some of which
have been described above, and axonal pathology has not always been determined.
Furthermore, animal models of neuropathic pain such as CCI, result in massive
demyelination of the injured nerve, implying that this process may have an important role in
the resulting chronic pain.
Therefore, it is of interest to investigate the mechanisms that underpin the production of
neuropathic pain associated with demyelination of peripheral nerves. This may be achieved
by utilising mouse models with mutations in various myelin genes, as well as experimental
models of demyelination.
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1.23 Mutant Mouse Models of Peripheral Demyelination
Several demyelinating neuropathies of genetic origin have now been modelled in mice by
inactivating genes expressed in myelinating Schwann cells (Anzini et al., 1997;Suter and
Snipes, 1995). Such animals are not only valuable for examining the biological function of
the proteins encoded by these genes, but they also provide an opportunity to study the
pathophysiology of the disease.
1.23.1 Protein zero (PO)
PO is a myelin structural protein and the main adhesive molecule of peripheral myelin
(Arroyo and Scherer, 2000), and is thought to be primarily concerned with myelin
compaction (D'Urso et al., 1990;Giese et al., 1992). Mice deficient in PO have changes in
their peripheral myelin such as severe hypomyelination and decompaction of myelin
followed by degeneration and onion bulb formation, which resemble some inherited human
neuropathies, such as CMT IB (Adlkofer et al., 1995;Giese et al., 1992).
1.23.2 Peripheral myelin protein 22 kDa (PMP22)
Axonal contact with a Schwann cell activates the insertion of PMP22 protein into the myelin
membrane (Kamholz et al.. 1999). Although less abundant than PO, its level of expression in
compact myelin is critical (Murakami et al., 1996;Snipes and Suter, 1995). Due to the
identification of the genetic mutations underlying the majority of CMT 1 cases, several
transgenic mouse models have been based upon the alteration of expression of the PMP22
gene. The mutant mice, trembler (Tr) and trembler-j (Tr-j), are dominant natural mouse
mutants with point mutations in one of the two PMP22 genes, leading to classic signs of a
demyelinating neuropathy (Adlkofer et al., 1995), including thinly myelinated axons,
aberrant Schwann cell proliferation, onion bulb structure formation and abnormal Schwann
cell-axon interactions (Robertson et al., 1997). Further transgenic mouse models with
similar phenotypes have been created with an increased PMP22 gene dosage, mimicking the
intrachromosomal duplication containing the PMP22 gene in human CMT 1A (Suter and
Klaus-Armin, 1999).
1.23.5 Connexin 32
X-linked CMT disease is the second most common known cause of hereditary neuropathy
(Scherer et al., 1998) and is caused by mutations in the gene for the gap junction protein
connexin-32 (Cx-32). This protein is expressed in peripheral nerve and is present in
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noncompact myelin in which it is likely to form channels. Cx-32 'knock-out' mice and
transgenic mice expressing mutant Cx-32, develop a late onset demvelinating neuropathy
similar to that observed in patients with CMTX (Anzini et ah, 1997;Scherer et al., 1998),
although specific pathology depends upon the nature of the mutation.
1.23.6 Periaxin
L-periaxin and the Prx-rm 11 mouse model of peripheral nerve demyelination have formed the
basis for this study and therefore will be reviewed in more detail than the previously
mentioned transgenic models.
L-Periaxin is a protein ofmyelinating Schwann cells thought to play a role in the later stages
ofmyelination (Gillespie et ah, 1994). The murine Periaxin (Prx) gene encodes two proteins
with PDZ domains, L-periaxin (147 kDa) and S-periaxin (16 kDa) (Dytrych et ah, 1998). L-
periaxin is localised to the plasma membrane and S- periaxin to the cytoplasm. Both contain
a single PDZ domain, typically present in proteins that interact with the cytoplasmic tail of
plasma membrane proteins and with the cortical cytoskeleton suggesting that L-periaxin
might be implicated in signal transduction pathways. During development and regeneration
of the peripheral myelinated nerve, L-periaxin is predominantly localised to the adaxonal
surface of Schwann cells, which apposes the axon. However, as the myelin sheath matures,
L-periaxin becomes concentrated in the abaxonal plasma membrane, which apposes the
basal lamina (Scherer et ah, 1995). This translocation of L-periaxin to a predominantly
abaxonal location is a feature of the maturation of the sheath and its expression coincides
with the early events in the establishment of axo-glial contact (Dytrych et ah, 1998;Scherer
et ah, 1995), suggesting that L-periaxin might participate in the recruitment of proteins to a
cortical structure involved in transmembrane signalling (Dytrych et ah, 1998;Scherer et ah,
1995).
A role for L-periaxin in transmembrane signalling has been recently been supported by
evidence for its interaction with dystrophin-related protein 2 (DRP2) which forms part of a
dystroglycan-DRP2 complex at the surface of myelin-forming Schwann cells (Sherman et
ah, 2001). Such complexes in the PNS are believed to have structural and signalling
functions (Bunge et ah, 1986;Eldridge et ah, 1989) and in the absence of L-periaxin. DRP2
is mislocalized and depleted, supporting a role for L-periaxin in associations with the
cytoplasmic domains of plasma membrane proteins involved in adhesion. Once the mature
myelin sheath is established, the amount of periaxin protein declines (Gillespie et ah, 1994),
suggesting that periaxin plays a role in ensheathment and spiralisation of Schwann cell
myelin and is less involved in the maintenance of myelin in mature nerves.
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1.24 The Periaxin-Deficient Mouse
A mutant mouse model has been characterised in which expression of the gene encoding
periaxin has been prevented due to the deletion of exon 6 and part of exon 7 of the Prx gene
(Gillespie et al.. 2000). It has been demonstrated that the Schwann cells of mutant mice
lacking the functional Prx gene initially ensheath and myelinate peripheral nerve axons in an
apparently normal manner. However, this sheath later destabilises, resulting in the
development of a severe demyelinating neuropathy (Gillespie et al., 2000). Animal models
of CMTX are similar to the Prx-null mouse in that they myelinate normally and show a late
onset pattern of demyelination with attempts to remyelinat. However, in contrast to the Prx-
null mouse the CMTX mouse model displays mild deficits in nerve conduction and nerve
fibres, such as in the saphenous nerve then show little evidence of demyelination (Anzini et
al., 1997).
At 6 weeks of age, the sciatic nerves of Prx-null {Prx''') mice are affected relatively mildly
(Gillespie et al., 2000) compared to mice with mutations in the genes encoding P0 or
PMP22, which display widespread derangements to the Schwann cell-axon unit from a much
earlier age (Adlkofer et al., 1995;Giese et al., 1992). Furthermore, levels of major myelin
proteins including MAG, P0 and MBP are normal in the Prx''' sciatic nerve at 6 weeks
however; there is evidence of focal thickenings (tomacula) and infoldings of internodal
myelin (see Figure 1.3b). By 6 months of age, the sensory, motor and autonomic nerves of
the Prx" show extensive segmental demyelination with profound disruption of axonal
ensheathment and deranged Schmidt-Lanternman incisures. In contrast, mice heterozygous
for the mutant allele of P0 or PMP22 show a propensity for sparing sensory versus motor
nerves (Adlkofer et al., 1995). By 6-8 months, naked or thinly myelinated fibres are
common in the Prx'' sciatic nerve. These axons are often surrounded by redundant basal
laminas and supernumerary Schwann cells, which form onion bulb structures, diagnostic of
attempts to remyelinate fibres (see Figure 1.3a,b). There is little evidence for macrophage
infiltrations indicating that this is not an inflammatory-mediated process. Importantly, there
is no evidence for axonal degeneration or cell loss in the DRG of the TVx-null mouse at 6
weeks of age (Gillespie et al., 2000). As a result, this study has used the Prx-null mouse as a
model in which to study neuropathic pain associated with peripheral demyelination.
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1.25 The /Vx-Null Mouse as a Model for Neuropathic Pain in Peripheral Demyelination
The homozygous Prx-null mouse is unique in the late onset and severity of the clinical
phenotype, which shows a parallel with demyelinating peripheral neuropathies of adult onset
(Dyck et al., 1993). It has been shown that the Prx-null mice have a marked reduction in
their peripheral nerve conduction velocities (see Figure 1.4) (Gillespie et al., 2000) and
electrophysiological investigations have identified the presence of spontaneous low
frequency discharge (l-2Hz) in the saphenous nerve. Furthermore, the similarities of the
human disease CMT4F, both clinically and histopathologically, to the phenotype of the Prx-
null mouse are striking (Boerkoel et al., 2002;Gillespie et al., 2000;Guilbot et al., 2001),






Figure 1.3 Light and electron microscopy of sciatic nerves from Prx-null mice. a). Resin
sections (1pm) from sciatic nerves of normal (A and C) and mutant (B and D) mice at 6
weeks (A and B) and 6 months (C and D) of age. The null mutant shows features typical of
a progressive demyelinating neuropathy with evidence of remyelination, as denoted by onion
bulbs and thin myelin sheaths (thick and thin arrow, respectively). Disproportionately thick
sheaths evident at 6 weeks of age are more numerous by 6 months of age (arrowhead)
(adapted from (Gillespie et al., 2000). b) Electron microscopy of wild-type (A) and mutant
saphenous nerves at 6 months (B and C) and at 8 months (D). C-fibre bundles appear
normal (arrowhead), but myelinated fibres are grossly hypermyelinated (B and C), with
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Figure 1.4. Conduction velocity profiles of saphenous nerves from /Vx-null mice as
compared to wild type littermates. The percentage of fibres was calculated displaying
each conduction velocity for Rrx-null Mice (■ ) as compared to wild type littermates ( □ )
(adapted from Gillespie et al., 2000).
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1.26 Focal Demyelination: Development of an Experimental Mouse Model
When using mutant mouse models, it is not possible to rule out indirect consequences of the
altered genotype or related compensatory mechanisms on development. Furthermore, for
purposes of this study, it was appropriate to refine the model of peripheral nerve
demyelination to target individual sensory nerves, thereby eliminating any motor deficits and
allowing specific investigation of sensory changes. To achieve this, we have developed a
model of focal demyelination in the sciatic nerve and in the predominantly sensory,
saphenous nerve using the non-toxic, myelinolytic agent, lysophosphatidyl choline
(lysolecithin) (see Chapter 3), a group of monoacyl phosphoglycerides obtained by the
hydrolysis of lecithin (van Deenen and De Haas, 1966).
The induction of demyelination in both peripheral and central nerves by micro-injection of
lysolecithin into the perineurium of nerves is well-characterised in the literature (Hall and
Gregson, 1971;Love et al., 1986). Lysolecithin has been used extensively in various animal
models to produce demyelination in the sciatic nerve (Hall, 1973;Hall and Gregson, 1971),
spinal cord (Hall, 1972), corpus callosum (Waxman et al., 1979) and nerve roots (Smith and
Hall, 1980). The lysis of myelin is thought to be related to the detergent-like ability of
lysolecithin to form complexes with lipids and proteolipids (Webster, 1961), rendering them
soluble in an aqueous medium.
For any analysis of the mechanisms underlying neuropathic pain as a consequence of myelin
loss it is of great importance to clarify whether or not there are any additional axonopathic
changes in this model. The use of lysolecithin as the myelinolytic agent in this model
appears to achieve this, since when injected via a glass micropipette of specific tip diameter
(18-20 pm) in controlled amount (1-2 pi) and low concentration (1 %) into the sciatic nerves
of adult mice, the action is rapid and restricted to the myelin sheath (Hall and Gregson,
1971). Reportedly, there was little damage to the Schwann cell cytoplasm or to the axon and
the resulting demyelination is confined to the immediate vicinity of the site of injection and
is of rapid onset (Love et al., 1986). Following topical application of lysolecithin to the
peripheral nerve, the Schwann cells remain viable, and therefore proliferate and remyelinate
the nerves (Gregson and Hall, 1973), and eventually the ensuing damage to the peripheral
nerve is reversed and the nerve recovers.
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1.27 AIMS
The aims of this study were to:
(1) utilise mouse models of peripheral nerve demyelination to investigate changes in sensory
processing that may lead to abnormalities involved in the production of associated
neuropathic pain phenomena. The models utilised were the Prx-null mouse and a model of
focal peripheral nerve demyelination following topical application of lysolecithin. The latter
model is a novel model of neuropathic pain.
(2) employ light and electron microscopy, as well as immunohistochemical approaches to
characterise the morphology of the nerves and cell bodies in the DRG in these models.
(3) use well-characterised behavioural reflex testing techniques, to determine the presence of
reflex behavioural changes characteristic of neuropathic pain in both models.
To examine functional changes in these models we have employed:
(4) peripheral nerve electrophysiological techniques to investigate activity changes in the
saphenous nerve that may underlie the associated development of neuropathic pain.
(5) immunohistochemical techniques to investigate any changes in the expression of markers
characteristic of other neuropathic pain models, such as the neuropeptides CGRP, Substance
P, galanin, VIP and NPY and the sodium channels SNS l/NavT8 and brain type III/Nav1.3 in
the cell bodies of the affected peripheral nerves.
(6) intrathecal application of various pharmacological agents to examine the possible
involvement of central changes in the behavioural reflex sensitivity displayed in both
models. We investigated the effects of antagonists to the NMDA receptor and NFkB, and




• Halothane (Zeneca Ltd., Cheshire, UK)
• Sagatal (Rhone Merieux Ltd., Hertfordshire,UK)
• Urethane (Zeneca Ltd., Cheshire, UK),
2.2 Development of Animal Models
• 1ml syringe (Merck-BDH, UK)
• 25Gxl needle (Terumo, Belgium)
• 4.0 suture thread (Ethicon Ltd., Edinburgh, UK)
• Glass capillaries (Clark Electromedical Ltd., Reading, UK)
• Lysolecithin (a-lysophosphatidylcholine; Sigma Chemical Co, Poole, UK)
2.3 Behavioural Reflex Testing
• Thermal stimulus (Hargreaves-Plantar apparatus, Ugo Basile, Italy) .
• Von Frey filaments (Stoelting Co., Wood Dale, Illinois).
2.4 Light and Electron Microscopy
• Araldite (Agar Scientific, Essex, UK)
• Dibutylpthalate (Agar Scientific, Essex, UK)
• Dodecenyl Succinic Anhydride (Agar Scientific, Essex, UK)
• Gluteraldehyde (Sigma Chemical Co, Poole, UK)
• Osmium tetroxide (Agar Scientific, Essex, UK)
• Paraformaldehyde (Sigma Chemical Co, Poole, UK)
• Propylene oxide (Agar Scientific, Essex, UK)
• Sodium cacodylate (Sigma Chemical Co, Poole, UK)
• Sodium cacodylate buffer (Agar Scientific, Essex, UK)
• Reichert OMU4 Ultracut microtome (Leica UK Ltd. Milton Keynes),
• Glass slides (Merck-BDH, UK)
• Philips BioTwain electron microscope (FEI UK Ltd, Cambridge,UK)
• ImM calcium chloride solution (Sigma Chemical Co, Poole, UK).
• 2,4,6-Tri (dimethylaminomethyl) phenol (DMP-30) (Agar Scientific, Essex, UK)
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2.5 G-ratio
• IP Lab Spectrum P programme (Scanalytics Corp. Fairfax,VA)
2.6 Electi ophysiology
• AC coupled differential amplifier (3160, Digitimer Ltd, Welwyn Garden City, Herts
UK)
• Claris Works 4.0 illustrator programme (Claris Corp, Smart Computing, Lincoln,
NE).
• Digitimer (D100, Digitimer LtdWelwyn Garden City, Herts UK)
• Dual beam oscilloscope (D13, Tektronix Inc., Beaverton, OR. USA),
• Ethyl chloride (Henry Stein, Glasgow, UK)
• Isolated stimulator (Mark IV, Lectromed Limited. St Quen, Jersey, Channel Islands)
• Powerlab/McLab Chart v3.6/s programme (AD Instruments Ltd, Oxford, UK)
• Spike processor (D. 130, Digitimer, UK)
2.7 Immunohistochemistrv
• Gelatine (Sigma Chemical Co, Poole, UK)
• Glass slides pre-coated with poly-L-lysine (Merck-BDH,UK)
• Heparin (Sigma Chemical Co, Poole, UK)
• Normal donkey serum (Diagnostics Scotland. Edinburgh, UK)
• Normal goat serum (Diagnostics Scotland, Edinburgh, UK)
• OCT mounting medium (Tissue Tek, UK)
• Paraformaldehyde (Sigma Chemical Co, Poole, UK)
• Sucrose (Sigma Chemical Co, Poole, UK)
• Triton X-100 (Sigma Chemical Co, Poole, UK)
• Vecta-Shield (Vector Laboratories, Burlingame, CA)
2.7.1 Antibodies
Primary
• Mouse monoclonal anti-neurofilament 200kDa (clone N52; Sigma, Chemical Co,
Poole, UK)
• Mouse monoclonal anti-peripherin (Chemicon International Ltd, Harlow, UK)
• Rabbit polyclonal anti-ATF3 (Santa Cruz Biotechnology, Santa Cruz, CA, USA)
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• Rabbit polyclonal anti-brain type III sodium channel/Navl .3 (Alomone Labs,
Jerusalem)
• Rabbit polyclonal anti-galanin (Advanced Chemtech Ltd, Cambridgeshire, UK)
• Rabbit polyclonal anti-NPY (Peninsula Laboratories Inc, Belmont, CA)
• Rabbit polyclonal anti-SNS/Nav1.8 (supplied by S.Tate, GlaxoSmithKline, UK)
• Rabbit polyclonal anti-Substance P (Affiniti, Exeter, UK)
• Rabbit polyclonal anti-VIP (Incstar, Corp, Stillwater, MN,USA)
• Rabbit polyclonal anti-VIP (human, porcine,rat) (Peninsula Laboratories Inc, San
Carlos, CA, USA)
• Sheep polyclonal anti-CGRP (Affiniti, Exeter, UK)
Secondary
• Donkey anti-sheep-FITC (Jackson ImmunoResearch Laboratories, Westgrove, PA)
• Goat anti-mouse-TRITC Southern Biotechnology Associates, Birmingham,
Alabama)
• Goat anti-rabbit-FITC (Cappel, ICN Biomedical, CA, USA)
2.8 Intrathecal injections
• 25Gxl needle (Terumo Belgium)
• Dimethylformamide (dmf) (Sigma Chemical Co, Poole, UK)
• Pontamine Sky Blue (Merck-BDH, UK)
2.8.1 Drugs used
• NMDA receptor antagonist: (R)-CPP (3-((R)-2-carboxypiperazine-4-yl)-propyl-l-
phosphonic acid), (Tocris Cookson Ltd, Bristol, UK)
• mu opioid receptor agonist DAMGO (D-Ala2, MePhe4, Gly-olenkephalin) (Tocris)
• NFkB antagonists Parthenolide (Alexis, Exeter, UK); CAPE (Caffeic acid
phenethyl ester) (Calbiochem, CN Bioscience, Nottingham,UK); Sulphasalazine
(Sigma Chemical Co, Poole, UK)
• Mixed CB]/CB2 cannabinoid receptor agonist WIN 55,212-2 (mesylate (R)-(+)-(2,3-
dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo(l,2,3-de)-l,4-benzoxazin-6-yl)-
1-naphthalenylmethanone), (Tocris Cookson Ltd, Bristol, UK)
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• Selective CBi receptor antagonist AM 251 (N-(piperidin-l-yl)-5-(4-iodophenyl)-l-
(2,3-dichlorophenyl)-4-methyl-lH-pyrazole-3-carboxamide) (Tocris Cookson Ltd,
Bristol, UK)
2.9 Miscellaneous
• Freezing spray (Greenhill Chemical Products Ltd., Burton-on-Trent, UK)
• Glass coverslips (22 x 50mm) (Merck-BDH,UK)
• Isopentane (Merk Ltd., Leics, UK)
• Silica gel (Merck-BDH,UK)
• Sterile saline (Sigma Chemical Co, Poole, UK)
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CHAPTER 3. MATERIALS AND METHODS
3. 1 Development of Animal Models
3.1.1 /Yx-null mouse model
Background on creation ofPrx -null mice (from (Gillespie et al., 2000)
To inactivate the mouse Prx gene, exon 6 and part of exon 7 were deleted by homologous
recombination in embryonic stem cells (Gillespie et al., 2000). Cells of two clones were
injected into C57/BL6 blastocysts and resulting heterozygous offspring were backcrossed to
the parental C57/BL6 strain before inter-crossing at the F6 generation. Homozygous
offspring were identified by Southern blotting, as previously described (Dytrych et al.,
1998). RNA was extracted from 16 day old mutants (Cathala et al., 1983), resolved and
probed with a cDNA fragment, of mouse periaxin cDNA which revealed that mutant mice
lacked the 4.6 and 5.2 kb mRNAs found in the peripheral nerves of wild-type littermate.
Protein levels were assessed in 3 month old Prx-null and wild-type littermate animals using
isoform specific antibodies in Western blots as described previously (Dytrych et al., 1998),
revealing that neither L- nor S- periaxin polypeptides were detectable in peripheral nerves
(Gillespie et al., 2000).
For all experiments involving the /Vx-null mouse, male mutant animals at either 6 weeks or
6 months of age were used as stated. All experiments were also carried out on age and sex
matched wild-type littermates.
3.2.2 Lysolecithin-induced focal nerve demyelination
Male C57/BL6 mice over the age of 6 weeks were used for all lysolecithin-induced
demyelination treatments and for all associated experiments. For the induction of
demyelination of the peripheral nerve via the application of lysolccithin, animals were
initially anaesthetised with 0.3 ml of 25% Sagatal (Rhone Merieux Ltd., Hertfordshire,UK)
in sterile physiological saline (0.9%) and maintained on halothane (Zeneca Ltd.. Cheshire,
UK) and 02> always ensuring that the pinch reflex of the hind limb was abolished For all
demyelination experiments, lysolecithin (Sigma Chemical Co, Poole, UK) was dissolved in
sterile physiological saline (0.9%) to give a final concentration of 15 mg/ml.
Method 1: Microinjection into sciatic nerve
Glass capillaries (Clark Electromedical Ltd., Reading, UK) were stretched out on an
electrode glass puller and subsequently knocked back on a curved glass rod under a light
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microscope to give a final tip diameter of between 15 and 20 pm. Using a 1 ml syringe
(Merck-BDH, UK), the glass pipette was filled with lysolecithin solution and attached to a
positive displacement pipette via tight fitting rubber tubing. The sciatic nerve of the right
hind leg (Figure 3.1) was dissected out at mid thigh level and the three branches; tibial,
peroneal and sural, separated and laid over a stabilised pair of forceps held open at a
separation of 5 mm. By clamping to a movable vice, the glass micropipette tip was injected
just under the perineurium of the larger two branches (tibial and peroneal) of the sciatic
nerve under a light dissection microscope. 1-2 pi of solution were then displaced from the
glass pipette in 0.5 pi aliquots into the nerve over 10 minutes to prevent over spill onto
surrounding tissue. The nerve was then rinsed with sterile saline and the overlying muscle
and skin closed with 4.0 suture thread (Ethicon Ltd., Edinburgh, UK), marking the
application site.
Method 2: Topical application to saphenous or sciatic nerve
a) Saphenous Nerve Demyelination
Whilst under anaesthesia, the saphenous branch of the femoral nerve was exposed at mid
thigh level (Figure 3.2) and 5-10 pi of lysolecithin solution was applied topically via a
25Gxl needle (Terumo, Belgium) over a length of 2-3 mm, ensuring that the nerve remained
coated with the solution for 10 minutes. Excess lysolecithin solution was then washed off
with sterile saline and the incision site closed with 4.0 suture thread, marking the application
site.
b) Sciatic Nerve Demyelination
The sciatic nerve was dissected at mid thigh level and the two larger braches (tibial and
peroneal) were carefully separated from the smaller sural branch which was subsequently
excluded from the preparation. Lysolecithin was again applied topically to the nerve via a
25Gxl needle over a length of 2-3 mm for 15 minutes; always ensuring the nerve remained
moist. Excess lysolecithin solution was washed off and both overlying muscle and skin were
then closed with 4.0 suture thread, marking the application site.
Sham control animals were prepared for both saphenous and sciatic nerve preparations by
omitting lysolecithin from the solution so that the nerve was exposed as above and sterile
saline applied topically for the relevant time.
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Figure 3.1. Schematic diagram of anatomy of the medial aspect of the hind limb of the
mouse with special reference to the saphenous nerve (adapted from (Popesko et al.,
1990))
igure 3.2. Schematic diagram of anatomy of the lateral aspect of the hind limb of the
mouse with special reference to the sciatic nerve (adapted from (Popesko et al., 1990))
66
3,2. Behavioural Reflex Testing
The threshold for hindpaw withdrawal in both animal models was measured in response to
graded mechanical and noxious thermal stimulation in conscious animals. Behavioural
reflex tests were carried out daily, over a period of 2 weeks, to determine stable thresholds
for the iVx-null (n=8), wild-type littermates (n=8) and stock C57/BL6 mice designated for
lysolecithin treatment of the saphenous (n=8) or sciatic (n=8) nerves.
3.2.1 Mechanical test
Mechanical thresholds were determined using von Frey filaments (Stoelting Co., Wood
Dale, Illinois), which provide a calibrated indentation pressure against the hairless skin of the
hindpaws. The threshold response was defined by the filament that caused foot withdrawal at
least five times in every ten applications (Chaplan SR et al.. 1997;Meyer, 1979).
3.2.2 Thermal test
The time for hindpaw withdrawal was measured in response to a quantified noxious thermal
stimulus (Hargreaves-Plantar apparatus, Ugo Basile, Italy) of infra-red intensity setting 30
(>50°C) applied to the mid-plantar surface of each hind paw (Hargreaves et ah, 1988). The
withdrawal was characterised as a brief paw flick and the withdrawal latency was recorded
in seconds.
For thresholds to both mechanical and thermal stimulation, measurements were repeated at
least 6 times with a minimum time of 5 minutes between each test. From this the average
threshold for each stimulus could be determined.
In sciatic or saphenous nerve lysolecithin-treated animals (n=16), behavioural reflex tests
were carried out one day before and on the day of treatment to obtain baseline thresholds.
Testing then re-commenced 5 days following surgery to allow for healing and was
subsequently carried out every day to identify the development of any heightened reflex
sensitivity in treated animals. Testing ceased once animals displayed recovery to normal
baseline thresholds. This tnne course was also used to test sham control animals (n=4 for
each nerve preparation). The threshold value at each time point tested was calculated as the
mean ± SEM. Any statistically significant differences (*P<0.05) in paw withdrawal
threshold from mechanical stimulation between a) TVx-null and wild-type littermate, b) paws
contralateral and ipsilateral to lysolecithin treatment or c) paws contralateral and ipsilateral
to sham treatment were determined by a Mann-Whitney Rank Sum test. Likewise any
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statistically significant differences in withdrawal latency from thermal stimulation were
determined by a Student's paired t-test.
3.3 Morphological Investigations
In order to test the integrity of lysolecithin-treated nerves, nerve morphology was examined
in animals that previously had a) microinjection or b) topical application of lysolecithin to
the sciatic nerve or c) topical application of lysolecithin to the saphenous nerve.
3.3.1 Processing and embedding
13 days post lysolecithin-treatment, the treated nerves were dissected from animals'
euthanised by C02 inhalation. The lysolecithin-treated area, marked by a small suture during
surgery, was selected and dissected with approximately 1 cm of normal nerve either side.
The affected area could therefore be identified once processed and embedded. Control
nerves were dissected at equivalent points.
Once dissected, the nerves were fixed for 4 hours in 2.5% glutaraldehvde solution containing
2.5% glutaraldehyde, 2% paraformaldehyde, 0.1 M sodium cacodylate buffer (pH 7.4) and
ImM calcium chloride solution. Solutions were all made up in ultra high purity water using
reagents from Sigma-Aldrich (Poole, UK) unless otherwise indicated Nerves were then
washed twice in 0.1 M sodium cacodylate buffer for 20 minutes; osmicated in 1% osmium
tetroxide for 1 hour; washed twice in sodium cacodylate buffer for 10 minutes and then
dehydrated through increasing concentrations (10-100%) of alcohol in distilled water for 1
hour. Sections were then washed twice in 10 mis propylene oxide for 30 minutes followed
by 10 mis 1:1 araldite mix (1:1 araldite and dodecenyl succinic anhydride (DDS)) with 10
mis propylene oxide for 1 hour and then overnight in araldite mix. Finally, the sections were
washed twice in 55.2 mis araldite mix with 1.95 mis accelerator (dibutylphthalate & 2,4,6-tri
(dimethylaminomethyl) phenol (DMP-30) for 2 hours in which they were then embedded
and left to harden in a 50 °C oven for at least 48 hours. All materials used for processing and
embedding were obtained from Agar Scientific (Essex, UK).
3.3.2 Light microscopy
For light microscopy, 1 pm resin sections of treated saphenous and sciatic nerve were cut
from araldite embedded blocks on a Reichert OMU4 Ultracut microtome (Leica UK Ltd.
Milton Keynes), heat dried to glass slides (BDH, Poole, UK) and subsequently stained with
Toluidine Blue. From this, the level of myelination and hence the area of demyelination
could be established by bright-field microscopy.
68
3.3.3 Electron microscopy
Ultrathin (80nm) sections were cut using the OMU4 microtome and stained with uranyl
acetate and lead citrate to allow examination on a Philips BioTwain electron microscope
(FEI UK Ltd, Cambridge, UK). Nerve counts were performed at the electron microscope
level so that the amount of demyelination and integrity of large diameter, myelinated and
small diameter, unmyelinated axons could be determined. C-fibres were identified as small
diameter unmyelinated fibres, present in bundles of fibres surrounded by Schwann cell
cytoplasm. From non-overlapping EM photographs of cross-sections of the entire nerve, the
actual number of intact C-fibres was calculated. To minimise experimental bias and error,
the images from all nerves (n=3 per group) were counted three times while blinded to the
specific nerve from which each image originated. Once all counts were complete, the
average number of fibres for each nerve was calculated. To count the number of myelinated
A-fibres, axons with all levels of myelination including those that were completely
demyelinated were considered. Therefore, A-fibres were identified as the larger diameter
axons with myelin or smaller diameter unmyelinated fibres that were solitary. This allowed
distinction of demyelinated fibres from unmyelinated fibres, which usually occur in bundles.
The statistical significance (*P<0.05) of any difference between treated and naive or sham
nerves was determined using a Kruskal-Wallis One-Way Analysis of Variance on Ranks an
all pairwise multiple comparisons procedure (Dunn's Method).
3.3.4 G-ratio
The G-ratio of an axon is a measure of myelin thickness calculated by dividing the axonal
diameter by the overall diameter of the axon and myelin sheath. This gives an indication of
the level of demyelination in axons that are not completely demyelinated by lysolecithin
treatment. G-ratios ofmyelinated fibres were calculated from EM photographs of the whole
cross sectional area of each nerve using the IP Lab Spectrum P programme (Scanalytics
Corp, Fairfax,VA). This also calculates the number of myelinated axons in the sample.
From this, the proportion of completely demyelinated axons per nerve was calculated by
counting the number of myelinated fibres per photograph (area represented by each
photograph = 292 pm2). The statistical significance of any difference between treated and
naive or sham nerves (*P<0.05) was determined by Kruskal-Wallis Onc-Way Analysis of
Variance on Ranks with an all pairwise multiple comparisons procedure (Dunn's Method).
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3.4. Electrophysiology
To determine the effects of lysolecithin treatment on nerve fibre activity,
electrophysiological recordings were carried out at different times following application of
lysolecithin.
3.4.1 Preparation
Electrophysiological recording of peripheral nerve activity was performed on animals which
had previously had focal demyelination induced in the saphenous nerve. Recording
experiments were carried out on days 3- and 5-post surgery, times at which behavioural
reflex sensitisation should not have developed and also on day's 11-, 12- and 13-post surgery,
corresponding to the peak time of development of behavioural reflex sensitisation, as tested
on mice previously. Mice were assessed for the development of behavioural sensitisation to
both thermal and mechanical tests, as described in section 3.2, and then anaesthetised with
5% urethane i.p. (1.25g/kg) and maintained at 36-37 °C with a radiant heat lamp. The
saphenous nerve was exposed in the medial thigh and dissected from its associated vein and
artery and cut centrally to the site of demyelination or at a corresponding level on the sham
and naive animals. After removal of the perineurium, further dissection under liquid paraffin
enabled the identification of afferent preparations comprising a small number of units. The
dissected afferents were placed over a bipolar recording electrode and the whole nerve
preparation was submerged in liquid paraffin (Figure 3.3).
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Figure 3.3. Nerve preparation for electrophysiological investigations
of the saphenous nerve.
The saphenous nerve was dissected from its associated vein and artery
and cut centrally to the site of demyelination or at a corresponding level on
the sham and naive animals. After removal of the perineurium, further
dissection under liquid paraffin enabled the identification of afferent
preparations comprising a small number of units. The dissected afferents
were placed over a bipolar recording electrode (R) and the whole nerve
preparation was submerged in liquid paraffin. The hind paw of the treated
animal was secured to a footplate (F) using plaster of Paris coated gauze
and the receptive field (RF) of the afferent preparation was identified by the




The electrophysiology apparatus was set up as represented in the box diagram (Figure 3.4).
Afferent activity, detected by the bipolar recording electrodes, was amplified using an AC
coupled differential amplifier (3160, Digitimer Ltd, Welwyn Garden City, Herts, UK) with a
band width setting of 80 Hz to 2.5 kHz. Shapes and latencies of individual impulses were
identified using the storage facility on the D13 oscilloscope (Tektronix Inc., Beaverton, OR.
USA) and single frame or overlapping multiple frames converted to TTL (transistor-
transistor logic) pulses using a spike processor (D.130. Digitimer, UK) which was connected
to a) a second oscilloscope with audio display and b) the Powerlab/McLab Chart v3.6/s
programme (AD Instruments Ltd, Oxford. UK). To stimulate the receptive field for thermal
threshold recordings, a calibrated temperature source controlled the radiant heat source in a
time dependent and temperature dependent manner. Conduction velocities were measured
using electrical excitation of receptive fields with bipolar needle stimulating electrode. A
Digitimer D100 (Digitimer Ltd) triggered an isolated stimulator (Mark IV, Lectromed
Limited, St Quen, Jersey, Channel Islands) to deliver square-wave pulses (range 0.5 - 1.0 ms,
0.1 -100 volts) at levels selected to be just above threshold for few-unit preparations via the
stimulating electrodes.
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3.4.3 Characterisation of peripheral receptive fields
The hind paw of the treated animal was secured by the lateral two toes to a footplate using
plaster of Paris coated gauze and the receptive field (RF) of the afferent preparation was
identified by the induction of impulse activity via gentle brushing of the medial aspect of the
hind paw. In some cases, a noxious pinch stimulus was also delivered to the identified RF
using metal forceps to test the responsiveness of high threshold afferents. The mechano-
sensitivity of sensory receptors with lower thresholds was measured using calibrated von
Frey filaments and the thermal threshold with a calibrated radiant heat source (Sobair et al.,
1997). Both mechanical and thermal response thresholds were defined in the central zone of
the identified receptive field.
3.4.4 Conduction velocity
The conduction velocity of single identified afferent fibres was determined using bipolar
electrodes and the peripheral stimulus technique (Iggo, 1958). Thereby, an electrical
stimulus was delivered to the peripheral receptive field and any resulting action potential
discharge was recorded from the nerve preparation (Figure 3.5). The distance between
stimulating and recording electrodes, and the time taken for a spike to reach the recording
electrode was measured by counting the time separation between the stimulating potential
and peak action potential on the oscilloscope. The conduction velocity was calculated as
distance/time. To obtain the full range of conductance velocities present, the procedure was
repeated by moving the stimulating electrode to a variety of locations within the receptive
field for each fibre. The percentage of axons in each conduction velocity range, from 0-3
m/s up to 18-21 m/s, was calculated and the statistical significance (*P<0.05) of any
difference between each group determined by a Kruskal-Wallis One-Way Analysis of
Variance on Ranks with all pairwise multiple comparisons procedure (Dunn's Method).
All recording traces of spike activity were obtained via a direct link of the oscilloscope to the
Powerlab/McLab Chart v3.6/s programme (AD Instruments Ltd, Oxford, UK). This was
subsequently analysed on the Claris Works 4.0 illustrator programme (Claris Corp, Smart
Computing, Lincoln, NE).
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Figure 3.5. Electrophysiology preparation for recording
conduction velocities of afferent fibres in the saphenous nerve.
The conduction velocity of single identified afferent fibres was
determined using bipolar electrodes and the peripheral stimulus
technique (Iggo, 1958). An electrical stimulus (S) is delivered to the
peripheral receptive field (RF) and any resulting action potential




For fixed-tissue immunohistochemistry, 6 week old /Vx-null and wild-type littermate
animals, and animals which had 13 days previously had lysolecithin treatment of the right
sciatic nerve or saphenous nerve, were deeply anaesthetised with halothane and perfused
through the heart with heparinised (Sigma) saline followed by 4% paraformaldehyde
(Sigma) in 0.1M phosphate buffer (Sigma). For, Prx-null and wild-type littermate animals,
all lumbar DRG were removed under a light microscope. For lysolecithin-treated animals,
the L3, L4, L5 and L6 DRG, ipsilateral and contralateral to the lysolecithin-treated nerve or
sham-operated nerve, were removed under a light microscope. All DRG were post-fixed
with 4% paraformaldehyde for 2 hours, transferred through increasing concentrations of
sucrose (Sigma) in 0.1M phosphate buffer for 1 hour and left overnight in 25% sucrose in
0.1M phosphate buffer. The DRG were then embedded in OCT mounting medium (Tissue
Tek, UK), frozen over liquid nitrogen and stored at -70°C.
For non-perfused tissue immunohistochemistry, 6 week old Prx-null and wild-type littermate
animals, and animals which had undergone lysolecithin treatment of the sciatic or saphenous
nerve 13 days previously were euthanised by C02 inhalation. The same DRG were removed
as in the fixed animals but were snap frozen over liquid nitrogen and embedded in OCT
mounting medium. Cryostat sections of all DRG (10 pm) were thaw-mounted onto glass
slides, which were pre-coated with poly-L-lysine (Merck-BDH).
For saphenous nerve-treated animals L3, L4 and L5 DRG were analysed, for sciatic-treated
animals and for Prx-null and wild-type littermate animals, L4, L5 and L6 DRG were
analysed.
3.5.2 Immunohistochemistry procedure
For localisation of the Na+ channel, SNS 1/Nav 1.8 or the peptides CGRP or NPY with the
A-fibre cell body marker, neurofilament 200 kDa (NF-200) (Lawson and Waddell,
1991;Michael and Priestley, 1999) or the C-fibre cell body marker, peripherin (Goldstein et
ah, 1991), non-perfused DRG sections were immersion-fixed for 15 minutes with 4%
paraformaldehyde in phosphate-buffered saline. Sections were pre-incubated in buffer (0.1M
PBS, pH 7.4, containing 0.2% Triton X-100 (Sigma) and 2% gelatine (Sigma)) containing
10% normal goat serum (Diagnostics Scotland (DS), Edinburgh, UK) or 10% normal donkey
serum (DS) (only for CGRP detection) for lhr at room temperature and then incubated with
primary antibodies diluted in buffer containing 4% goat or donkey serum overnight at 4°C.
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Perfused tissue was used for detecting any expression of the brain type III Na'
channel/Nav1.3, the peptide galanin or the transcription factor ATF3 (Tsujino et al., 2000)
with the A-fibre marker, neurofilament 200 kDa (NF-200). The immunohistochemical
procedure used was as for fresh tissue, omitting the immersion fixation step.
3.5.3 Antibodies
Antibodies were used at the following concentrations: rabbit polyclonal anti-SNS 1/Nav1.8
(1:200; K107 supplied by S.Tate, GlaxoSmithKlme, UK; the specificity of K107 having
been tested by pre-incubating primary antibody with dilutions of the relevant antigenic
peptide, (Amaya et al., 2000); rabbit polyclonal anti-brain type III sodium channel/Nav1.3
(1:200, Alomone Labs, Jerusalem, (Black et al., 1999); sheep polyclonal anti-CGRP (1:1500;
Affiniti, Exeter, UK, (Todd. 1997); rabbit polyclonal anti-substance P (1:1000 Affiniti)
rabbit polyclonal anti-NPY (Peninsula Laboratories Inc. Belmont. CA 1:1000,(Polgar et al.,
1999); rabbit polyclonal anti-galanin (1:2000; Advanced Chemtech Ltd. Cambridgeshire,
UK); rabbit polyclonal anti-VIP (human, porcine.rat) (1:400; Peninsula Laboratories Inc, San
Carlos, CA, USA); rabbit polyclonal anti-VIP (1:400, Incstar, Corp, Stillwater, MN.USA);
rabbit polyclonal anti-ATF3 (1:400; Santa Caiz Biotechnology, Santa Cruz, CA); mouse
monoclonal anti-neurofilament 200kDa (1:2000; clone N52; Sigma, (Bennett et al., 1998c);
and mouse monoclonal anti-periphenn (1:1000; Chemicon International Ltd. Harlow, UK,
(Amaya et al., 2000). Sections were then washed in buffer and incubated for 2 hours at room
temperature with the appropriate secondary antibodies linked to either tetramethyl
rhodamine isothiocyanate (TRITC) (goat anti-mouse-TRITC, 1 200; to detect all mouse
primary antibodies; Southern Biotechnology Associates, Birmingham. Alabama) or
fluorescein isothiocyanate (FITC) [goat anti-rabbit-FlTC, 1:200; to detect all goat primary
antibodies; (Cappel, ICN Biomedical, CA, USA) or donkey anti-sheep-FITC, 1:100; to
detect anti-CGRP primary antibody; (Jackson ImmunoResearch Laboratories, Westgrove,
PA)]. Three final washes in 0.1M PBS were conducted before cover-slipping with Vecta-
Shield (Vector Laboratories, Burlingame, CA) for analysis. Control sections were processed
as above omitting the primary antibodies. Observations were made and sections
photographed on a Leitz microscope equipped for epifluorescence. Counts of profiles
labelled for immunopositive cells were performed on 3-4 randomly selected 10 pm sections
(separation of 100 pm) from each of four animals in each group and only neurons with clear
nuclei were counted. Results were expressed either as a proportion of labelled profiles per
section or the proportion per total number of single or double-labelled profiles from all 12
sections. The statistical significance of differences between groups was tested by Kruskal-
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Wallis One-Way ANOVA on Ranks with all pairwise multiple comparison procedures
(Dunn's Method).
3.6. Intrathecal administration of drugs
Animals which had previously had focal demyelination induced in the saphenous nerve via
topical application of lysolecithin, were used for all intrathecal injection experiments. 6
week old Prx-null and wild-type littermate animals were also used for investigations using
intrathecal injection of the NMDA receptor antagonist (R)-CPP. For all injections, baseline
measurements for mechanical allodynia and thermal hyperalgesia were recorded over a
period of up to 2 hours prior to injection. The mice were briefly anaesthetised with
halothane and 02and injected intrathecally at the L4 level of the spinal cord using a 25Gxl
needle (Terurno) with the pharmacological agent of interest or the appropriate vehicle
control. Injections were performed blinded to the pharmacological agent or vehicle used.
Each drug was injected into at least 6 separate animals. A maximum of 4 animals were
injected at one time and no individual animal was used on 2 consecutive days of injections.
To determine the effects of each drug on both mechanical allodynia and thermal
hyperalgesia, behavioural reflex testing commenced 15 minutes following injection to allow
recovery from anaesthesia and continued every 5 minutes thereafter until readings returned
to baseline levels. For all drugs tested, the statistical significance (p<0.05) of any difference
between ipsilateral and contralateral paw withdrawal thresholds following lysolecithin
treatment or, between Prx-null and wild-type littermate paw withdrawal thresholds was
tested by a Mann-Whitney Rank Sum test for mechanical stimulation or a paired Student's t-
test for thermal stimulation. Any statistically significant difference (p<0.05) of the post-
injection paw withdrawal from baseline paw withdrawal thresholds was determined by a
One-Way Repeated Measures Analysis of Variance (ANOVA) with Dunnet's multiple
comparisons versus control group post hoc analysis. Extensive control studies have shown
that intrathecal injection of the vehicles, saline or 0.1-0.5% dimethylformamide (dmf) in
saline have no effect on these behavioural reflex measures. Furthermore, dye injections
using Pontamine Sky Blue (BDH) demonstrated that over various time periods up to 60
minutes after injection, there was no spread of dye to the PNS.
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3.6.1 NMDA receptor antagonist
In lysolecithin-treated animals and Prx-null and wild-type littermate animals, the selective
NMDA receptor antagonist (R)-CPP (3-((R)-2-carboxypiperazine-4-yl)-propyl-l-phosphonic
acid), (Tocris Cookson Ltd, Bristol, UK) was injected at a concentration of 100 pmol in 10
pi saline.
3.6.2 mu-opioid receptor agonist
The selective mu-opioid receptor agonist, DAMGO (D-Ala2, MePhe4, Gly-olenkephalin)
(Tocris) was injected at a concentration of 10 pmol in 10 pi saline
3.6.3 NFkB -pathway inhibitors
The actions of three structurally different NFkB pathway inhibitors were investigated;
a) parthenolide (Alexis, Exeter, UK) was injected at a concentration of 0.3 nmol in 10 pi
saline with 0.3% dimethylformamide (dmf) (Sigma), b) caffeic acid phenethyl ester (CAPE)
(Calbiochem, CN Bioscience, Nottingham,UK) was injected at a concentration of 0.3 nmol
in 10 pi saline and c) sulphasalazine (Sigma) was injected at a concentration of 5nmol in 10
pi saline with 0.5% (dmf).
3.6.4 Cannabinoid receptor agonists
The mixed CB!/CB2 cannabinoid receptor agonist WIN 55,212-2 (mesylate (R)-(+)-[2,3-
dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[l,2,3-de]-l,4-benzoxazin-6-yl]-l-
naphthalenylmethanone), (Tocris Cookson Ltd), was injected at a concentration of 60 pmol
in 10 pi saline with 0.02% dmf. The highly selective CB, receptor antagonist AM 251 (N-
(piperidin-l-yl)-5-(4-iodophenyl)-l-(2,3-dichlorophenyl)-4-methyl-lH-pyrazole-3-
carboxamide) (Tocris.), was injected at a concentration of 100 pmol in 10 pi saline with
0.3% dmf. Finally, a combination of WIN 55,212-2 plus AM 251 was injected at a
concentration of 100 pmol in 10 pi saline with 0.3% dmf.
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CHAPTER 4. CHANGES IN THE PERIPHERAL NERVOUS SYSTEM IN MODELS




Investigations into the behavioural reflex sensitivities of 6 week old Prx-null mice,
demonstrated that these mice have significantly lower thresholds for hindpaw withdrawal
responses to mechanical (Fig 4.1a(i)) and noxious thermal (Fig 4.1 b(i)) stimuli, indicating
the presence of heightened reflex sensitisation indicative of thermal hyperalgesia and
mechanical allodynia, (Gillespie et al., 2000). Therefore, it was of interest to investigate if
similar, or more pronounced, changes were apparent in 6 month old Prx-null mice by which
age morphological derangement of myelinated nerves is more marked (Gillespie et ah,
2000).
At 6 months of age, .Prx-null mice display significantly lower thresholds when compared to
the wild-type in reflex tests of cutaneous mechanical sensation using calibrated von Frey
filaments (Fig 4.1a(ii)) and of thermal hyperalgesia using an infra-red beam applied to the
mid plantar region of the hind paw (Fig 4.1 b(ii)) (Fig 4.1 c,d). Therefore, at 6 months the
Prx-null mice display a heightened reflex sensitisation, similar to that displayed at 6 weeks
of age, indicative of mechanical allodynia and thermal hyperalgesia.
b) Lysolecithin-induced demyelination
Mice which previously had topical application of lysolecithin to the saphenous or sciatic
nerve displayed a markedly lowered ipsilateral threshold in reflex tests of cutaneous
mechanical sensitisation using calibrated von Frey filaments (Fig 4.2a) and of thermal
nociceptive sensitivity (Fig 4.2 c). The heightened reflex sensitivity to both stimuli was
apparent from day 5 after lysolecithin treatment of saphenous or sciatic nerve but reached
peak values from days 9 until day 15 post surgery. The threshold in both tests recovered to
baseline levels by 23 days post treatment. Reflex responses from the contralateral hind paw
of lysolecithin-treated mice showed no changes following treatment. Sham-operated mice
showed no change from baseline reflex values following surgery (Fig 4.2b.d).
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Figure 4.1. Development of mechanical allodynia and thermal hyperalgesia in 6 week
and 6 month old FVx-null mice.
a) Minimum filament indentation pressure thresholds for paw withdrawal responses to
mechanical stimulation with von Frey filaments were measured for (i) 6 week old
(n=8) and (ii) 6 month old TVx-null mice (□ ) (n=8) and wild-type (WT) littermates
(♦) (n=8). Baseline measurements were obtained at 2-day intervals. Statistical
significance of differences between Prx-null and wild-type (WT) thresholds
(*P<0.05) was determined by a Mann-Whitney Rank Sum test. Each value is the
mean ± SEM.
b) The time taken for hindpaw withdrawal from a noxious thermal stimulus was
measured for (iii) 6 week old (n=8) and (iv) 6 month (n=8) old TVx-null mice (□ ) and
wild-type (WT) littermates (♦) (n=8). Baseline measurements were obtained at 2-
day intervals. Statistical significance of differences between /Vx-null and wild-type
(WT) thresholds (*P<0.05) was determined by a paired Student's t-test. Each value is
























































Figure 4.2. Development of mechanical allodynia and thermal hyperalgesia ipsilateral
to lysolecithin treatment of the saphenous or sciatic nerve.
a) Minimum filament indentation pressure thresholds for repeat paw withdrawal
responses to mechanical stimulation with von Frey filaments in conscious animals
were measured for C57/BL6 mice following lysolecithin treatment (T) to (i) one
saphenous (n=6) or (ii) one sciatic nerve (n=6). Statistical significance of differences
between ipsilateral (□) and contralateral (♦ ) paws (*P<0.05) was determined by a
Mann-Whitney Rank Sum test. Each value is the mean ± SEM.
b) Minimum filament indentation pressure thresholds for repeat paw withdrawal
responses to mechanical stimulation with von Frey filaments in conscious animals
were measured for C57/BL6 mice following sham treatment (T) to (i) one saphenous
(n=4) or (ii) one sciatic nerve (n=4) commencing on post treatment day 5. Statistical
significance of differences between ipsilateral ( D ) and contralateral (♦ ) paws
(*P<0.05) was determined by a Mann-Whitney Rank Sum test. Each value is the
mean ± SEM.
c) The time taken for hindpaw withdrawal from a noxious thermal stimulus was
measured for C57/BL6 mice following lysolecithin treatment (t) to (i) one
saphenous (n=6) or (ii) one sciatic nerve (n=6). Statistical significance between
ipsilateral (□ ) and contralateral (♦ ) paws (*P<0.05) was determined by a paired
Student's t-test. Each value is the mean ± SEM.
d) The time taken for hindpaw withdrawal from a noxious thermal stimulus was
measured for C57/BL6 mice following sham treatment (t) to (i) one saphenous (n=4)
or (ii) one sciatic nerve (n=4). Statistical significance between ipsilateral (□ ) and
contralateral (♦ ) paws (*P<0.05) was determined by a paired Student's t-test. Each
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4.1.2. Morphology of the lysolecithin-treated nerve
To determine the extent of demyelination as a result of lysolecithin treatment of the
saphenous or sciatic nerve, we examined the treated region of the peripheral nerve
(determined at time of embedding) of demyelinated, sham and naive mice by light and
electron microscopy at peak behavioural change (post-treatment day 11-13) and at
behavioural recovery time (post-treatment day 23).
Method 1: Microinjection of lysolecithin
It was clear from LM and EM images of the sciatic nerve treated by microinjection of
lysolecithin via a glass micropipette that structural damage of the axons had occurred.
Therefore, we continued no further with our investigations of this model as it is of critical
importance that there is no traumatic damage to axons in any model designed to assess
demyelination-induced changes Therefore, from this point onwards, any reference to
lysolecithin-treated nerves relates to those treated topically with lysolecithin (Method 2).
Method 2: Topical application of lysolecithin
aj Saphenous nerve: On days 11-13 post lysolecithin treatment, 40% of A-fibres in the
saphenous nerves were completely demyelinated as compared to the contralateral nerve and
many remaining myelinated fibres had myelin of reduced thickness. This was observed
initially by light microscopy (Fig 4.3a(i,ii)) and then calculated from the number of
myelinated fibres or formerly myelinated fibres present in each EM image (representing
292pm2 of the nerve). Lysolecithin-treated saphenous nerves (n=3) contained 4.9 ± 0.9
myelinated axonal profiles per image (155 myelinated axonal profiles over 33 images
analysed) and control nerves (n=3) contained 8.2 ±1.7 myelinated axonal profiles per image
(261 myelinated axonal profiles over 32 images analysed). Samples were taken from the
entire nerve of 3 animals per group. The G-ratio, a relative measure of myelin thickness as a
ratio of the axonal diameter to overall diameter (1:1 indicating no myelin sheath) was
calculated for the remaining myelinated A-fibres following treatment with lysolecithin. The
G-ratio significantly increased in the demyelinated nerve from 0.61 ± 0.01 in naive nerves to
0.76 ± 0.01 in demyelinated nerves (Fig 4.2b) indicating a general decrease in myelin
thickness of remaining myelinated fibres. There was no significant difference in the level of
myelination in sham-operated animals or in recovery (day 23) animals from control naive
animals (Fig 4.3a,b) (*P<0.05) as determined by Kruskal-Wallis One-Way Analysis of
Variance on Ranks with an all pairwise multiple comparisons procedure (Dunn's Method).
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Figure 4.3. Effects of lysolecithin treatment on the myelination state of the saphenous
nerve.
a) Resin sections (1 pm) from the (i) ipsilateral and (ii) contralateral saphenous nerves
of lysolecithin-treated animals on post-treatment day 13, (iii) ipsilateral saphenous
nerve of lysolecithin-treated animals on post treatment day 23 (recovery), (iv)
ipsilateral saphenous nerve of sham-treated animals post-treatment day 13 were
analysed by light microscopy (n=3 in each case). Post lysolecithin treatment day 13
ipsilateral nerves display complete demyelination in about 40% of A-fibres with
partial demyelination of many remaining myelinated fibres. Contralateral nerves
from post lysolecithin treatment day 13, lysolecithin-treated nerves on post-treatment
day 23 and nerves ipsilateral to sham treatment all appeared to be morphologically
normal with consistent levels ofmyelination across the nerve. Scale bar: 10pm.
b) Quantification of the degree of myelination of A-fibres following lysolecithin
treatment to the saphenous nerve was determined as a G-ratio from electron
microscope images of (i) the contralateral and (ii) ipsilateral saphenous nerves of
lysolecithin-treated animals on post-treatment day 13 and (iii) ipsilateral saphenous
nerve of sham-treated animals post-treatment day 13 (n=3) in each case). Results are
shown as the G-ratio of each fibre as a function of the axon diameter (i-iii) and the
data are summarised as bar charts below (iv). The data show a general decrease in
myelin thickness i.e. increased G-ratio following lysolecithin treatment, but not sham
surgery. Statistical significance (*p<0.05) between conditions was determined by
Kruskal-Wallis One Way Analysis of Variance on Ranks with an all pairwise
























































Electron microscopy (Figure 4.4) demonstrated that lysolecithin-treated saphenous nerves
contained bundles of myelin debris and macrophages, which are involved in the process of
myelin debris removal from the site and have been observed in other models of peripheral
nerve demyelination (Carenini et al., 2001;Smith, 1999). Flowever, unmyelinated C-fibre
bundles appeared to be morphologically normal and fibre counts revealed that there was no
statistically significant decrease in number of unmyelinated C-fibres (lysolecithin-treated
nerve contained on average 60.1 ± 2.0 C-fibres per area sampled compared to 62.9 ± 1.9 in
the control nerve and 57.3 ± 1.3 in sham control treated nerve) following treatment with
lysolecithin. Similarly there was no detectable decrease in the number of larger A fibres that
were either myelinated or demyelinated (lysolecithin-treated nerves contained on average
10.1 ± 0.5 A-fibres per area sampled compared to 11.8 ± 0.2 in the control nerve and 9.7 ±
0.3 in sham-treated nerves) (*P<0.05). Analyses were performed by Kruskal-Wallis One-
Way Analysis of Variance on Ranks with an all pairwise multiple comparisons procedure
(Dunn's Method) indicating that the treatment with lysolecithin does not affect the integrity
of the axons (Figure 4.4).
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Figure 4.4. Effects of lysolecithin treatment on afferent axons in the saphenous nerve.
Electron microscopy images of the contralateral and ipsilateral saphenous nerves of
lysolecithin-treated animals on post-treatment day 13 and ipsilateral saphenous nerve of
sham-treated animals post-treatment day 13 were compared (n=3 in each case). The images
demonstrate typical sections from; (i & ii) the lysolecithin-treated nerve, which shows
markedly reduced myelination of (i) A-fibres (arrow) while (ii) C-fibres (arrowhead) remain
intact, and sections from (iii) contralateral, untreated nerve and (iv) ipsilateral sham treated
nerve (x5000, Scale bar: 2 pm). Unmyelinated axons were identified as small diameter fibres
devoid of any myelin sheath, which were present in bundles, surrounded by Schwann cell
cytoplasm and were individually counted for all groups (v). A-fibres (with or without
lysolecithin treatment) were identified as the larger diameter axons with myelin sheaths or
smaller diameter thinly-myelinated fibres or occasionally those with no myelin which were
solitary. All of these fibre types were individually counted (vi). Data for both fibre types are
presented as average numbers of fibres per image (292 pm2) ± SEM. A Kruskal-Wallis One











b) Sciatic nerve: From observations at the LM level of the sciatic nerve following topical
application of lysolecithin, a similar degree of demyelination had occurred as in the
saphenous nerve (Fig 4.5a). The G-ratio significantly increased in the demyelinated nerve
from 0.56 ± 0.02 in naive nerves to 0.81 ± 0.03 in demyelinated nerves (Fig 4.5b) indicating
a general decrease in myelin thickness of remaining myelinated fibres. There was no
significant difference in the level of myelination in sham operated animals from control
naive animals (Fig 4.5b) (*P<0.05) as determined by Kruskal-Wallis One-Way Analysis of
Variance on Ranks with an all pairwise multiple comparisons procedure (Dunn's Method).
At the EM level, as with the saphenous nerve, there was no indication of axonal damage to
A- or C-fibres (Fig 4.6). As in the lysolecithin-treated saphenous nerve, electron microscopy
demonstrated that lysolecithin-treated sciatic nerves contained bundles of myelin debris and
macrophages, which are involved in the process of myelin debris removal from the site of
demyelination. Unmyelinated C-fibre bundles appeared to be morphologically normal and
fibre counts revealed that there was no statistically significant decrease in number of
unmyelinated C-fibres (lysolecithin-treated nerve contained on average 45.1 ± 9.0 C-fibres
per area sampled compared to 42.9 ± 8.9 in the control nerve and 39.3 ± 7.3 in sham control
treated nerve) or larger A-fibres that were either myelinated or demyelinated (lysolecithin-
treated nerves contained on average 6.8 ± 1.5 A-fibres per area sampled compared to 7.9 ±
2.2 in the control nerve and 6.7 ± 3.3 in sham-treated nerves) (*P<0.05) as determined by
Kruskal-Wallis One-Way Analysis of Variance on Ranks indicating that the treatment with
lysolecithin does not affect the integrity of the axons (Figure 4.6).
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Figure 4.5. Effects of lysolecithin treatment on the myelination state of the sciatic nerve.
a) Resin sections (1 pm) from the (i) ipsilateral and (ii) contralateral sciatic nerves of
lysolecithin-treated animals on post-treatment day 13 were analysed by light
microscopy (n=3 in each case). Post lysolecithin treatment day 13 ipsilateral nerves
display complete demyelination in about 40% of A-fibres with partial demyelination
of many remaining myelinated fibres. Contralateral, nerves appear to be
morphologically normal with consistent levels of myelination across the nerve. Scale
bar: 10 pm.
b) Quantification of the degree of myelination following lysolecithin treatment to the
sciatic nerve was determined as a G-ratio from electron microscope images of (i) the
contralateral and (ii) ipsilateral sciatic nerves of lysolecithin-treated animals on post-
treatment day 13 and (iii) ipsilateral sciatic nerve of sham-treated animals post-
treatment day 13 (n=3 in each case). Results are shown as the G-ratio of each fibre
as a function of the axon diameter (i-iii) and the data are summarised as bar charts
below (iv). The data show a general decrease in myelin thickness following
lysolecithin treatment, but not sham surgery. Statistical significance (*p<0.05)
between conditions was determined by Kruskal-Wallis One Way Analysis of





















































Figure 4.6. Effects of lysolecithin treatment on afferent axons in the sciatic nerve.
Electron microscopy images of the contralateral and ipsilateral sciatic nerves of lysolecithin-
treated animals on post-treatment day 13 and ipsilateral sciatic nerve of sham-treated animals
post-treatment day 13 were compared (n=3 in each case). The images demonstrate typical
sections from; (i & ii) the lysolecithin-treated nerve, which shows markedly, reduced
myelination of (i) A-fibres (arrow) while (ii) C-fibres (arrowhead) remain intact, and sections
from (iii) contralateral, untreated nerve and (iv) ipsilateral sham treated nerve (x5000, Scale
bar: 2 pm). Unmyelinated axons were identified as small diameter fibres devoid of any
myelin sheath, which were present in bundles, surrounded by Schwann cell cytoplasm and
were individually counted for all groups (v). A-fibres (with or without lysolecithin treatment)
were identified as the larger diameter axons with myelin sheaths or smaller diameter thinly-
myelinated fibres or occasionally those with no myelin which were solitary. All of these were
individually counted (vi). Data for both fibre types are presented as average numbers of fibres
per image (292 pm2) ± SEM. A Kruskal-Wallis One Way ANOVA on Ranks showed no

















4.1.3. Electrophysiology of the lysolecithin-treated saphenous nerve.
a) 3 and 5 days following lysolecithin treatment, before development of behavioural
change
At these time points, reflex testing showed no detectable change in either mechanically or
thermally-evoked responses, indicating that a sensitised state had not yet developed.
Correspondingly, there was no presence of any abnormal afferent fibre activity at either time
point. A summary of results is displayed in Table 1.
b) Time of peak behavioural change following lysolecithin treatment.
At the time of peak behavioural change (11-13 days post treatment), the size of the
peripheral receptive field and responsiveness to innocuous brush stimulation of the
demyelinated saphenous nerve was normal as compared to naive and wild-type animals.
There was no significant difference between normal, sham and demyelinated nerves in the
response thresholds to von Frey filament (threshold force of 8.41 mN/mm") (Fig 4.7a) or the
response to thermal nociceptive stimulus which only produced a response to approximately
48-50°C (Fig 4.6b), indicating that any changes in peripheral transduction mechanisms are
probably not responsible for the behavioural reflex sensitisation observed (Table 1). The
focal nature of the demyelination and the integrity of the axons were reflected in a range of
conduction velocities that were not discernibly different from those of sham and naive
nerves. The range included slow conduction velocities of less than 1ms"1 up to the fastest in
the range of 20ms 1 and the number of units recorded for each conduction velocity did not
differ significantly between the lysolecithin-treated, sham and naive nerves (Fig 4.7c)
(*P<0.05) as determined by Kruskal-Wallis One-Way Analysis of Variance on Ranks with
all pairwise multiple comparisons procedure (Dunn's Method). A common feature of
lysolecithin-demyelinated nerves over a range of 10-14 days post application was the
presence of a spontaneous low frequency discharge (2-3 impulses/sec) (Fig 4.7d).
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Table 1. Effects of topical lysolecithin treatment of the saphenous nerve on afferent
fibre characteristics.
Electrophysiological recordings of peripheral nerve activity and cutaneous responsiveness
were performed on animals 3, 5 (n=2 each) and 11, 12 & 13 days (n=6) following
lysolecithin treatment to the saphenous nerve, 11-13 days after sham treatment (n=4) and on
naive animals (n=3). Any sensitisation of mechanical sensory receptors with high thresholds
was measured using calibrated von Frey filaments and the presence of any sensitisations of
thermally responsive receptors was measured with a calibrated radiant heat lamp. The
conduction velocity range of afferent fibres was determined using the peripheral stimulus
technique via bipolar electrodes. There was no difference in threshold for unit firing in
response to mechanical or thermal stimulation or conduction velocity range between any of
the groups. The lysolecithin-treated nerves, 11-13 days following treatment, displayed the



































Figure 4.7. Effects of topical lysolecithin treatment of the saphenous nerve on afferent
fibre characteristics.
Electrophysiological recording of peripheral nerve activity and function was performed on
animals 3-5 days (n=2 each), 11- 13 days (n=6) following lysolecithin treatment to one
saphenous nerve, 11-13 days after sham treatment (n=4) and on naive animals (n=3).
Examples of electrophysiological recordings from these nerves are displayed in each case for
i) naive, ii) sham, iii) 3-5 days post-lysolecithin, or iv) 11-13 days post-lysolecithin.
a) The mechanosensitivity of low threshold sensory receptors was tested using
calibrated von Frey filaments ranging from 6.21 to 8.41 mN/mm2. The traces shown
are in response to threshold indentation pressure (8.41 mN/mm2) in each test group.
Application represented by arrow (^).
b) The thermal sensitivity was measured with a calibrated radiant heat lamp. There was
no difference in threshold for unit firing in response to thermal stimulation. Traces
show the response of each nerve to a temperature range of maximum 50 °C over 10
seconds. There was no response to lower temperatures in any test group. The
stimulus heat ramp is superimposed onto each trace recording to indicate the onset of
threshold temperature (50°C) which is also indicated on the x-axis by an arrow (^).
c) The lysolecithin-treated nerve of animals on days 11-13 post-treatment displayed a
range of conduction velocities that were not discernibly different from those of naive
nerves (*P<0.05) as determined by Kruskal-Wallis One-Way Analysis of Variance
on Ranks with all pairwise multiple comparisons procedure (Dunn's Method). The
range included slow conduction velocities of less than 1ms"1 up to the fastest in the
range of 20ms"1 and the number of units recorded for each conduction velocity did
not differ significantly between the lysolecithin-treated d), naive (Q) and sham Q])
nerves.
d) The lysolecithin-treated nerve of animals on days 11-13 post-treatment displayed
spontaneous activity with a frequency of 2-3 impulses pre second, which was not
observed in nerves of animals 3-5 days following lysolecithin treatment nor in the
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4.1.4. Immunohistochemical investigations into the phenotype of DRG cells of the Prx-
null mouse and following lysolecithin treatment.
a) Expression of NF-200, peripherin and the indicator of axonal damage, ATF3.
In order to assess the integrity of the cell bodies of 6 week old FVx-null mice, 6 week old
wild-type mice and of mice 13 days following lysolecithin treatment of the saphenous or
sciatic nerve, we analysed the expression of NF-200, which labels the larger diameter,
myelinated DRG cell population (Lawson and Waddell, 1991;Michael and Priestley, 1999)
and peripherin, a type III intermediate filament, which is normally expressed selectively by
unmyelinated sensory neurons (Amaya et al., 2000). No difference was observed in the
average number of neurons per section immunoreactive for either peripherin or NF-200 in
DRG ipsilateral to, versus DRG contralateral to lysolecithin treatment of the sciatic nerve
(peripherin; ipsilateral, 129.7 ± 19.6, contralateral 119.7 ± 4.6); (NF-200; ipsilateral 78.5 ±
3.2, contralateral 77.3 ± 2.2) or of the saphenous nerve (peripherin; ipsilateral 120.4 ± 11.6,
contralateral 124.7 ± 8.6); (NF-200; ipsilateral 67.1 ± 6.2, contralateral 74.3 ± 13.9) or sham
treatment of the sciatic nerve (peripherin; ipsilateral 109 .46 ± 9.6 contralateral; 103 .9± 9.1) ;
(NF-200; ipsilateral 68.1 ± 9.6;contralateral; 73.4 ± 2.7) (*P<0.05) as determined by
Kruskal-Wallis One-Way Analysis of Variance on Ranks with all pairwise multiple
comparisons procedure (Dunn's Method) (Fig 4.8a). Likewise, no difference was observed
in the average number of DRG neurons immunoreactive for peripherin or NF-200 between
Prx-null or wild-type mice (peripherin; Pnr-null. 115.6 ± 14.4, wild-type 133.1 ± 9.8) (NF-
200; TVx-null 89.8 ± 14.9, wild-type 104.4 ± 8.7) (*P<0.05) as determined by a Student's
paired t-test (Figure 4.9a).
We also analysed the expression of the activating transcription factor 3 (ATF3); a member of
the activating transcription factor/cAMP-responsive element binding protein (ATF/CREB)
family (Hai et al., 1999) in the cell bodies of 6 week old Prx-null mice, 6 week old wild-type
and mice 13 days following lysolecithin treatment or sham treatment of the sciatic nerve.
ATF3 expression is induced in the DRG after peripheral nerve injury and can therefore be
utilised as a marker identifying axotomised or injured neurons (Tsujino et al., 2000). As a
positive control, we analysed the expression of ATF3 in the DRG of mice which were at the
peak of neuropathic sensitisation following CCI to the sciatic nerve and found expression of
ATF3 in 69 ± 16% of DRG neurons. However, there was no significant increase in the
average proportion of ATF3-immunopositive cells in the DRG ipsilateral to lysolecithin
treatment (7.3 ± 3.2%) as compared to the contralateral side (6.1 ± 1.4 %) or to sham treated
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animals (ipsilateral 8.2 ± 3.4%;contralateral; 5.1 ± 3.2%) (*P<0.05) as determined by
Kruskal-Wallis One-Way Analysis of Variance on Ranks with all pairwise multiple
comparisons procedure (Dunn's Method) (Fig 4.8b) or in the DRG of FVx-null mice (8.2 ±
2.4%) as compared to wild-type mice (6.6 ±1.7 %) (*P<0.05) as determined by a Student's
paired t-test (Fig 4.9b). All control sections, which had the primary antibodies omitted,
showed no immunofluorescence confirming the specificity of the secondary antibodies
which were subsequently used for all immunohistochemistry. For a summary of results see
Tables 2a and 2b.
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Figure 4.8 Immunohistochemical assessment of NF-200 and peripherin in DRG cells 12
days post lysolecithin treatment of the saphenous or sciatic nerve, and the marker
indicative of axonal damage, ATF3, in DRG cells 12 days post lysolecithin treatment of
the sciatic nerve.
a) The expression of the neuronal structural markers peripherin (i,iii) and NF-200 (ii,iv) in
ipsilateral and contralateral DRG sections from animals following lysolecithin treatment
to the sciatic (i,ii) or saphenous (iii,iv) nerve on post treatment day 13 (n=4). Peripherin
is expressed by small diameter unmyelinated cells and NF-200 by the medium to large
diameter myelinated cells. As determined by a paired Student's t-test, there was no
statistically significant difference in the number of cells expressing either marker
following treatment with lysolecithin. Data are presented as the average number of
immunopositive cells per DRG section ± SEM. Examples of cells immunopositive for
peripherin are shown in images in Figures 4.10a and examples of cells immunopositive
for NF-200 in Figures 4.8b, 4.9b and 4.10b-d.
b) The expression of the activating transcription factor 3 (ATF3) in ipsilateral and
contralateral DRG sections from sciatic nerve lysolecithin-treated or sham treated
animals on post treatment day 13 (n=4). There was no statistically significant increase in
expression of ATF3 from that seen in control DRG following lysolecithin treatment or
sham-treatment, although there was following CCI on day 12 corresponding to peak
neuropathic change (Garry et al., 2001). The statistical significance (*P<0.05) as
determined by Kruskal-Wallis One Way Analysis of Variance on Ranks with all pairwise
multiple comparisons procedure (Dunn's Method). Images show ATF3-immunopositive
cells labelled with FITC (green) and NF-200-immunopositive cells labelled with TRITC
(red) in (i) ipsilateral DRG from CCI operated animals, (ii) ipsilateral and (iii)
contralateral DRG from lysolecithin-treated animals. Scale bar: 20 pm.
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Figure 4.9. lmmunohistochemical assessment of NF-200 and peripherin and the marker
indicative of axonal damage, ATF3 in DRG cells of 6 week old Prx-null mice and wild-
type littermates.
a) The expression of the neuronal structural markers peripherin (i) and NF-200 (ii) in
DRG sections from 6 week old Prx-mi\\ mice (n=4) and wild-type (WT) littermates
(n=4). Peripherin is expressed by small diameter unmyelinated cells and NF-200 by
the medium to large diameter myelinated cells. As determined by a paired Student's
t-test, there was no statistically significant difference in the number of cells
expressing either marker following treatment with lysolecithin. Data are presented as
the average number of immunopositive cells per DRG section ± SEM. Examples of
cells immunopositive for peripherin are shown in images in Figure 4.11a and
examples of cells immunopositive for NF-200 in Figures 4.1 lb,c and 4.12.
b) The expression of the activating transcription factor 3 (ATF3) in DRG sections from
6 week old /Vx-null mice (n=4) and wild-type (WT) littermates (n=4). There was no
significant increase in expression of ATF3 from that seen in control DRG following
lysolecithin treatment or sham-treatment. The statistical significance of any
difference was determined by a Kruskal-Wallis One Way ANOVA on Ranks with all
pairwise multiple comparison procedures (Dunn's Method). Images show ATF3-
immunopositive cells labelled with FITC (green) and NF-200-immunopositive cells
labelled with TRITC (red) in DRG from (i) 6 week old Prx-null animals and (ii)
wild-type (WT) littermates. Scale bar: 20 pm.
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Table 2. Cell counts from immunohistochemical assessment of NF-200, peripherin and
the indicator of axonal damage ATF3, in the DRG following lysolecithin treatment of
the sciatic nerve and in the DRG of 6 week old EVw-null mice and wild-type littermates.
a) The expression of NF-200, peripherin and the indicator of axonal damage, activating
transcription factor 3 (ATF3) in DRG cells ipsilateral and contralateral to either
lysolecithin treatment of the sciatic nerve or saphenous nerve on post treatment day
13 (n=3 in each case). There was no difference in the number of cells expressing NF-
200, peripherin or ATF3 following treatment with lysolecithin as compared to
contralateral DRG as determined by a Kruskal-Wallis One-Way ANOVA on Ranks.
Data are presented as the average number of immunopositive cells per DRG section
± SEM for NF-200 and peripherin or as average percentage of NF-200
immunopositive cells expressing ATF3 per DRG section ± SEM.
b) The expression of NF-200 and peripherin and the indicator of axonal damage
activating transcription factor 3 (ATF3) in DRG cells from 6 week old FVx-null mice
(n=4). There was no difference in the number of cells expressing NF-200, peripherin
or ATF3 in cells from Prx-null mice as compared to wild-type (WT) littermates
(n=4) as determined by Kruskal-Wallis One Way ANOVA on Ranks. Data are
presented as the average number of immunopositive cells per DRG section + SEM
for NF-200 and peripherin or as average percentage of NF-200 immunopositive cells













NF-200 78.5 ±3.2 77.3 ±2.2 68.1 ± 9.6 73.4 ± 2.7
peripherin 129.7 ± 19.6 119.7 ±4.6 109.4± 9.6 103,9± 1.9
Average number of immunopositive cells per DRG
section as % ofNF-200 immunopositve cells
ATF3 7.3 ±3.2% 6.1 ± 1.4 % 8.2 ±3.4% 5.1 ±3.2%
b)
Antigen Average number of immunopositive cells per DRG section
Prx -null Wild Type
NF-200 89.8 ± 14.9 104.4 ± 8.7
peripherin 115.6 ± 14.4 133.1 ± 9.8
Average number of immunopositive cells per DRG
section as % ofNF-200 immunopositve cells
ATF3 8.2 ± 2.4% 6.6 ±1.7%
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b) Expression of selected peptides in DRG; CGRP, galanin, VIP and NPY.
Following traumatic injury to the peripheral nerve, a number of neurochemical and
morphological changes occur in the peripheral nerve fibres and centrally in the spinal cord
(Dray et al., 1994;Hokfelt et al., 1994), which can contribute to altered sensory transmission
such as that associated with chronic pain states. A key event is the characteristic phenotypic
change that occurs in many primary afferent neurons, reflected in the altered expression of
neuropeptides in their cell bodies in the DRG (Hokfelt et ah, 1994;Villar et ah, 1991).
Following injury, there are known to be marked changes in the expression of several
neuropeptides including CGRP, SP, galanin, VIP and neuropeptide Y (NPY). We therefore
investigated whether some of these characteristic changes occur in our models of
demyelination to compare the presence of any similarities to those occurring in other models
of neuropathic pain in which axonal damage is a major factor.
CGRP is normally expressed by approximately 50% of unmyelinated DRG neurons as well
as one-fifth of AS myelinated neurons (Hokfelt et ah, 1994;McCarthy and Lawson,
1990;Rosenfeld et ah, 1983). It is known that the expression of CGRP is downregulated
following peripheral nerve injury such as axotomy and CCI (Dumoulin et ah, 1992;Noguchi
et ah, 1990). However, there was no significant difference in the numbers of DRG cells
expressing lmmunoreactive CGRP following lysolecithin treatment of one sciatic nerve
(ipsilateral 145.9 ± 19.7, contralateral 154.5 ± 9.1) or of one saphenous nerve (ipsilateral
129.9 ± 8.7, contralateral 135.3 ± 7.4) (*P<0.05) as determined by a Student's paired t-test,
suggesting that lysolecithin treatment caused no extensive damage to CGRP-expressing cells
in the DRG (Fig 4.10a). Likewise, there was no significant difference in the numbers of
DRG cells expressing immunoreactive CGRP in /Vx-null mice as compared to wild-type
mice (/Vx-null 145.7 ± 27.0, wild-type 143.3 ± 20.1) (*P<0.05) as determined by a Student's
paired t-test (Fig 4.11a). Furthermore, in line with previously reported patterns of CGRP
expression in the DRG, we observed colocalisation of CGRP in approximately 50% of DRG-
cells expressing peripherin as well as approximately 20% which were peripherin-negative in
the DRG from lysolecithin-treated mice and /Vx-null mice. As there was no change in
expression of CGRP in either model when investigated immunohistochemically using
peripherin as a co-stain, we did not repeat the immunostaining experiment with co-staining
for NF-200. SP is normally expressed by -20% of DRG neurons which are mainly of small
diameter (Hokfelt et ah, 1975;Ju G et ah, 1987). Following peripheral nerve injury such as
axotomy and CCI. the expression of SP is also dramatically downregulated (Jessell et ah,
1979;Nielsch et ah, 1987). However, there was no significant difference in the numbers of
DRG cells expressing immunoreactive SP following lysolecithin treatment of one sciatic
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nerve (ipsilateral 55.6 ± 4.2, contralateral 59.4 ± 5.4) or of one saphenous nerve (ipsilateral
61.1+ 5.7, contralateral 57.2 ± 4.4) (*P<0.05) as determined by a Student's paired t-test (Fig
4.10a) suggesting that lysolecithin treatment also caused no extensive damage to SP-
expressing cells in the DRG which correlates with the fact that most SP containing cells also
contain CGRP. Likewise, there was no significant difference in the number of DRG cells
expressing immunoreactive SP in Prx-null mice as compared to wild-type mice (/Vx-null
49.7 ± 6.0, wild-type 52 ± 6.1) (*P<0.05) as determined by a Student's paired t-test (Fig
4.11b).
As we had demonstrated there to be no change in the number of NF-200 or peripherin-
immunoreactive cell bodies in the DRG of either model of peripheral nerve demyelination,
we decided to restrict further immunohistochemical investigations to the sciatic model of
lysolecithin-induced demyelination and the /Vx-null mouse (with appropriate controls).
Furthermore, as there is no change in the expression of CGRP or SP following lysolecithin
application to either the sciatic or saphenous nerve, it would appear that the effects of
demyelination are similar regardless of the nerve affected by lysolecithin. We chose the
sciatic model as opposed to the saphenous nerve model due to the sciatic nerve being a larger
nerve with more afferent axons and therefore a larger proportion of cell bodies in the lumbar
DRG as opposed to the saphenous nerve. Therefore, any effect of demyelination on the
phenotype of associated cell bodies should be easier to detect in the model of sciatic nerve
demyelination. Galanin is a peptide normally expressed at very low levels in sensory and
sympathetic neurons. However, following peripheral nerve lesions, it is strongly upregulated
mainly in small and medium sized neurons (Hokfelt et ah, 1987;Villar et ah, 1989)
especially those that normally contain substance P and CGRP (Kashiba et ah, 1992b), the
majority of which are unmyelinated. However, we observed no significant immunoreactivity
for galanin in DRG cells either ipsilateral or contralateral to lysolecithin-induced focal
demyelination of one sciatic nerve or in the cells of the DRG ofPrx-null mice. As a positive
control to test the specificity of the antibody, we used DRG dissected from mice at peak
neuropathic sensitisation following CCI treatment to the right sciatic nerve (Garry et ah,
2001). These sections showed a significant proportion of mainly small diameter cells
positive for galanin (ipsilateral 9.3 ±2.4 cells per section; contralateral 0), verifying that the
antibody could successfully detect the presence of galanin and its increased expression (Fig
4.10c) and that there is, in contrast, no significant upregulation following lysolecithin
treatment or in /Vx-null mice (no data presented due to lack of change).
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VIP is normally expressed only at very low levels in DRG neurons and in neurons in LI and
LII of the spinal dorsal horn (Gibson SJ et al., 1981;Rittenhouse et al., 1996). However,
following nerve injury, levels of VIP are also markedly increased, predominantly in small to
medium- sized afferent neurons, especially those that normally contain SP and CGRP
(Kashiba et al., 1992;Xu XJ et al., 1990;Zhang et al., 1995). We attempted to investigate
whether such changes were present in either model of demyelination. However, the
immunostaining we achieved with different, recommended, VIP antibodies (see Chapter 3)
was not of sufficient quality for the accurate analysis of data. Therefore, we have not
included any results on VIP immunoreactivity in the DRG in either model of demyelination.
NPY is not normally expressed in DRG cells. However, the expression of NPY is strongly
upregulated in DRG neurons after nerve injuries such as axotomy (Kashiba et al.,
1994;Wakisaka et al., 1991) and CCI (Munglani et al., 1995;Nahin et al., 1994). This
upregulation occurs mainly in large primary sensory neurons containing the 200kDa subunit
of neurofilaments (Kashiba et al., 1994;Marchand et al., 1999). In line with this we observed
significant NPY-immunoreactivity in 15.9 ± 2.2 % cells following demyelination of one
sciatic nerve (185 NPY-positive cells from 1164 NF-200-positive cells counted over 26
sections (n=3)) as opposed to no detectable immunoreactivity in contralateral or sham nerves
(Fig 4.10d) (*P<0.05) as determined by Kruskal-Wallis One-Way Analysis of Variance on
Ranks with all pairwise multiple comparisons procedure (Dunn's Method). A similar,
significant upregulation was observed in /Vx-null mice, which demonstrated NPY-
immunoreactivity in 13.6 ± 2.6 % of cells in the DRG (150 NPY-positive cells from 1104
NF-200-positive cells counted over 16 sections (n=3) 2 as opposed to no significant
immunoreactivity in wild-type DRG cells (Fig 4.11c) (*P<0.05) as determined by a
Student's paired t-test. All NPY-immunopositive cells were also immunoreactive for NF-200
indicating that they were cells with myelinated fibres and therefore, the immunostaining for
NPY was not also repeated with co-staining for peripherin. For summary of results as
compared to axotomy and CCI changes (described in Chapter 1) see Table 3.
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Figure 4.10. Immunohistochemical assessment of the neuropeptides CGRP and SP in
DRG cells 13 days post lysolecithin treatment of the sciatic nerve.
a) The expression of the peptide CGRP in ipsilateral and contralateral DRG sections
from animals following lysolecithin treatment to (i) the sciatic or (ii) the saphenous
nerve on post treatment day 13 (n=4). The expression of CGRP is known to decrease
following nerve injury in various models of neuropathic pain. There was no change
in the number of cells expressing CGRP following treatment with lysolecithin. The
statistical significance (*P<0.05) of any difference was determined by a paired
Student's t-test. Data are presented as (i & ii) average number of CGRP-
immunopositive cells per DRG section ± SEM and images show CGRP
immunopositive cells labelled with FITC (green) and peripherin-immunopositive
cells labelled with TRITC (red) (with colocalised immunoreactivity appearing
yellow) in (iii) ipsilateral and (iv) contralateral DRG from sciatic lysolecithin-treated
animals. Scale bar: 20 pm.
b) The expression of the peptide SP in ipsilateral and contralateral DRG sections from
animals following lysolecithin treatment to (i) the sciatic or (ii) the saphenous nerve
on post treatment day 13 (n=4). The expression of SP is known to decrease following
nerve injury in various models of neuropathic pain. There was no change in the
number of cells expressing SP following treatment with lysolecithin. The statistical
significance (*P<0.05) of any difference was determined by a paired Student's t-test.
Data are presented as (i & ii) average number of immunopositive cells per DRG
section ± SEM and images show SP-immunopositive cells labelled with FITC
(green) and NF-200 immunopositive cells labelled with TRITC (red) (with
colocalised immunoreactivity appearing yellow) in (iii) ipsilateral and (iv)












































































Figure 4.10 cont.... Immunohistochemical assessment of the neuropeptides galanin and
NPY in DRG cells 12 days post lysolecithin treatment of the sciatic nerve.
c) The expression of the peptide galanin in DRG of animals at peak neuropathic
sensitisation following lysolecithin treatment to the sciatic nerve on post-treatment
day 13 (n=4) as compared to DRG from animals following CCI treatment to the right
sciatic nerve on post treatment day 13. The immunopositive cells in the DRG from
CCI-treated animals demonstrated the specificity of the antibody. No
immunoreactivity was seen in the DRG of animals following lysolecithin treatment
of the sciatic nerve (n=4). The statistical significance of any difference from CCI
(*P<0.05) was determined by a paired Student's t-test. Data are presented as (i)
average number of immunopositive cells per DRG section ± SEM and (ii) images
shows galanin-immunopositive cells labelled with FITC (green) and NF-200
immunopositive cells labelled with TRITC (red) (with colocalised immunoreactivity
appearing yellow) in the DRG of CCI-treated animals. Scale bar: 20 pm.
d) The expression of the peptide NPY in ipsilateral and contralateral DRG sections from
animals following lysolecithin treatment to the sciatic nerve on post-treatment day 13
(n=4). Following lysolecithin treatment of the sciatic nerve we saw a significant
number of NF-200 immunopositive cells expressing NPY (15.9 ± 2.2 %) (*P<0.05)
as determined by Kruskal-Wallis One Way Analysis of Variance on Ranks with all
pairwise multiple comparisons procedure (Dunn's Method). No NF-200 negative
cells expressed NPY. There was no detectable expression of NPY in the DRG from
naive or sham treated animals. Data are presented as (i) average number of
immunopositive cells per DRG section ± SEM and images show NPY-
immunopositive cells labelled with FITC (green) and NF-200 immunopositive cells
labelled with TRITC (red) (with colocalised immunoreactivity appearing
yellow/green) in DRG (ii) ipsilateral to lysolecithin treatment as opposed to no
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Figure 4.11. Immunohistochemical assessment of the neuropeptides CGRP, SP and
NPY in DRG cells of 6 week old /Vx-null mice and wild-type littermates.
a) The expression of the peptide CGRP in DRG sections from 6 week old /Vx-null mice
(n=4) and wild-type (WT) littermates (n=4).. There was no statistical difference in
the number of cells expressing CGRP between /Vx-null and wild-type DRG
(*P<0.05) as determined by a paired Student's t-test. Data is presented as (i) average
number of immunopositive cells per DRG section ± SEM and images show CGRP-
immunopositive cells labelled with FITC (green) and peripherin-immunopositive
cells labelled with TR1TC (red) (with colocalised immunoreactivity appearing
yellow) in DRG sections from (ii) 6 week old /Vx-null mice and (iii) wild-type (WT)
littermates. Scale bar: 20 pm
b) The expression of the peptide SP in DRG sections from 6 week old /Vx-null mice
(n=4) and wild-type (WT) littermates (n=4).. There was no change in the number of
cells expressing SP between /Vx-null and wild-type DRG (*P<0.05) as determined
by a paired Student's t-test. Data are presented as (i) average number of
immunopositive cells per DRG section ± SEM and images show SP-immunopositive
cells labelled with FITC (green) and NF-200 immunopositive cells labelled with
TR1TC (red) (with colocalised immunoreactivity appearing yellow) in DRG sections
from (ii) 6 week old /Vx-null mice and (iii) wild-type (WT) littermates. Scale bar: 20
pm.
The data regarding the expression of galanin is not shown as there were no
immunopositive cells present in the DRG of /Vx-null or wild-type (WT) mice. For
counts and images of the positive control DRG from CCI-treated animals see Fig
4.8c.
c) The expression of the neuropeptide NPY in DRG sections from 6 week old /Vx-null
mice (n=4) and wild-type (WT) littermates (n=4). We saw a significant number of
NF-200-immunopositive cells expressing NPY (13.6 ± 2.6 %) in the DRG of /Vx-
null mice (*P<0.05) as determined by a paired Student's t-test. No NF-200-negative
cells expressed NPY. There was no expression of NPY in the DRG from wild-type
(WT) animals. Images show NPY-immunopositive cells labelled with FITC (green)
and NF-200 immunopositive cells labelled with TRITC (red) (with colocalisation
appearing yellow) in DRG of (i) /Vx-null mice as opposed to the lack of positive
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c) Expression of the Na+ channels; SNS 1/ Nav1.8 and brain type III/ Nav1.3.
DRG neurons express a complex repertoire of sodium channel transcripts (Waxman et al.,
1999b) distinguished by their sensitivity to tetrodotoxin (TTX) (Black and Waxman, 1996).
The TTX-resistant sodium channel SNS 1/Nav1.8 has been shown to be expressed normally
in approximately 50% of cells with small diameter unmyelinated axons (Amaya et al., 2000)
and in around 20% ofmedium to large diameter myelinated cells. Our results agree with this
pattern of expression. In the contralateral DRG of lysolecithin-treated animals, we saw an
average rate of SNS 1/Nav1.8 expression in 1078 of 2130 (51%) peripherin-immunopositive
cells sampled and 500 of 2086 (24%) NF-200 -immunopositive cells sampled. This is similar
to levels of expression in the DRG of wild-type mice where we saw SNS 1/Nav1.8
expression in 1090 of 2083 (57%) peripherin-immunopositive cells sampled and 389 of 1561
(25%) NF-200-immunopositive cells sampled. Likewise, in sham controls we saw SNS
1/Nav1.8 expressed in 51% of peripherin-immunopositive cells ipsilaterally, 48%
contralaterally and in 23% of NF-200-immunopositive cells ipsilaterally and 22 %
contralaterally.
It has been shown previously that following axotomy and CCI, expression of SNS 1 is
downregulated in neurons in the DRG (Dib-Flajj et al., 1999;Dray and Urban, 1996), a
change that may contribute to the production of a neuropathic pain state. Therefore we have
employed immunohistochemical techniques to detect the presence of any changes in
expression of SNS 1/Nav1.8 in the /Vx-null mouse and following lysolecithin-induced
demyelination of the sciatic nerve. In the L4, L5 and L6 DRG taken from animals 13 days
post lysolecithin -treatment to the sciatic nerve, there was a 34 ± 6.3 % reduction of SNS
1/Nav1.8 expression in the ipsilateral DRG (62.4 ± 3.4 SNS 1/Navl.8-immunopositive cells
per section) versus the contralateral DRG (94.7 ± 4.7 SNS 1/Navl .8-immunopositive cells
per section) and sham DRG (95.7 ± 6.0 SNS 1/Navl.8-immunopositive cells per section) (Fig
4.12a) as determined from sections co-stained with either peripherin or NF-200. Co-staining
with these cell-type specific markers demonstrated that this reduction appeared to be
restricted to NF-200-immunopositive cells, i.e. those presumed to have formerly myelinated
axons (Fig 4.12a). Counts of SNS 1/Nav1.8 immunostained sections costained for NF-200
revealed a significant reduction (by 38.4 ± 4.2 %) in the average number of SNS 1/Nav1.8 -
immunopositive cells per section which were immunoreactive for NF-200 in the DRG
ipsilateral to the demyelinated sciatic nerve (15.7 ± 1.6 %), compared to the DRG
contralateral to the demyelinated sciatic nerve (25.3 ± 2.6%) (Fig 4.12a), which accounted
for all of the overall reduction in SNS 1/Nav1.8 expression in the ipsilateral DRG. No
change in the number of cells coexpressing SNS 1/Nav1.8 and NF-200 was observed
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between the ipsilateral DRG (22.5 ± 2.7%) or contralateral DRG (22.2 ± 2.9%) of sham
control animals (Fig 4.12a). There was no decrease in the proportion of peripherin-
immunoreactive cells expressing SNS 1/Nav1.8 following lysolecithin treatment (ipsilateral
54.8 ± 3.7 %, contralateral 49.1 ± 6.3 %) (Fig 4.12a).
In the DRG from Prx-null mice there was a 42 ± 7.8 % reduction of SNS 1/Nav1.8
expression (72.6 + 7.8 SNS 1/Nav1.8 -immunopositive cells per section) as compared to the
wild-type mouse (124 ± 7.4 SNS 1/Nav1.8 -immunopositive cells per section) (Fig 4.13a).
Co-staining with cell-type specific markers also demonstrated that this reduction was
restricted to NF-200-immunopositive cells thought to have formerly myelinated axons. As
with the lysolecithin-treated animals, there was decrease in the proportion of peripherin-
immunoreactive cells expressing SNS 1/Nav1.8 {Prx-null mouse 55.8 ± 3.7 %, wild-type
mouse 59.1 ± 6.3 %); and again the significant reduction by 48.4 ± 2.6 % in the average
number of SNS 1/Nav 1.8-immunopositive cells per section that were immunoreactive for
NF-200 in the DRG of /Vx-null mice (13.3 ± 4.0 %) as compared to the DRG of wild-type
mice (25.3 ± 2.7%) accounted for the overall reduction in SNS 1/Nav1.8 expression (Fig
4.13a).
The brain type III sodium channel/Nav1.3 is normally found in DRG only during
development. However, its expression has been reported to increase in sensory neurons
following axotomy (Black et al., 1999), CCI and spinal nerve ligation (Kim et ah, 2001a).
Therefore we have also employed immunohistochemical techniques to detect the presence of
any changes in expression of the type III/ Nav1.3 sodium channel following lysolecithin-
induced demyelination of the sciatic nerve. There were, on average, 9.1 Nav1.3-
immunopositive cells out of 49.4 NF-200-immunoreactive cells per DRG section (18.5 ±
2.4%) ipsilaterally (Fig 4.12). Similarly, the cells in the DRG of /Vx-null mice showed on
average 9.6 Nav 1.3-immunoreactive cells out of 61.3 NF-200-immunoreactive cells per DRG
section (15.6 ± 2.5%) (Fig 4.13). In both models, all brightly fluorescent sodium channel
type III/Nav 1.3-immunoreactive cells were NF-200-positive (Fig 4.12b and 4.13b). In both
cases, the upregulation of type III/ Nav1.3 was significant compared to the lack of any
obvious bright immunoreactivity above background levels observed in the DRG contralateral
to lysolecithin treatment or in sham control DRG (*P<0.05) as determined by Kruskal-Wallis
One-Way ANOVA on Ranks with all pairwise multiple comparisons procedure (Dunn's
Method or in wild-type httermates of /Vx-null mice (*P<0.05) as determined by a Student's
paired t-test. For a summary of results as compared to CCI and axotomy changes (Hokfelt et
ah, 1994) see Table 3.
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Figure 4.12. Immunohistochemical assessment of the sodium channels; SNS 1 /
Nav1.8 and brain type III/ Nav1.3 in DRG cells 13 days post lysolecithin treatment of
the sciatic nerve.
a) The expression of the sodium channel SNS 1/Nav1.8 in ipsilateral and contralateral
DRG sections from lysolecithin-treated animals on post-treatment day 13, and sham-
treated animals post-treatment day 14 (n=3 in each case). Following lysolecithin
treatment of the sciatic nerve we saw (i) a statistically significant decrease of 34 ± 6.3
% in the number of cells expressing SNS 1/Nav1.8 in ipsilateral DRG compared to
contralateral DRG, all of which were (ii) immunopositive for NF-200 and there was
(iii) no decrease of SNS 1 expression in peripherin immunopositive cells. There was
no significant decrease in expression following sham treatment. The statistical
significance (*p<0.05) of any difference was determined by a Kruskal-Wallis One
Way ANOVA on Ranks with an all pairwise multiple comparisons procedure
(Dunn's Method). Data is presented as (i) average number of immunopositive cells
per DRG section ± SEM and as (ii) % of NF200 cells immunpositive for SNS
1/Nav1.8 or (iii) % of peripherin cells immunpositive for SNS 1. Images show SNS
l/Navl.8-imnuinopositive cells labelled with FITC (green) and NF-200
immunopositive cells labelled with TR1TC (red) (with colocalised immunoreactivity
appearing yellow) in (iv) ipsilateral and (v) contralateral DRG from lysolecithin-
treated animals. Scale bar: 20 pm.
b) The expression of the brain type III sodium channel/ Nav1.3 in ipsilateral and
contralateral DRG sections from lysolecithin-treated animals on post treatment day
13 (n=4). We saw a statistically significant increase in expression of type III/Navl .3
expression ipsilateral to the lysolecithin treated nerve (*p<0.05) as determined by a
paired Student's t-test. Data is presented as (i) % of NF200 cells immunpositive for
type III/Nav1.3 Images show type III/Nav1.3-immunopositive cells labelled with
FITC (green) and NF-200 immunopositive cells labelled with TRITC (red) (with
colocalised immunoreactivity appearing yellow) in (ii) ipsilateral DRG from
lysolecithin-treated animals as opposed to no type III/Nav1.3-immunopositive cells in
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Figure 4.13. Immunohistochemical assessment of the sodium channels; SNS 1/Nav1.8
and brain type III/ Nav1.3 in DRG cells of 6 week old /Vx-null mice and wild-type
littermates.
a) The expression of the sodium channel SNS 1/Nav1.8 in DRG sections from 6 week
old Prx-null mice (n=4) and wild-type (WT) littermates (n=4). (i) /Vx-null mice
showed a statistically significant decrease of 42% ± 7.8 in expression of SNS
1/Nav1.8 as compared to wild-type (WT), all of which were (ii) immunopositive for
NF-200 and there was (iii) no decrease of SNS 1/Nav1.8 expression in peripherin
immunopositive cells. The statistical significance (*p<0.05) of any difference was
determined by a Kruskal-Wallis One Way ANOVA on Ranks with an all pairwise
multiple comparison procedure (Dunn's Method). Data is presented as (i) average
number of immunopositive cells per DRG section ± SEM and as (ii) % of NF-200
cells immunpositive for SNS 1/Nav1.8 or (iii) % of peripherin cells immunpositive
for SNS 1/Nav1.8. Images show SNS 1/Nav1.8 -immunopositive cells labelled with
FITC (green) and NF-200 immunopositive cells labelled with TRITC (red) (with
colocalised immunoreactivity appearing yellow) in DRG of (iv) /Vx-null mice and
(v) wild-type (WT) mice. Scale bar: 20 pm.
b) The expression of the brain type III sodium channel/ Nav1.3 in DRG sections from 6
week old /Vx-null mice (n=4) and wild-type (WT) littermates (n=4). We saw a
statistically significant increase in expression of type III/ Nav1.3 expression in DRG
from 6 week old /Vx-null mice (*p<0.05) as determined by a paired Student's t-test.
Data is presented as (i) % of NF200 cells immunpositive for type III/ Nav1.3. Images
show type III/Nav 1.3-immunopositive cells labelled with FITC (green) and NF-200
immunopositive cells labelled with TRITC (red) (with colocalised immunoreactivity
appearing yellow) in DRG of (ii) /Vx-null mice as opposed to no detectable type III/















































Table 3. Changes in expression of neuropeptides and the sodium channels in the DRG
following lysolecithin treatment of the sciatic nerve and DRG of 6 week old Prv-null
mice as compared to reported changes following axotomy and CCI.
The changes in expression of the peptides CGRP, SP, galanin and NPY and sodium channels
SNS 1/ Nav1.8 and brain type III/Nav1.3 are compared for DRG sections ipsilateral to
lysolecithin treatment on post-treatment day 13 (peak behavioural sensitisation) (n=4), DRG
sections from 6 week old /Vx-null mice and reported changes at times of peak behavioural
sensitisation following nerve injury models axotomy and CCI. Downregulation of expression
in small diameter cells of unmyelinated afferents is represented by (-u), in just medium to
large diameter cells of myelinated afferents by (-m) and in both small and medium to large
diameter cells by (—). Upregulation in just small diameter cells of unmyelinated afferents is
represented by (+u), in just large diameter cells of myelinated afferents by (+m) and in both
small and medium to large diameter cells by (++). No change in expression between



















SP - u +m - u 0 0
Galanin +4- ++ 0 0
NPY +m + m + m + m
SNS 1 - m - m
Type III + + + + + m + m
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4.2: Discussion
Correlates of neuropathic pain such as spontaneous pain, hyperalgesia and allodvnia are
often symptoms associated with human demyelinating neuropathies such as Multiple
Sclerosis (MS), Charcot-Marie-Tooth type I disease (CMT) and Guillain-Barre Syndrome
(GBS). Although sensory deficits are usually less severe than motor deficits, pain has been
reported to be a problem in 70% of CMT sufferers (Carter et al., 1998) indicating it as a
substantial clinical problem. Even though axonal pathology has not always been adequately
investigated in demyelinating neuropathies, it is generally believed that pain associated with
demyelinating conditions results from axonal damage. As a result, the consequences of the
lack of myelin alone have, to date, been largely ignored. Furthermore, existing animal
models of neuropathic pain, such as CCI, involve massive demyelination of the injured
nerve, implying that this process could have an important role in the resulting chronic pain.
Nevertheless, mechanisms underlying neuropathic pain which occur as a consequence of
demyelination of the peripheral nerve are poorly understood (Rasminsky, 1981). Therefore,
we have utilised a recently described model of peripheral nerve demyelination. the Prx-mx\\
mouse, and subsequently developed an animal model of focal peripheral nerve
demyelination, using the myelinolytic agent lysolecithin, in order to study neuropathic pain
following peripheral dcmyelination.
4.2.1. Altered afferent characteristics and behavioural reflex sensitivity in /Vx-null
mice
The /Vx-null mouse is unique in the late onset and the severity of its demyelinating
phenotype, which shows parallels with demyelinating neuropathies of adult onset (Dyck et
al., 1993). Furthermore, mutations in the human PRX gene have recently been linked to the
condition, CMT4F, the clinical and histopathological features of which show striking
similarities to the phenotype of the Prx-null mouse (Boerkoel et ah, 2002;Gillespie et al.,
2000;Guilbot et ah, 2001). This evidence substantiates the /Vx-null mouse as a model of
CMT-like demyelinating disease (Guilbot et ah, 2001) indicating it as a good model in which
to study pain associated with demyelination. At 6 weeks of age, the function of the sciatic
nerves of Prx-null mice are affected relatively mildly when compared to other mice in which
myelin proteins have been altered (Gillespie et al., 2000). This is reflected in the lack of any
overt motor deficit in these animals using the mechanical grip test (Meyer, 1979). However,
afferent conduction velocities are reduced by approximately 50% indicative of
demyelination of axons. By 6 months of age, extensive demyelination is observed in a
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variety of myelinated nerves throughout the PNS of the mutant and conduction velocities in
the sciatic and saphenous nerves of the mutant animal are reduced by 67% as compared to
wild-type animals. Previous work, investigating the electrophysiological properties of the
saphenous nerve in 6 week old TVx-null animals, revealed that although there is no evidence
for changes in the stimulus-response relationship in C- or A- fibres to either cutaneous
mechanical or thermal nociceptive stimulation, spontaneous discharge of 1-2 impulses per
second is present in saphenous fibres across the conduction velocity range (Gillespie et al.,
2000). This spontaneous activity is of interest to this study due to the fact that the generation
of impulses at abnormal locations along the axon of sensory neurons (Devor and Seltzer,
1999) is thought to play an important role in the generation of neuropathic pain. Such
'ectopic' activity is known to emerge due to various components of the injury, which can
include an area of demyelination (Baker and Bostock. 1992;Calvin et ah, 1982;Rasminsky,
1978;Smith and McDonald, 1980), and is likely to be the origin of ectopic discharge in our
models of peripheral nerve demyelination. Furthermore, although repetitive C-afferent axon
stimulation is required to bring about a neuropathic pain state in many animal models of
nerve injury (Coderre, 1993); (Amaya et ah, 2000), it may also be maintained and promoted
by Ap-fibre input (Woolf and Costigan. 1999) and ectopic activity in A-fibres alone has been
suggested to be sufficient to trigger tactile allodynia in some models of peripheral
neuropathic pain (Liu et ah, 2000; Wu et ah, 2000). Therefore, this feature of the phenotype
prompted us to investigate the behavioural reflex sensitivities of 6 week old and 6 month old
Prx-null mice. We have demonstrated that at both ages, the Prx-null mice have significantly
sensitised thresholds for hindpaw withdrawal responses to mechanical and noxious thermal
stimuli, indicating the presence of behavioural correlates of abnormal thermal hyperalgesia
and mechanical allodynia indicative of a neuropathic pain-like state.
143
4.2.2. Immunohistochemical investigation of evidence for DRG cell loss or axonal
damage in the /Vx-null mouse.
For any analysis of the mechanisms underlying neuropathic pain as a consequence of myelin
loss it is of great importance that there are no axonopathic changes associated i.e. any axonal
damage. Previous work characterising the phenotype of the 6 week old /Vx-null mouse
indicated no evidence for axonal degeneration or cell loss in the DRG (Gillespie et al.,
2000). We confirmed this by investigating the presence of NF-200, which labels the larger
diameter, myelinated DRG cell population (Lawson and Waddell, 1991;Michael and
Priestley, 1999), and peripherin, a type III intermediate filament, which is normally
expressed selectively by unmyelinated sensory neurons (Amaya et al., 2000). We
demonstrated that there was no difference in the number of cells expressing either marker
between the DRG of Prx-null and wild-type mice. Importantly there was also no evidence
for significant expression of the indicator of axonal injur}', ATF3 (Tsujino et al., 2000).
Therefore we can find no evidence that this model of peripheral nerve demyelination shows
any associated axonopathy or cell loss at 6 weeks of age.
4.2.3. Altered behavioural reflex sensitivity following lysolecithin-induced, focal
demyelination of the peripheral nerve.
The emerging link between peripheral nerve demyelination and neuropathic pain in the /Vx-
null mouse prompted us to create a more refined model of peripheral nerve demyelination in
which to address the study of neuropathic pain. Furthermore, we felt that it was important
for such a study of neuropathic pain that firstly, the effects of demyelination in motor fibres
were kept to a minimum; and secondly, that any whole body effects of inactivating a gene, in
pre- and post-natal development, were eliminated. Therefore, we sought to refine a model of
peripheral nerve demyelination to target individual sensory nerves with areas of focal
demyelination. To achieve this we have developed a model of focal demyelination in the
predominantly sensory, saphenous nerve, and in the sciatic nerve using the non-toxic,
myelinolytic agent, lysophosphatidyl choline (lysolecithin) (Hall and Gregson. 1971).
Following lysolecithin-treatment of either the saphenous or sciatic nerve, we have
demonstrated the development of sensitised hindpaw withdrawal responses to mechanical
and noxious thermal stimuli, indicative of the presence of thermal hyperalgesia and
mechanical allodynia. This increased behavioural sensitivity peaked over days 9-14
following treatment and returned to baseline levels by 3 weeks. Therefore, we have
demonstrated, for the first time, the development of pain-related behaviour following
induction of focal demyelination using lysolecithin and of particular importance, following
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changes in the sensory saphenous nerve, a nerve which is rarely manipulated in models of
neuropathic pain.
4.2.4. Morphology of the demyelinated nerve.
For any analysis of the mechanisms underlying neuropathic pain as a consequence of myelin
loss it is again of great importance that there are no additional axonopathic changes in this
model. We chose lysolecithin as our myelinolytic agent as, based on previous reports on the
use of lysolecithin to induce demyelination of the sciatic nerves of adult mice, its action is
rapid and restricted to the myelin sheath (Hall and Gregson, 1971) with resulting
demyelination remaining confined to the site of application. Importantly, there is little
damage to the Schwann cell cytoplasm or to the axon (Love et al., 1986). Nevertheless, as
this is the first time that lysolecithin application to the peripheral nerve has been used to
study demyelination of sensory nerves associated with neuropathic pain, we have conducted
thorough morphological investigations to ensure that i) significant demyelination occurs
following lysolecithin-treatment and ii) that there is no evidence that axon damage has
occurred. Based on previously reported methods of delivery to the peripheral nerve, we
initially developed two methods of lysolecithin application; sub-perineurial injection and
topical application. However, when injected into the nerve via a glass nucropipette, it was
clear from EM images that mechanical damage of the nerves had occurred. This is in line
with a report of small diameter fibre damage following injection of lysolecithin into the
nerve (Mitchell and Caren, 1982) and we therefore could continue no further with our
investigations using this method. We sought to avoid this problem by employing a topical
application technique. In our model, such controlled topical application of lysolecithin to the
saphenous or sciatic nerve produces a focal region of essentially complete demyelination of
approximately 40% of the previously myelinated axons (plus partial losses in others) at times
corresponding to peak behavioural reflex sensitisation. This demyelination occurred without
any detectable axon damage or loss as assessed by light and electron microscopy of
afferents. Therefore, this suggests we have developed a novel model of a neuropathic pain
state associated with peripheral nerve demyelination that does not seem to be accompanied
by axonal loss.
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4.2.5. Immunohistochemical investigation of evidence for DRG cell loss or axonal
damage in the lysolecithin-treated saphenous/sciatic nerves.
Corresponding to LM and EM investigations of topical lysolecithin application to either the
sciatic or saphenous nerve, immunohistochemical investigations demonstrated no loss of
neuronal somata in the DRG as identified by the medium to large diameter cell marker, NF-
200, or the small diameter cell marker, periphcrin. Importantly there was also no evidence
for significant expression of the indicator of axonal injury, ATF3 (Tsujino et al., 2000).
Therefore, as in the 6 week old Prx-nu\\ mouse, the lysolecithin-induced model of peripheral
nerve demyelination appears to be unaccompanied by axonopathy or cell loss and
demonstrates that we have developed a novel experimental model of a neuropathic pain state
associated with peripheral nerve demyelination.
4.2.6. Electrophysiological characteristics of the lysolecithin-demyelinated saphenous
nerve.
Demyelination of peripheral nerve axons initially results in conduction block rendering the
nerve incapable of action potential transmission to and from the CNS, which presumably
accounts for symptoms experienced, such as motor dysfunction and sensory loss
(Rasminsky, 1981). However, reorganisation of membrane electrical properties, involving
redistribution of ion channels allows action potential conduction through the demyelinated
segment. However, such reorganisation may lead to hyperexcitability, reflected in
spontaneous action potential discharge, mechanosensitivity, and sustained after-discharge
(Baker and Bostock. 1992), which may lead to the development of persistent pain.
Therefore, we have investigated the electrophysiological characteristic of the lysolecithin-
demyelinated saphenous nerve at times corresponding to peak behavioural change.
Based on evidence suggesting that peripheral sensitisation can be a significant contributor to
neuropathic pain behaviour in a variety of models of central (spinal) sensitisation
(Koltzenburg, 1998;Woolf and Costigan, 1999), we initially investigated the presence of any
changes in peripheral transduction thresholds following lysolecithin treatment of the
saphenous nerve. We could find no evidence for significant changes in the threshold for
action potential generation in either A or C fibres to either cutaneous mechanical or thermal
nociceptive stimulation.
We were therefore interested to investigate what changes, if any, in afferent fibre properties
could be contributing to the behavioural reflex sensitisation observed in animals following
lysolecithin treatment. As mentioned previously, ectopic repetitive firing has been proposed
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to be the origin of abnormal sensation in diseases characterised by segmental demyelination,
particularly where there is no evidence for axonopathic changes (Rasminsky, 1981 ;Tal and
Eliav, 1996) which is the situation represented by our model of lysolecithin-induced focal
demyelination. Demyelinated segments can serve as foci for spontaneous action potential
generation (Baker and Bostock, 1992;Calvin et al.. 1982;Smith and McDonald, 1980) and
there is good evidence that mechanical hypersensitivity observed in tactile allodynia is
mediated by myelinated A-fibres (Koltzenburg, 1998;Woolf, 1997), a fact that may be of
great importance in the development of neuropathic pain following demyelination.
Furthermore, it has been suggested that spontaneous activity in myelinated afferents is
sufficient to induce neuropathic pain behaviours in animal models of nerve injury (Liu et al.
2000; Wu et al.. 2000). Therefore, it is of much interest that we observed the presence of
spontaneous low frequency discharge (2-3 impulses/sec) in the primary afferents of the
focally demyelinated nerve, only at times which corresponded with peak behavioural reflex
sensitivity. This is similar to the spontaneous activity shown to be a feature of the /Vx-null
mouse. Although we have not dissected out which afferents are firing spontaneously, due to
the fact that there appears to be no damage to the unmyelinated afferents, it is likely that
such activity may be arising from formerly myelinated afferents in both models. We cannot,
however, rule out the possibility of ephaptic transmission of spontaneous activity to
unmyelinated afferents at sites of demyelination (Rasminsky, 1978). Ephaptic crosstalk may
cause normally nociceptive afferent neurons to be driven by electrical activity in low
threshold afferents (Devor and Seltzer, 1999) such as the demyelinated A-fibre afferents in
our preparation, which may, in turn, further sensitise the spinal dorsal horn neurons (see
Chapter 6). It would be of interest to follow this discovery with further investigations into
electrophysiological changes resulting from demyelination of the peripheral nerve. Firstly, it
is important to reveal the specific fibre type in which this spontaneous activity is occurring.
Also, as the preparation used for these investigations involved decentralisation of the
peripheral nerve to eliminate any activity occurring in any efferent axons or in axons of the
sympathetic nervous system, the electrophysiological consequences of demyelination of the
peripheral nerve proximal to the point of decentralisation, were also eliminated. For
example, any changes in characteristics of DRG neurons could be of significance as they
have been shown to fire spontaneously in other models of neuropathic pain (Abdulla and
Smith, 2001;Amir et al., 2002;Liu et al., 2000c). Also recording from dorsal roots may give
a more accurate indication of the magnitude of any hyperexcitablity arising for the peripheral
nerve. It is likely that such investigations would reveal activity of a greater magnitude than
has been demonstrated here, which could likely play a major role in enhanced transmission
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to the dorsal horn of the spinal cord, inducing cellular changes thought to bee associated with
the development of central sensitisation (see Chapter 6).
Nevertheless, we have demonstrated the presence of abnormal afferent electrical properties
following lysolecithin-induced demyelination, which may be of a frequency great enough to
be a likely contributor to the development of a neuropathic pain state (see Chapter 6).
4.2.7. Phenotypic Changes in the DRG
a) Neuropeptides
Following peripheral nerve lesions, prominent changes are seen in the expression of peptides
in primary sensory neurons and in the spinal cord. The changes observed are thought to
represent primarily adaptive, and restorative responses of the nervous system to limit damage
to the organism and to promote survival and recovery of the neuron. However, secondary
actions of upregulated peptides may cause enhanced transmission to the dorsal horn of the
spinal cord contributing to the induction of a sensitised state, which may underlie the
development of the chronic pain (Hokfelt et al., 1994). We therefore decided to investigate
whether some of these characteristic changes occur in our models of demyelination in order
to assess whether the pain behaviours displayed are associated with changes similar to those
seen in other models of neuropathic pain. The question of whether any changes are restricted
to specific cell types is also of interest, since our model appears to affect the morphology of
only the larger myelinated fibres.
CGRP and SP
We initially investigated the expression of CGRP. which is normally expressed by
approximately 50% of unmyelinated DRG neurons as well as a proportion of medium
diameter myelinated neurons (Gibson et al., 1984;Hokfelt et al., 1994;Rosenfeld et al.,
1983). Following traumatic peripheral nerve injury, the expression of CGRP is dramatically
downregulated (Dumoulin et al., 1992;Noguchi et al., 1990). However, we could find no
evidence of a decrease in CGRP expression in the DRG cells of the Prx-null mouse at 6
weeks when compared to the DRG of wild-type littermates, or in DRG ipsilateral to
demyelination of one saphenous or one sciatic nerve, when compared to the DRG
contralaterally or of sham controls. This prompted us to also investigate the expression of
SP in both models, the expression of which is also dramatically downregulatcd following
axotomy or CCI (Jessell et al., 1979;Nielsch et al.. 1987). We demonstrated no changes in
SP expression levels in either model. The lack of a change in the expression of either
peptide may be a reflection of the lack of damage to the small unmyelinated cells or the
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axons of the larger A-class neurons. It has been suggested that the decrease in CGRP
expression is due to interrupted retrograde transport of NGF from peripheral target tissue
(Shadiack et al., 2001). Therefore, the fact that we see no decrease in CGRP expression
suggests that such retrograde transport may not be affected by the demvelination, implying
that the axons are still functionalh' intact (see section 5.2.3).
Due to there being no change in the number of cell bodies in the DRG of either model of
peripheral nerve demyelination, we decided to restrict further immunohistochemical
investigations to the model of lysolecithin-induced demyelination of the sciatic nerve, and to
the Prx-null mouse. As mentioned in Chapter 3, we chose the sciatic model as opposed to
the saphenous nerve model because it is a larger nerve and therefore has a larger proportion
of cell bodies in the lumbar DRG as opposed to saphenous nerve. We have demonstrated
that there is no damage to A- or C-fibres following lysolecithin application to either nerve as
well as no indication of cell loss in the DRG or change in the expression of CGRP or SP
suggesting that lysolecithin results in a comparable condition following application to either
nerve. Therefore, any effect of demyelination on the phenotype of associated cell bodies
should be comparable but easier to detect in the model of sciatic nerve demyelination.
Galanin
We investigated the presence of any changes in the expression of galanin following
demyelination of the sciatic nerve as it is known to increase in cells of the DRG following
axotomy and CCI (Hokfelt et al., 1987;Villar et al., 1989). We could detect no increased
expression in cells of DRG from mice following lysolecithin treatment or from the /Vx-null
mouse at 6 weeks of age. This again suggests that the axons in the preparation are supplying
sufficient levels of NGF from the periphery which is also thought to influence the expression
of galanin (Shadiack et al., 2001).
The alterations of CGRP, SP and galanin in various models of neuropathic pain have been
proposed to be involved in the development of neuropathic pain. However, we saw no
change in these peptides in our models of peripheral nerve demyelination, which have
associated behaviours indicative of neuropathic pain. This suggests that although these
neuropeptides can play a functional role in enhancing the production of a sensitised state
(Wynick et al., 2001), changes in their expression are perhaps not critical for the production
of neuropathic pain. Therefore, their role may be of less significance than previously
thought, which may help to explain why therapeutics targeting such peptides have yet to be
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proved efficacious (Bennett et al., 2000). Furthermore, it is of importance that changes
characteristic of nerve injuries that usually occur in the small diameter cells of unmyelinated
axons, are not observed in either of our models. This further substantiates the evidence that
in our models of neuropathic pain there is a lack of involvement of the unmyelinated fibres
that are thought to be critical for the production of chronic pain in many other models and
the fact that changes in myelinated fibres alone may be sufficient for the development of a
neuropathic pain state
NPY
It has been demonstrated that following axotomy (Kashiba et al., 1994;Noguchi et al.,
1993;Wakisaka et al., 1991), partial sciatic injury (Ma and Bisby, 1998), CCI of the sciatic
nerve (Munglani et al., 1995;Nahin et al., 1994) and following streptozotocin-induced
diabetic neuropathy (Rittenhouse et al., 1996), the expression of NPY increases in large
diameter primary sensory neurons, distinguished by the presence of the 200kDa subunit of
neurofilament protein (Kashiba et al., 1994;Marchand et al., 1999). In line with such studies,
we observed an upregulation of the expression of NPY in large NF-200-positive cells in the
Prx-null mouse and ipsilateral to the focal demyelination of one sciatic nerve.
It is of particular importance that this is a change also restricted to NF-200-positive cells on
all models of neuropathic pain as this suggests that via demyelination. we have induced
comparable changes to such models in myelinated neurons, whilst eliminating the changes
associated with unmyelinated neurons. The increase in expression of NPY following nerve
transection varies from 16% (Shi et al., 2001) to 30% (Kashiba et al., 1994) in the literature.
Therefore, the increase in NPY expression we observe (10% in Prx-null DRG; 16% in DRG
ipsilateral to lysolecithin) is lower than in most models of sciatic nerve transection which
may correspond to the lack of axon damage involved in both our models of demyelination
compared to more severe models of neuropathic pain.
Upregulation of NPY may represent an adaptive response by primary sensory neurons to
traumatic injury, regardless of the initiating event. This implies that in our model of
demyelination, NPY has been upregulated, in the cells of demyelinated axons, as an adaptive
response of the nervous system to damage of the myelin sheath. Flow this upregulation is
specifically controlled is unknown. The upregulation of NPY may have additional
consequences upon primary afferent actions upon cells in the dorsal hom supported by
evidence for the centrifugal transport of NPY in primary afferents to the spinal cord (Zhang
et al., 1993;Wakisaka et al., 1991). NPY acts via two metabotropic receptors; Y, and Y2.
The actions of NPY via the Yi receptor are usually excitatory via its actions upon voltage-
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gated ion channels and the release on intracellular calcium via activation of IP3. In contrast
the actions of NPY via the Y2 receptor are inhibitory due to the inhibition of calcium entry
into the cell (Bleakman et al., 1991;Ewald et al., 1988). A role for NPY in pain perception is
suggested by the fact that following nerve injury, NPY upregulation follows the time-course
of injury-induced Ap-fibre firing (Fnsen et al ., 1992). thought to be related to the appearance
of allodynia (Woolf and Doubell, 1994). Furthermore, levels of NPY in the spinal cord, in
axons of myelinated sensory input, relates to the degree of hyperalgesia displayed by the
animal (Munglani et al., 1995). This would suggest that a similar role of NPY might be
occurring in our models of peripheral nerve demyelination, in which myelinated fibre
changes are produced, and implies a role for NPY in the production of some of the
behavioural reflex sensitisation we observe. Furthermore, the fact that in all nerve injury
models NPY expression is associated with cells of myelinated fibres provides a logical
explanation for why it is the only peptide in which we observe an expression change.
Intrathecal application ofNPY suggests that Yj receptors are located on dorsal horn neurons
(Duggan et al., 1991). Therefore, an increase in NPY release from primary afferents fibres
may lead to an increase in intracellular calcium in these cells, a change crucial for the
production of central sensitisation (see Chapter 6). However, the overall role of NPY in
nociception is controversial. Levels of NPY have been demonstrated to increase in animals
without any development of behavioural sensitisation (Benoliel et al., 2001). Furthermore,
mice lacking the Y] receptor develop hyperalgesia and mechanical sensitivity (Naveilhan et
al., 2001) suggesting a role for the receptors in the production of analgesia and it has been
suggested that NPY plays an antinociceptive role via its actions upon Y2 receptors
peripherally (Hokfelt et al., 1997). Nevertheless, theory would imply that the actions of
NPY on spinal Y] receptors might play a role in sensitisation of dorsal horn cells indicating a
possible role for its upregulation in the behavioural sensitisation displayed by our animal
models of peripheral nerve demyelination.
A further mechanism by which peripheral NPY release may play a role in the maintenance of
neuropathic pain, is via it interactions with the sympathetic nervous system, with a possible
role in potentiating algesic effects of released noradrenaline (Edvinsson et al., 1984).
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b) Na+ channel expression
In models of neuropathic pain such as following axotomy (Waxman et al., 1994b) and CCI
(Dib-Hajj et al., 1999), changes are seen in the expression of several Na+ channel genes
leading to changes in the properties of the Na+ current in sensory neurons. These changes
include the down regulation of the tetrodotoxin-resistant channel SNS 1/ Nav1.8 (Akopian et
al., 1996;Dib-Hajj et al., 1996;Novakovic et al., 1998;Sangameswaran et al., 1996;Waxman
et al., 1999b), paralleled by the upregulation in expression of the (brain) type III Na*
channel/ Nav1.3 (Waxman et al., 1994Waxman, 1999). We have demonstrated that in line
with other models of neuropathic pain, there is a selective decrease in the expression of SNS
1/ Nav1.8 channels in the DRG of the /Vx-null mouse (48% decrease) and following
lysolecithin-induced, focal demyelination of the sciatic nerve (34% decrease). However, in
contrast to the axotomy and CCI models, following demyelination this decrease in SNS 1/
Nav1.8 expression appears to be restricted to NF-200-positive cells, all of which have
myelinated or now demyelinated axons. This further supports the role of changes in A-fibres
in the production of neuropathic pain and suggests that mechanisms underlying sensitisation
and pain associated with demyelination of the peripheral nerve may differ in some respects
from other models of neuropathic pain. The results of the type 111 Na+ channel/ Nav1.3
localisation experiments suggest that there is an upregulation of the type III Na+ channel in
around 16% and 18% of the NF-200-immunoreactive neuron population of the DRG of the
Prx-null mouse and the demyelinatcd sciatic nerve respectively. The population of cells
upregulating the type III Na+ channel/ Nav 1.3 following nerve injury in previous reports
appears to vary with the model used. Following sciatic nerve transection, type III Na"
channel/ Nav 1.3 immunoreactivity was observed in most small diameter neurons (Black et
al., 1999). In contrast to this, following spinal nerve ligation, type 111/ Nav 1.3
nnmunoreactivity was observed in 15-21% of medium to large DRG neurons (Kim et ah,
2001a). These studies used the same antibody as we have employed here. We are aware that
the specificity of this antibody has been questioned previously, and agree that background
fluorescence is observed when using this antibody. Nevertheless, there was a clear increase
in immunofluorescence in specific cells when compared to others from the same DRG and to
those in control sections, which was of a sufficient magnitude to indicate a clear difference
of type III/ Nav 1.3 expression in the cells. It is of interest that the changes we observe in our
model of peripheral nerve dcmyelination are restricted to myelinated cells with a similar
proportion as that observed in the SNL study (Kim et al., 2001a). This further supports the
importance of A-fibres in the development of neuropathic pain and that changes in their
phenotype alone may be as sufficient for the induction of changes underlying persistent pain
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as changes occurring in both myelinated and unmyelinated fibres in other models of
neuropathic pain.
The changes that we observed in the expression of the SNS 1/ Nav1.8 and type III/ Nav 1.3
Na" channels may be of functional importance, and due to their differing channel current
properties, are likely to be involved in the production of spontaneous action potential
discharge displayed in the demyelinated nerves of both models. The SNS class of Na'
channels produce slowly inactivating current (Akopian et al., 1996;Sangameswaran et ah,
1996;Waxman et ah, 2000). Therefore their decreased expression in DRG neurons may lead
to a hyperpolarizing shift in resting potential increasing the fraction of TTX-sensitive
channels available for activation (Dib-Hajj et ah, 1999;Waxman et ah, 2000). Upregulation
of the type III/ Nav 1.3 channel results in a switch in the properties of the TTX-sensitive
currents in DRG neurons, with the emergence of a rapidly repriming current (Waxman et ah,
1999c) Therefore, DRG neurons that express it should be able to sustain higher firing
frequencies which may lead to hyperexcitability in the cell. This hyperexcitability may be
sufficient to generate sustained ectopic discharge necessary to maintain central sensitisation
(Porrcca et ah. 1999). A further possible functional correlate of the changing expression of
sodium channels in the DRG neurons, is the relocation of SNS 1/ Nav1.8 channels to the
demyelination site along with the de novo expression and distribution of type III/ Nav 1.3
channels. It is known that following demyelination associated with nerve injury, Na'
channels accumulate along patches of demyelination (Devor et ah, 1989;Novakovic et ah,
1998). Immunohistochemical studies have demonstrated the accumulation of abnormal
aggregations of Na1 channels at the distal tips of injured axons (Devor et ah, 1989; England
et ah, l994;Renganathan et ah. 2000) including type III/ Nav 1.3 (Black ct ah. 1999) and
SNS 1/ Nav 1.8 (Novakovic et ah, 1998). Therefore, it is possible that the loss of SNS 1/ Nav
1.8 immunoreactivity in L4-L6 DRG may represent subsequent redistribution and
accumulation of channel protein in nerve proximal to injury (Novakovic et ah, 1998c) or in
this case, demyelination. Changes in the distribution and type of channel expressed in the
axon are generally considered to lead to changes in distinct kinetic properties that could
contribute to hyperexcitability and ectopic pacemaker activity (Cummins and Waxman.
1997;Devor et ah, 1994;Matzner and Devor, 1992;Matzner and Devor. 1994;Omana-Zapata
et ah, 1997;Waxman, 1999) which again may be necessary to evoke and/or maintain central
sensitisation. Evidence that Na+ channel-blocking agents can be effective analgesics not only
in experimental neuropathic pain conditions but also in chronic neuropathic pain in humans
(Devor M et ah, 1992;Chabal et ah, 1992;Omana-Zapata et ah, 1997;Rizzo, 1997), suggests
that changes in expression of specific Na+ channel subunits in our model of focal peripheral
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nerve demyelmation may indicate useful therapeutic targets for the treatment of pain
associated with demyelination. Furthermore, although currently available Na+ channel-
blocking agents appear to lack the specificity required to target neuropathic pain effectively
without the complications of side effects, work is in progress to create more specific Na"
channel-blocking agents. Therefore, it may be of interested to follow this study with
investigations to detect the localisation of the SNS 1/ Nav1.8 and type III/ Nav 1.3 Na+
channels in the demyelinated peripheral nerves of both our models followed by investigating
the effects of applying Na+ channel-blocking agents to the demyelinated nerve on both the
electrophysiological properties of the demyelinated nerve, as well as upon the behavioural
reflex sensitisation displayed. These investigations may give a clearer insight into the level
of the involvement ofNa+channels in our model of neuropathic pain.
4.3 Summary
The investigations into the changes occurring in the PNS following demyelination of the
peripheral nerve, have indicated that changes previously shown to be of importance in the
production of neuropathic pain following nerve injury, such as axotomy and CC1, arc also
likely to play a role in our models of peripheral nerve demyelination, however, they are not
entirely comparable. Of interest, we could only detect the presence of phenotvpic changes in
the cells of myelinated fibres. Moreover, changes known to occur in unmyelinated fibres
following nerve injury models, such as axotomy and CCI, were not present in the DRG cells
from either of our models of peripheral nerve demyelination. These results suggest that
demyelination of the peripheral nerve has induced no changes in unmyelinated axons or their
cell bodies. This highlights the important functional role that A-fibres are capable of playing
in the induction of neuropathic pain and that conversely, C-fibre involvement, although
associated with previous models of neuropathic pain, may not be necessary for its
emergence. Of interest, we observed a change in the expression of Na+ channel subtype in
the cells of myelinated axons, a change that may have an important functional consequence
in the development of neuropathic pain.
These investigations have also indicated that there are no obvious differences between the
effect of genetic demyelination, as created in the Prx-null mouse model, and focally induced
demyelination as in the lysolecithin model. This not only aids to assure that deleting the Prx
gene has little indirect consequence on developmental factors relevant to this study, but
strengthens the evidence that peripheral nerve demyelination. be it focal or widespread, can
have consistent consequences on the nervous system and its function and likely plays an
important role in all models of neuropathic pain.
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Importantly, in both models, the demyelinated nerve displayed the presence of ectopic,
spontaneous activity, a mechanism thought to be crucial for the induction of changes in the
spinal cord that underlie persistent pain states. Therefore, the focus of this study moved
centrally, to the spinal cord, to investigate the involvement of various specific changes that
may indicate potential therapeutic targets.
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CHAPTER 5. CHANGES IN THE CENTRAL NERVOUS SYSTEM IN MODELS OF
PERIPHERAL NERVE DEMYELINATION:
5.1 Results
5.1.1. Intrathecal administration of drugs
Various drugs selective for receptors or signal transduction pathways were intrathecally
administered to /Vx-null mice or to mice displaying peak behavioural reflex changes
following lysolecithin treatment to the saphenous nerve. The saphenous nerve preparation
was used due to the focus of this study being upon the sensory aspects of demyelination and
therefore our studies have aimed to concentrate on the effects following demyelination of the
sensory saphenous nerve where possible.
a) The role of the NMDA receptor in the behavioural sensitisation displayed by Prx-
null mice or following lysolecithin treatment.
A key change in neuropathic pain states involves sensitisation of cells in the dorsal horn in
the spinal cord, which is thought to involve activation of the NMDA receptor. A role for
spinal NMDA receptors in the mechanical allodynia displayed by 6 week old /Vx-null
animals and in the ipsilateral hindpaw in animals with focal demyelination of one saphenous
nerve was demonstrated by the reversal of the behavioural sensitisation to von Frey filaments
following spinal administration of the highly selective NMDA receptor antagonist (R)-CPP
(Lehmann et al., 1987) (Figs 5.1a and 5.2a). Similarly, the reduction in thermal nociceptive
response latency displayed by both groups was reversed by (R)-CPP without effect on wild-
type littermates or in naive animals (or in the case of lysolecithin-treated animals without
effect on the contralateral side) (Fig 5.1a and 5.2a). With the exception of the first 20
minutes following injection on thermal withdrawal responses in the /Vx-null mouse,
equivalent injections of the saline vehicle had no significant effect on reflex responses in the
/Vx-null mouse or wild-type littermates or, ipsilateral and contralateral to lysolecithin
treatment (Fig 5.1b and 5.2b). This apparent effect of saline on the thermal withdrawal
latency in the /Vx-null mouse does not correlate with the time course of the effect of (R)-
CPP and is therefore likely to be a behavioural anomaly. The statistical significance of
differences from pre-injection baseline values following all injections was determined by a
One-Way Repeated Measures ANOVA) with Dunnet's multiple comparisons versus control
group post-hoc analysis (*P<0.05).
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Figure 5.1. Effects of intrathecal administration of the NMDA receptor antagonist (R)-
CPP on the sensitised behavioural reflex responses to von Frey filaments and to radiant
heat in FVx-null mice.
Paw withdrawal thresholds, in response to cutaneous mechanical stimulation with von Frey
filaments and cutaneous noxious thermal stimulation, were measured in 6 week old fVx-null
and wild-type (WT) littermate animals.
For Prx-null investigations, Prx-null (a ) and WT (♦ )values are displayed before and after
intrathecal administration of each pharmacological agent. All paw withdrawal thresholds are
displayed in mN/mm2 for mechanical stimulation or mean paw withdrawal latency (seconds)
for thermal stimulation. Each value is the mean ± SEM and any statistically significant
(*P<0.05) difference at each time point post injection from pre-injection baseline values was
determined by a One-Way Repeated Measures Analysis of Variance (ANOVA) with
Dunnct's multiple comparisons versus control group post-hoc analysis.
a) The NMDA receptor antagonist R-CPP (100 pmol in 10 pi) reversed the behavioural
reflex sensitisation to mechanical and noxious thermal stimulation observed in 6 week
old Prx-mi\\ animals (n=8) for up to 55-60 minutes after intrathecal application.
b) Saline resulted in no significant change in the behavioural reflex sensitisation to
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Figure 5.2. Effects of intrathecal administration of the NMDA receptor antagonist (R)-
CPP on the sensitised behavioural reflex responses to von Frey filaments and to radiant
heat in animals following lysolecithin treatment.
Paw withdrawal thresholds, in response to cutaneous mechanical stimulation with von Frey
filaments and cutaneous noxious thermal stimulation, were measured in animals at their peak
behavioural reflex sensitivity following topical application of lysolecithin to one saphenous
nerve. Ipsilateral (□ ) and contralateral (♦ ) values are displayed. All paw withdrawal
thresholds are displayed in mN/mnf for mechanical stimulation or mean paw withdrawal
latency (sees) for thermal stimulation. Each value is the mean ± SEM and any statistically
significant (*P<0.05) difference at each time point post-injection from pre-injection baseline
values was determined by a One-Way Repeated Measures Analysis of Variance (ANOVA)
with Dunnet's multiple comparisons versus control group post-hoc analysis.
a) The NMDA receptor antagonist R-CPP (100 pmol in 10 p.1) reversed the behavioural
reflex sensitisation to mechanical and noxious thermal stimulation observed in
lysolecithin-treated animals (n=8) for up to 60-70 minutes after intrathecal
application.
b) Saline resulted in no change the behavioural reflex sensitisation to mechanical and
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b) The effect of the morphine analogue DAMGO on lysolecithin-induced central
sensitisation
Since animal models of neuropathic pain states often show a relative insensitivity to spinal
opioid analgesia compared to acute or peripheral inflammatory pain states (Arner and
Meyerson, 1988;Fleetwood-Walker SM et al., 1988;Yaksh and Harty, 1988), we assessed the
effects of the potent and selective p-opioid receptor agonist DAMGO in the lysolecithin
model. At the highest dose of intrathecal DAMGO that could be administered before overt
psychomotor side effects were seen (1Opmol in 10 pi), there was no specific reversal of the
mechanical allodynia or thermal hyperalgesia seen ipsilateral to lysolecithin treatment (Fig
5.1c). Significance (*P<0.05) from pre-injection baseline values following all injections was
determined by a One-Way Repeated Measures Analysis of Variance (ANOVA) with
Dunnet's multiple comparisons versus control group post-hoc analysis. Further
investigations may be necessary to explore the possible effects of a full dose-curve of
DAMGO on the behavioural reflex sensitisation displayed by animals following lysolecithin
treatment of the saphenous nerve. Nevertheless, these investigations suggest that focal
demyelination with lysolecithin is a model of neuropathy without involvement of any
significant p-opioid-sensitive component of the chronic pain such as would be expected to
be observed in inflammatory pain states.
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Figure 5.3. Effects of intrathecal administration of the selective mu-opioid receptor
agonist, DAMGO on the sensitised behavioural reflex responses to von Frey filaments
and to radiant heat in animals following lysolecithin treatment.
Paw withdrawal thresholds, in response to cutaneous mechanical stimulation with von Frey
filaments and cutaneous noxious thermal stimulation, were measured in animals at their peak
behavioural reflex sensitisation following topical application of lysolecithin to one saphenous
nerve. Ipsilateral ( □ ) and contralateral (♦ ) values are displayed. All paw withdrawal
thresholds are displayed in mN/mnf for mechanical stimulation or mean paw withdrawal
latency (sees) for thermal stimulation. Each value is the mean ± SEM and any statistically
significant (*P<0.05) difference of each time point post injection from pre-injection baseline
values was determined by a One-Way Repeated Measures Analysis of Variance (ANOVA)
with Dunnet's multiple comparisons versus control group post-hoc analysis. For saline
control see Fig 5.1b.
a) The selective mu-opioid receptor agonist, DAMGO (10 pmol in 10 p.1) resulted in no
change the behavioural reflex sensitisation to mechanical and noxious thermal
stimulation observed in lysolecithin-treated animals (n=3).
164
Figure 5.3.
























































c) A potential role for NFKB in lysolecithin-induced central sensitisation
NFkB is known to be a crucial signal for glial and neuronal cell function during
inflammation injury and neural plasticity (see review) (O'Neill and Kaltschmidt, 1997). It is
likely that NFkB is involved in intracellular signalling in sensory neurons under
physiological conditions and furthermore, factors such as TNF, IL-1 and NGF which may be
produced by Schwann cells and macrophages following partial nerve injury, can cause NFkB
activation in the PNS and CNS (Carter et al., 1996;Moynagh et al., 1994;Wood, 1995)
(Laughlin et al., 2000) which may lead to events involved in the development of chronic pain
(Ma and Bisby, 1998a). Furthermore, it has been suggested that changes which may occur in
dorsal horn cells following peripheral nerve injury including the activation of NMDA and
non-NMDA ionotropic glutamate receptors (Guerrini et al., 1997;Kaltschmidt et al.,
1995;Nakai et al., 2000) and intracellular activation of protein kinases such as PKA
(Mosialos and Gilmore, 1993;Neumann et al., 1995) and PKCy (Leitges et al., 2001) may be
capable of activating NFkB. Therefore, it was of interest to investigate whether the
activation of NFkB in the spinal cord is associated with the behavioural reflex changes
displayed in our model of lysolecithin-induced peripheral nerve demyelination. Individual
spinal administration of 3 separate and distinctly acting antagonists of NFkB activation;
parthenolide, sulfasalazine and CAPE have indicated a significant role for NFkB in the
sensitised pain induced by our animal model of peripheral nerve demyelination. All three
antagonists caused a complete reversal of mechanical allodynia and thermal hyperalgesia
(Fig 5.1d-f). This effect persisted for at least 55 minutes post injection of each drug
returning to baseline levels after approximately 70 minutes without any effect on
contralateral paw withdrawal threshold. Vehicle control injections showed no effect on the
withdrawal thresholds to either mechanical or thermal stimuli. Statistical significance of
differences (*P<0.05) from pre-injection baseline values following all injections was
determined by a One-Way Repeated Measures Analysis of Variance (ANOVA) with
Dunnet's multiple comparisons versus control group post-hoc analysis.
It must be considered that all of these drugs are unspecific in their actions upon NFkB and in
theory may be acting via different mechanisms to affect the behavoural reflex sensitisation
displayed in our model of lysolecithin-induced peripheral nerve demyelination. However,
the fact that all three act commonly to block the activation ofNFkB suggests that this is the
key pathway by which they are acting to reverse the behavioural reflex sensitisation as is
observed.
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Figure 5.4. Effects of intrathecal administration of the selective NFkB activation
antagonists parthenolide, CAPE and sulphasalazine on the sensitised behavioural reflex
responses to von Frey filaments and to radiant heat in animals following lysolecithin
treatment.
Paw withdrawal thresholds, in response to cutaneous mechanical stimulation with von Frey
filaments and cutaneous noxious thermal stimulation, were measured in animals at their peak
behavioural reflex sensitisation following topical application of lysolecithin to one saphenous
nerve. Ipsilateral (□ ) and contralateral (♦ ) values are displayed. All paw withdrawal
thresholds are displayed in mN/mm2 for mechanical stimulation or mean paw withdrawal
latency (sees) for thermal stimulation. Each value is the mean ± SEM and any statistically
significant (*P<0.05) difference of each time point post injection from pre-injection baseline
values was determined by a One-Way Repeated Measures Analysis of Variance (ANOVA)
with Dunnet's multiple comparisons versus control group post-hoc analysis.
a) The NFkB antagonist parthenolide (0.3 nrnol in 10pl) reversed the behavioural reflex
sensitisation to mechanical and noxious thermal stimulation observed in lysolecithin-
treated animals (n=8) for up to 65-70 minutes after intrathecal application. The vehicle
saline resulted in no change the behavioural reflex sensitisation to mechanical and
noxious thermal stimulation when injected alone (see Fig 5 .1b).
b) The NFkB antagonist CAPE (0.3 nmol in 10pi) reversed the behavioural reflex
sensitisation to mechanical and noxious thermal stimulation observed in lysolecithin-
treated animals (n=8) for up to 55-60 minutes after intrathecal application. The saline
vehicle resulted in no change in the behavioural reflex sensitisation to mechanical and
noxious thermal stimulation when injected alone (see Fig 5.1b).
a) The NFkB antagonist sulphasalazine (5 nmol in 10pl) reversed the behavioural reflex
sensitisation to mechanical and noxious thermal stimulation observed in lysolecithin-
treated animals (n=8) for up to 55 minutes after intrathecal application.
b) The vehicle (2% dmf in saline) resulted in no change in the behavioural reflex
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d) Effects of the endogenous cannabinoid system on lysolecithin-induced central
sensitisation.
An alternative spinal modulatory system that can exert selective antinociceptive effects in
both neuropathic and inflammatory hyperalgesia is the endogenous cannabinoid system (Fox
et al., 2001;Herzberg et al., 1997;Richardson et al., 1998). This is of particular interest
because of evidence that cannabinoids may exert beneficial analgesic effects in
demyelinating diseases such as multiple sclerosis (Consroe et al., 1997;Robson, 2001) and
are under assessment as clinical therapeutic agents for this disorder (Robson, 2001). We
were able to show a clear modulatory role for the cannabinoid system in the sensitised pain
behaviour induced in our animal model of peripheral nerve demyelination. Spinal
administration of the cannabinoid receptor agonistWIN 55,212-2 attenuated the reduction in
thermal reflex latencies and mechanical nociceptive thresholds that were displayed ipsilateral
to lysolecithin (Fig 5.1h). This attenuation appeared to be more marked on thermal than on
mechanical sensitised responses, but in both cases changes in responses were seen only on
the sensitised side, ipsilateral to lysolecithin. A role for the CEf receptor in particular was
demonstrated by spinal administration of the selective CB] receptor antagonist AM 251,
which completely reversed the effects of WIN 55,212-2 on mechanical sensitisation and
partially reversed its effects on thermal sensitisation (Fig 5.1 i). However, when administered
alone, AM 251 had no significant effect, indicating that endogenous spinal CB] receptors
had not become tonically activated as a result of the lysolecithin treatment (Fig 5 . lj).
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Figure 5.5. Effects of intrathecal administration of targets of the endogenous
cannabinoid system; WIN 55,212-2 and AM 251 on the sensitised behavioural reflex
responses to von Frey filaments and to radiant heat in animals following lysolecithin
treatment.
Paw withdrawal threshold, in response to cutaneous mechanical stimulation with von Frey
filaments and cutaneous noxious thermal stimulation, were measured in animals at their peak
behavioural reflex sensitisation following topical application of lysolecithin to one saphenous
nerve. Ipsilateral ( n ) and contralateral (♦ ) values are displayed. All paw withdrawal
thresholds are displayed in mN/mm2 for mechanical stimulation or mean paw withdrawal
latency (sees) for thermal stimulation. Each value is the mean ± SEM and any statistically
significant (*P<0.05) difference of each time point post injection from pre-injection baseline
values was determined by a One-Way Repeated Measures Analysis of Variance (ANOVA)
with Dunnet's multiple comparisons versus control group post-hoc analysis.
a) The mixed CEf/CEE cannabinoid receptor agonist WIN 55,212-2 (60 pmol in 10 pel)
partially reversed the behavioural reflex sensitisation to mechanical and fully reversed the
behavioural reflex sensitisation to noxious thermal stimulation in lysolecithin-treated
animals (n=7) for up to 60 minutes after intrathecal application. The vehicle (0.5% dmf in
saline) had no effect on behavioural reflex sensitisation to either mechanical or thermal
stimulation (see Fig 5 .4d)
b) The CB, receptor antagonist AM 251 (100 pmol in 10 pi) resulted in no change of the
behavioural reflex sensitisation to mechanical and noxious thermal stimulation in
lysolecithin-treated animals (n=7). The vehicle (0.5% dmf in saline) had no effect on
behavioural reflex sensitisation to either mechanical or thermal stimulation (see Fig 5.4d)
c) When injected in combination, WIN 55,212-2 and AM 251 produced no significant effect
on the behavioural reflex sensitisation to noxious thermal stimulation in lysolecithin-
treated animals (n=8) suggesting that the effect of WIN 55,212-2 was prevented by AM
251 acting at the CEf receptor. The vehicle (0.5% dmf in saline) had no effect on
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5.2.1. NMDA receptor-dependent central sensitisation
Afferent hyperexcitability and spontaneous action potential generation, as displayed by the
saphenous nerves of Prx-null mice and normal saphenous nerves treated with lysolecithin,
provides a basis for ongoing input to the CNS. Such input may induce functional changes in
the sensory processing mechanisms within the dorsal horn creating a phenomenon referred to
as 'central sensitisation'. These changes manifest behaviourally as hypersensitivity to pain
that spreads from the site of injur) causing primary and secondary hyperalgesia, which can
include tactile Ap-fibre-mediated mechanical allodynia (Gracely et al., 1992;Woolf, 1997);
behavioural phenomena that we have shown to be part of the phenotype of both models of
peripheral nerve demyelination. In a variety of models of chronic pain, it is thought that
mechanical allodynia and thermal hyperalgesia, similar to that seen in our models of
peripheral nerve demyelination, are underpinned by changes in NMDA receptor activation in
the spinal dorsal horn. This is considered to be one of the key factors underlying central
sensitisation (Bennett, 1994;Chaplan et al., 1997;Dickenson and Sullivan, 1987;Mao et al.,
1993;Woolf and Costigan, 1999) (see Chapter 6).
Using the intrathecal application of pharmacological agents, we have demonstrated that
NMDA receptor-dependent events at a central site, in the spinal cord, were essential for the
phenomena of mechanical allodynia and thermal hyperalgesia, both of which become
manifest in /Vx-null mice and in mice following lysolecithin treatment of the saphenous or
sciatic nerve. This indicates that central changes including NMDA-receptor-dependent
central sensitisation are involved in the production of the mechanical allodynia and thermal
hyperalgesia observed. This implies that as in other models of neuropathic pain, changes are
occurring in the spinal cord, which are comparable to those occurring in hippocampal LTP
(Sandkuhler, 2000). Therefore, by taking example of the extensive work being carried out in
to the mechanisms of LTP in the hippocampus, we can formulate many hypotheses of the
pathways involved in the induction of central sensitisation (see Chapter 6).
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5.2.2 Lack of analgesic effects of mu-opioid receptors in demyelination-induced pain
models
Neuropathic pain models display a relative insensitivity to spinally administered opioid
analgesics (Arner and Meyerson, 1988;Lee et al., 1995;Yaksh and Harty, 1988) which are
much more effective for the treatment of inflammation associated pain conditions (Lombard
and Besson, 1989). The fact that intrathecal administration of the mu-opioid receptor
agonist DAMGO failed to affect the behavioural reflex sensitisation displayed by
lysolecithin treated mice corresponds with other models of neuropathic pain and suggests
that our model does not involve a significant inflammatory component, verifying its use as a
model of neuropathic pain. However, a more thorough study using various doses of the
spinal mu-opioid receptor antagonist would be appropriate to investigate any possible role
that spinal mu-opioid receptors may play in inducing analgesia in both of our models of
peripheral nerve demyelination. This may highlight a potential clinical use for opiods in the
treatment of pain associated with demyelinating conditions in humans.
5.2.3. A possible role of NFkB in demyelination induced neuropathic pain
The transcription factor, NFkB, is known to be a caicial signal for glial and neuronal cell
function during injury and neural plasticity (O'Neill and Kaltschmidt, 1997). Inducible
NFkB is expressed in 30-45% of neurons of all sizes, but particularly by medium to large
neurons, in L4 and L5 ganglia in the rat (Doyle and Hunt, 1997;Ma and Bisby, 1998a),
suggesting that it may be involved in intracellular signalling in sensory neurons under
physiological conditions. After nerve injury, NFkB (p65/p50 heterodimer) expression
reportedly decreases acutely in both large and small cells (Doyle and Hunt, 1997). However,
the proportion of activated NFkB (i.e. that released from IkB and therefore capable of
translocation to the nucleus where it can regulate gene transcription) has been reported to
increase within ipsilateral DRG neurons, particularly in medium diameter cells (Ma and
Bisby, 1998a), which presumably have myelinated axons. This increase occurs 2 weeks
after nerve injury (Ma and Bisby, 1998a) when behavioural signs of neuropathic pain have
become established implying a role for NFkB in neuropathic pain; an area in which NFkB
involvement has been little investigated, with much focus remaining upon its role in
modulation of inflammatory processes. The activation of NFkB, leading to the induction of
upregulation of, or the new expression of, multiple genes, can occur as a consequence of
various events, which are associated with nerve injury. Of particular relevance to this study
is the evidence for the activation of NFkB following NMDA and non-NMDA ionotropic
glutamate receptor activation (Guerrini et al., 1997;Kaltschmidt et al., 1995;Nakai et al.,
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2000). We have demonstrated a role for spinal NMDA receptors in the behavioural reflex
sensitisation displayed by both models of demyelination. Therefore, their activation could
subsequently lead to the activation of NFkB in the dorsal horn neurons of the spinal cord and
the subsequent induction of multiple gene expression, which may lead to events involved in
the development of chronic pain (see Chapter 6). It has also been demonstrated that NFkB
may be stimulated via the activation of metabotropic, G-protein coupled receptors (Cowen et
al., 1997;Kravchenko et al., 1995). Many receptor subtypes of this family, including
metabotropic glutamate receptors and neuropeptide receptors, such as NKt, are involved in
transmission of nociceptive information from the PNS to the spinal cord and are thought to
play an important role in the induction of persistent pain states. Therefore, it is plausible that
such receptors could provide a further substrate for the activation of NFkB following
peripheral nerve injury. Furthermore, it has been suggested the protein kinases such as PKA
(Mosialos and Gilmore, 1993;Neumann et al., 1995) and PKCy (Leitges et al., 2001) are
capable of activating NFkB. Both kinases have been implicated in persistent pain states
(Cerne et al., 1993;Malmberg et al., 1997;Sluka and Willis, 1997) and may be stimulated in
dorsal horn cells following nerve injury via second messenger pathways of metabotropic
receptors (Bleakman et al., 1992;Bond and Lodge, 1995;Bliss and Collingridge, 1993).
Therefore, evidence would suggest a strong possibility for the activation of NFkB in
response to changes in the activity of receptors and their intracellular pathways following
nerve injury. An extensively researched area of NFkB activation involves factors such as
TNF, IL-1 and NGF which are capable of activating NFkB in cells of the PNS and CNS
(Carter et al., 1996;Moynagh et al., 1993;Moynagh et al., 1994Wood. 1995). Following
partial nerve injury, TNF, IL-1 and NGF are produced in increased quantities by Schwann
cells. It is plausible that such factors produced by Schwann cells may not only act upon cells
of the DRG to activate NFkB, but may also be capable of acting upon cells in the dorsal horn
via their secretion into the spinal cord at central termination sites. It seems likely that a
similar upregulation may occur following demyelination, in which Schwann cells are
activated to remyelinate the axon. In line with these proposed mechanisms of NFkB
activation, and the evidence for NFkB activation in previous models of nerve injury, we
have demonstrated a role for spinal NFkB in the behavioural reflex sensitisation, which
develops following lysolecithin treatment to the saphenous nerve, as indicated by effects of
three structurally distinct NFkB pathway inhibitors; parthenolide, CAPE, and sulphasalazine.
It must be kept in mind that these inhibitors are unspecific in their actions upon NFkB in that
they can also act as anti-inflammatory agents due to their affects on other mechanisms (Song
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et al., 2002; Uchi et al., 2002). For example, sulphasalazine is also used to treat
inflammatory conditions due to its NSAID-like properties (CFDell et al., 2002) and CAPE
has been shown to directly inhibit catalytic activity of inducible nitric oxide synthase (Song
et al., 2002) as well as its expression via its actions on NFkB. Such actions could be
involved in the reversal of the behavoural reflex sensitisation displayed in our model of
lysolecithin-induced peripheral nerve demyelination, However, the fact that all three drugs
act commonly to block the activation of NFkB suggests that this is the key pathway by
which they are acting to reverse the behavioural reflex sensitisation as is observed.
Following this discovery, it would be of interest to localise the specific cells in which NFkB
is activated and whether or not any activation is restricted to cells of damaged afferents. It
may also be of interest to investigate any activation of NFkB in DRG cells to i) see if this
correlates with previous work, which is so far limited, and ii) if any activation occurring is
restricted to cells ofmyelinated afferents. Furthermore, it would be of interest to investigate
which genes NFkB may be regulating and how their expression might relate to the
development and/or maintenance of neuropathic pain associated with nerve injury and
demyelination. Such dissection of specific gene regulation could potentially point the way to
new therapeutic targets for the treatment of neuropathic pain.
Due to the implications of various roles of growth factors not only in the activation of NFkB
but the production of pain in general, this may be a good point at which to suggest further
investigations into changes in, and the possible role of, growth factors in our models of
peripheral nerve demyelination. It would be of interest to measure levels of expression of
growth factors such as TNF, NGF and GDNF and their receptors, as well as inflammatory
mediators such as IL-6, in Schwann cells. DRG cells and locally in the dorsal horn of the
spinal cord. These investigations may provide insight in to which growth factors, if any, are
changing and at which location they might be acting. Using blocking agents for their
receptors would give an idea of the importance of their role in the development of
behavioural reflex sensitisation in our models of peripheral nerve demyelination and thereby
may indicate possible targets for therapeutic intervention.
The measurement of NGF and GDNF expression would be of particular interest in light of
other work investigating their effects on neuropathic pain and related mechanistic changes.
NGF expression levels in our models would be of interest as the results from the work
investigating neuropeptide expression in the DRG would suggest that the demyelination does
not result in changes in peptides, such as CGRP and SP down-regulation, thought to result
from NGF deprivation. However, NGF deprivation is also thought to play a role in the
modulation of expression of Na+ channels, resulting in the decreased expression of SNS 1/
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Nav1.8 and the corresponding upregulation of type III/ Nav1.3 (Black et al., 1997;Dib-Hajj et
al., 1998;Okuse et al., 1997), changes which we have demonstrated to be a feature of our
models of demyelination Therefore, our results of phenotypic changes in the DRG
following peripheral nerve demyelination may present a conflict in theory with regard to the
role of NGF in neuropathic pain. GDNF may also play a role in the regulation of sodium
channel expression (Fjell et al., 1999) (Bennett et al., 2000) and evidence indicates that
GDNF treatment may reverse changes in Na' channel expression whilst preventing the
development of pain-associated behaviours in various animal models of neuropathic pain
(Bennett et al., 2000). Of particular relevance to this study is evidence indicating a potential
role for the use of GDNF treatment in reducing spontaneous activity arising almost
exclusively in myelinated afferents in the period of development and establishment of the
neuropathic pain state following SNL (Bennett et al., 2000). This suggests that perhaps
GDNF might be of use to target the spontaneous activity arising in the fibres of the
demyelinated nerves in our models of peripheral nerve dcmyelination. Therefore,
investigations into the levels of GDNF in our models of neuropathic pain may indicate
whether or not any changes in its expression levels have occurred as a result of
demyelination and therefore, whether increasing the local supply of GDNF may help to
minimise the neuropathic pain.
5.2.4. Cannabinoids
Reports of the therapeutic use of cannabis ^-tetrahydrocannabinol) date back as far as 5000
years ago when reports from China recommended its use for malaria, constipation, rheumatic
pains and childbirth (Mechoulam, 1986). It was not until the 19th century that cannabis
became a mainstream medicine in Britain following observations of its use as an analgesic as
well as an anticonvulsant, anti-spasmodic and anti-emetic drug in India (Robson, 2001). It
became a popular drug and was, (and according to anecdotal reports still is), used to treat
pain, muscle cramps and spasms, associated with conditions such as MS (Consroe et al.,
1997). There are also anecdotal reports of benefits in bone and joint pain, cancer pain and
labour pain (Grinspoon and Bakalar, 1993). Cannabis was available over the counter in
pharmacies until 1928 when it was outlawed and by 1971, the prescription of cannabis was
prohibited. However, the therapeutic effects of cannabis are still acknowledged and its
considerable potential in neuropathic pain treatment recognised (Joy et al., 1999) which has
led to much research to develop cannabinol analogues to combat conditions such as chronic
pain.
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The discovery of the 'endogenous cannabinoid system' has led to the development of
selective CIT and CB2 receptor ligands, which may represent a valuable alternative strategy
for the relief of chronic pain. There is considerable evidence supporting a role for
cannabinoids in the modulation of nociception and many reports have shown them to be
effective in reversing hyperalgesia in models of chronic inflammatory pain (Martin et al.,
1999;Richardson et al., 1998c) and neuropathic pain (Bridges et al., 2001;Fox et al.,
2001 ;Herzberg et al., 1997a;Kelly and Chapman, 2001). The majority of these effects
appear to be mediated by CB, cannabinoid receptors (Richardson et al., 1998c) which are
located at both peripheral and central sites.
Strong evidence is emerging to link the efficacy of cannabinoids in the treatment of
neuropathic pain and, of particular relevance to this study, their actions upon myelinated A-
fibres. For example, evidence suggests that in the PNS cannabinoid receptors are synthesised
predominantly by medium and large sized DRG cell bodies i.e. those with myelinated axons
(Hohmann and Herkenham, 1999). This suggests that aberrant activity in A-fibres which
underlies allodynia (Gold. 2000) may be a possible target for modulation by cannabinoids.
However, of particular interest to this study are reports indicating that spinal CBi receptors
may be predominantly located on spinal interneurons which suggests that cannabinoids may
also play a crucial role in regulating dorsal horn activity. This suggests that at a central
level, cannabinoids can be involved in the modulation of incoming afferent activity arising
from various fibre types. A recent study has suggested that the potent cannabinoid agonist,
HU210, has selective effects on the responses of dorsal horn neurons in nerve-injured rats
(Chapman, 2001; Kelly and Chapman, 2001). This study claims that following SNL, the
normal inhibitory effects of the agonist on C-fibre mediated responses of spinal neurons
were lost, yet inhibitory influences upon A8-fibre mediated responses remained. It is
suggested that under normal conditions, spinal cannabinoid receptors predominantly regulate
the activity of C-fibre input to the spinal cord modulating the transmission of nociceptive
input. However, the distinction between C- and A5-fibre afferent inputs to the spinal cord
cells is perhaps harder to define than is implied due to the overlap in conduction velocity
range of the two fibre groups. However, these claims do suggest that changes occur in the
efficacy of the cannabinoid system in the SNL model of neuropathic pain. Such a hypothesis
may be reflected in the results of behavioural studies in various models of neuropathic pain
(Bridges et al., 2001;Fox et al., 2001 ;Herzberg et al., 1997a) in which C-fibre activity is
likely to be elevated and cannabinoid agonists show a marked reduction of mechanical
allodynia with more limited effect on thermal hyperalgesia. However, in a situation in which
there is no increase in the activity of C-fibre input, and where any constant afferent drive is
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of low frequency, as may be the case in our models of demyelination, cannabinoids may be
more effective in reducing all pain-related behaviours.
In line with this hypothesis, we found that intrathecal administration of the CB receptor
agonist, WIN 55,212-2, attenuated the behaviour indicative of mechanical allodynia and
thermal hyperalgesia seen in mice with lysolecithin treated saphenous nerves. The effects of
WIN 55,212-2 were largely reversed by the selective CBi receptor antagonist AM 251,
although, in agreement with similar investigations in other models of neuropathic pain. AM
251 alone did not heighten the allodynia or hyperalgesia (Kemp et al. 1996) . In contrast to
previous studies of cannabinoids in models of neuropathic pain, we observed a substantial
attenuation of thermal hyperalgesia, which was apparently greater than the effect upon
mechanical allodynia. This suggests that because C-fibre primary afferents are unaffected in
our model of demyelination-associated neuropathic pain, the central antinociceptive effect of
cannabinoids is maintained, unlike the situation following nerve injury involving damage to
axons. As a result, sensitisation of dorsal horn neurons to incoming C-fibre activity would
still be suppressed via activation of the CBi receptor at these sites. This implies that in
situations in which central sensitisation is induced by activity in A-fibres alone, the
sensitisation of the CNS to incoming noxious thermal stimulation (reflected by behavioural
correlates of thermal hyperalgesia) may also be effectively targeted by cannabinoids.
It may be of interest to further investigate the expression of CBi receptors in the DRG cells
and spinal cord, in our models of afferent demyelination-induced pain to see whether they
differ from neuropathic pain models that involve axonal damage. While contrasting to a
degree with other nerve injury models, our observation of a reversal of both mechanical and
thermal sensitivities has important implications for the treatment of conditions which arise
due to peripheral nerve demyelination.
The fact that AM 251 alone did not produce any changes in behavioural reflex thresholds
suggests that the endogenous cannabinoid system does not appear to be tonically activated in
response to demyelination-induced neuropathic changes. However, our results suggest that it
could be effectively targeted as a possible therapeutic intervention site in demyelinating
disorders.
The use of cannabinoid analogues and CB receptor agonists may therefore prove very useful
in the treatment ofpain associated with peripheral nerve demyelination.
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5.3 Summary
The investigations into changes in the spinal cord following peripheral nerve demyelination
have indicated the presence of a number of key changes. This work could not only lead to
the development of possible therapeutic targets but could aid the direction of further studies
of central changes which may play important roles in the production of neuropathic pain.
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CHAPTER 6. SUMMARY DISCUSSION AND CONCLUSIONS
Neuropathic pain is a condition often associated with peripheral demyelinating neuropathies
such as Charcot-Marie-Tooth disease, types I and IV (CMT1 & CMT4). However,
mechanisms that may link neuropathic pain to peripheral nerve demyelination are poorly
understood (Rasminsky, 1981). To address this problem, we have investigated two models
of peripheral nerve demyelination. The first model is the previously characterised /Vx-null
mouse, in which the peripheral nerve myelin protein, L-periaxin, is disrupted creating a late
onset peripheral demyelinating neuropathy. The second model is a novel animal model of
neuropathy that we have developed by inducing focal demyelination of the peripheral nerve,
using the myelinolytic agent lysolecithin.
We have demonstrated that both animal models display behaviour indicative of the
development of a neuropathic pain state and that neither have any evidence for axonal
damage or cell loss in the DRG. Therefore, both can be considered as new models in which
to study pain associated with demyelination alone. In both models there is no evidence for
changes in peripheral stimulus transduction thresholds and it would appear that the
behavioural reflex sensitivity displayed is due to central changes involving the NMDA
receptor, known to be crucial for development of the central sensitisation, which forms the
basis for persistent pain.
Electrophysiological investigations have revealed the presence of spontaneous activity in the
peripheral nerve of both models that is likely to be capable of inducing of central changes
involved in the development and maintenance of a centrally sensitised state. We have
demonstrated changes in the PNS including in the expression of sodium channel subtypes
that might potentially account for such hyperexcitability. Importantly, we have
demonstrated that these changes differ from those associated with other models of
neuropathic pain in which axons of all types are damaged pointing towards an important role
for myelinated fibres in the production of neuropathic pain.
Central sensitisation of dorsal horn cells is thought to be analogous in many ways to
mechanisms of LTP in the hippocampus, which exists in homosynaptic and heterosynaptic
forms. Both forms of LTP are likely to occur at synapses in the spinal cord. It has been
demonstrated that conditioning stimulation of afferents at intensities sufficient to activate
A5-fibres and at frequencies ranging from 2-100 Hz induces LTP at synapses of the active
afferents in the spinal cord; an example of homosynaptic LTP (Randic et al., 1993).
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However, prolonged burst-like stimulation of the sciatic nerve at A5-fibre strength has been
shown to induce LTP at synapses of C-fibres (Liu and Sandkuhler, 1998), suggesting that
heterosynaptic LTP can also be evoked in the superficial spinal dorsal horn. This
mechanism could potentially be involved in our models of demyelination-induced pain, in
which although spontaneous activity appears to arise from, demyelinated A-fibres, the
animals behaviourally demonstrate signs indicative of increased sensitivity to C-fibre
mediated thermal stimuli suggestive of sensitisation/LTP at C-fibre synapses.
A further hypothesis that could help to account for the induction of C-fibre related
hypersensitivity in our models, in which there is no indication of C-fibre damage, is the fact
that potentiation of excitatory synaptic transmission may occur between A-fibres and spinal
interneurons, which may in turn presynaptically regulate central C-fibre terminals.
Therefore, the activation of interneurons by A-fibres could indirectly activate C-fibre
receptors causing sufficient depolarisation of C-fibre terminals to release neurotransmitters
into the spinal dorsal horn (Sandkuhler, 2000).
The spontaneous action potential discharge we have observed is of a relatively low
frequency compared to frequencies used to induce LTP in the hippocampus, which require s
a brief high frequency input (Woolf, 1996). However, it has been shown that low frequency
trains of stimuli are sufficient to induce excitability changes such as those used in the
experimental induction of windup (Mendcll & Wall. 1965; Mendell. 1966), which although
using C-fibre stimulation intensities, occurs maximally following stimulation at l-2Hz
(Schouenborg, 1984). Potentiation of synapses, as induced in windup, manifests only during
a train of repetitive inputs due to the summation of synaptic potentials (Thompson, et al.
1993) . Therefore, repetitive afferent drive of low frequency (as is a feature of the
demyelinated nerves in our models) may be sufficient for inducing persistent changes in
dorsal horn cell sensitivity due to a similar summation of synaptic potentials which could
provide a basis for the development of central sensitisation.
For central sensitisation to occur, key changes are necessary in dorsal horn neurons, which
sensitise them to primary afferent input. Such changes can include increased activity in
intracellular second messenger cascades via the activation of cell surface G protein-coupled,
metabotropic receptors such as mGluRs and NKi, which can in turn result in an increase in
the intracellular calcium concentration ([Ca2+],) the activation of intracellular kinases such as
CaMKII, PKC (and perhaps even PKA) and transcription factors. Together such changes can
lead to an increased response of the cell to normal primary afferent input forming the basis
for central sensitisation (Woolf, 1996). For example, a large enough increase in ([Ca2+],)
will produce sufficient depolarisation of the cell to remove the Mg2+ block of the NMDA
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receptor ion channel (Woolf, 1996). This allows NMDA receptor activation by incoming
glutamate, resulting in the influx of Na+ and Ca2+ into the cell, which will cause further
depolarisation of the cell and remove the Mg2+ block from additional NMDA receptors.
Voltage-dependent Ca2 channels and activated protein kinases can further potentiate the
activation of the NMDA channel. Therefore, relatively small changes in afferent input may
be sufficient to trigger the induction of changes in the NMDA receptor on dorsal horn
neurons, an event that can ultimately trigger a cascade of events resulting in the induction of
hypersensitivity of the whole system. The spontaneous action potential generation, which is
a feature of the demyelinated nerves in our models of neuropathic pain, is therefore likely to
cause the release of afferent glutamate into the dorsal horn and initiate many of these
changes. Even when such activity is restricted to A-fibres, ephaptic mechanisms may trigger
C-fibre release of glutamate and colocalised neuropeptides such as SP, which we have
shown to be expressed in the DRG of the demyelinated nerve. We have demonstrated that
the activation of the NMDA receptor is involved in the sensitised behaviours displayed in
our animal models of neuropathic pain suggesting that events such as those described above
are induced in response to changes in the demyelinated nerve.
LTP-like changes occurring in dorsal horn neurons as a result of increased primary afferent
input may subsequently lead to delayed changes in gene expression which may contribute to
late phases of hyperalgesia (Neumann et al., 1996;Dubner and Ruda, 1992;Woolf and
Costigan, 1999), the process of which involves activation of transcription factors such as
NFkB. This perhaps explains why we see a reversal of signs of behavioural reflex
sensitisation upon antagonism of NFkB at up to 2 weeks following induction of
demyelination. Furthermore, the possibility that activation of NFkB is occurring as a
consequence of activation of receptors such as the NMDA receptor (Guerrini et al.,
1997;Kaltschmidt et al., 1995;Nakai et al., 2000), would provide an explanation for the fact
that spinal antagonism of either mediators reverses signs of behavioural sensitisation
displayed in our model of neuropathic pain. Clearly other transcription factors will also be
involved in the altered pattern of gene expression following demyelination.
Mechanisms of central sensitisation such as these may account for the relatively delayed
onset of behavioural sensitisation. Brief but strong excitation of C-fibres, such as occurs in
severe axotomising nerve injuries, rapidly induces hyperalgesia. However, less severe
injury, as is the case in our models of peripheral nerve demyelination, is likely to result in a
slower induction of increased afferent input resulting in a slow summation of synaptic
potentials, building up intracellular changes over a prolonged period of time. This would
result in a delayed onset of central sensitisation indicated by the later onset of behavioural
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correlates of neuropathic pain. However, the increased input to the spinal cord triggers a
chain of events maintaining the central sensitisation for at least a number of weeks, as
demonstrated in the lysolecithin model of peripheral nerve demyelination, or if the injury is
intractable, as in the case of the Prx-null mouse, for an extensive period of time.
Once such changes in gene transcription have begun, it may become less likely that
pharmacological targeting of changes in the periphery will combat the central sensitisation
underlying the persistent pain. Furthermore, due to a lack of specificity, currently available
Na+ channel blocking agents have yet to be proven as satisfactory in eliminating established
neuropathic pain. This suggests that the search for adequate therapies needs to focus upon
central targets. Our studies in the CNS have pointed to two potential targets for therapeutic
intervention in demyelination-induced pain. Firstly, by blocking its activation, we indicated
that the transcription factor, NFkB, is involved in the production of the behavioural reflex
sensitisation at times corresponding to peak behavioural changes following lysolecithin
treatment of the peripheral nerve. Therefore, additional investigations into the cell
population in which it is activated, and subsequently which genes it is regulating, may give
an indication of possible targets for therapeutic intervention. Secondly, we have
demonstrated that agonists of the endogenous cannabinoid system are effective in reversing
the neuropathic pain behaviour displayed following the induction of focal demyelination.
The endogenous cannabinoid system appears to be a very promising target for the
development of pharmaceutical agents to treat chronic pain conditions and our investigations
suggest that this may indeed be a very effective target in combating pain induced following
peripheral nerve demyelination.
In conclusion, we have developed two models in which neuropathic pain results from either
general or focal peripheral nerve demyelination, apparently without the involvement of
axonal damage. The lysolecithin model is a novel model of neuropathic pain and is unique
in the production of pain-related behaviour from a focal region of demyelination in the
purely sensory saphenous nerve. Possible mechanisms underlying the production of pain in
this model are similar to other models of neuropathic pain but are not identical. This model
should therefore prove valuable not only for the study of pain associated with demyelination
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The Prx gene in Schwann cells encodes L- and S-peri-
axin, two abundant PDZ domain proteins thought to
have a role in the stabilization of myelin in the peripheral
nervous system (PNS). Mice lacking a functional Prx
gene assemble compact PNS myelin. However, the
sheath is unstable, leading to demyelination and reflex
behaviors that are associated with the painful conditions
caused by peripheral nerve damage. Older Prjr/_ ani¬
mals display extensive peripheral demyelination and a
severe clinical phenotype with mechanical allodynia and
thermal hyperalgesia, which can be reversed by intrathe¬
cal administration of a selective NMDA receptor antago¬
nist. We conclude that the periaxins play an essential
role in stabilizing the Schwann cell-axon unit and that
the periaxin-deficient mouse will be an important model
for studying neuropathic pain in late onset demyelinating
disease.
Introduction
The Schwann cell is the major glial cell of the vertebrate
peripheral nervous system (PNS), where its prime func¬
tion is to myelinate nerve fibers and to promote rapid
nerve impulse transmission. Schwann cells have a sig¬
nificant secondary role in providing trophic support for
spinal motoneurons and dorsal root ganglion neurons
(Riethmacher et al., 1997) and in promoting nerve regen¬
eration in the PNS (Bunge, 1993). Hence, these versatile
cells play a vital role not only in the normal development
of the PNS but also in the process of repair.
Extracellular signals, including those from the axon,
are believed to be responsible for the induction of the
genes required for myelination in the Schwann cell, and
they are also thought to determine the thickness of the
§To whom correspondence should be addressed (e-mail: peter.
brophy®ed.ac.uk).
II These authors contributed equally to this work.
myelin sheath (Aguayo et al., 1977; Lemke and Chao,
1988; Yin et al., 1998). As in other cell types, the down¬
stream pathways that transduce these signals are likely
integrated by the cytoskeleton (Tapon and Hall, 1997)
since it has an essential role in mediating both the
changes in cell shape and the regulation of gene expres¬
sion required for axonal ensheathment (Fernandez-Valle
et al., 1997). Hence, it was of interest that biochemical
analysis of the cytoskeleton-associated proteins of my¬
elinating Schwann cells revealed periaxin as a protein
with a possible role in the later stages of myelination
(Gillespie et al., 1994). As myelin sheaths mature, peri¬
axin becomes concentrated in the abaxonal plasma
membrane, and this shift in localization suggested that
it might participate in the recruitment of proteins to a
cortical structure involved in transmembrane signaling
(Scherer et al., 1995).
Consistent with a role in cortical signaling, the murine
Prx gene encodes two proteins with PDZ domains,
L-periaxin and S-periaxin, of 147 and 16 kDa, respec¬
tively (Dytrych et al., 1998). PDZ motifs are protein inter¬
action modules of ~90 amino acids named after the
three proteins in which they were first identified, namely
postsynaptic density protein PSD-95, Drosophila discs
large (dlcf) tumor suppressor, and the tight junction-
associated protein ZO-I (Kornau et al., 1995). The PDZ
motif is present in a variety of proteins believed to have
an organizing function at sites of cell-cell contact, where
they are implicated in the assembly of macromolecular
signaling complexes (Kornau et al., 1997; Tsunoda et
al., 1997). Such proteins can multimerize homotypically
and heterotypically (Hsueh et al., 1997; Srivastava et al.,
1998). They may also interact with the cytoplasmic tail of
transmembrane proteins, such as glutamate receptors
(Dong et al., 1997; Sheng and Wyszynski, 1997; Srivas¬
tava et al., 1998).
The evidence so far suggests that the periaxins partic¬
ipate in the later stages of axonal ensheathment, possi¬
bly in the stabilization of the myelin sheath (Scherer et
al., 1995). If this is correct, inactivation of the Prx gene
should destabilize the relationship of the axon with its
ensheathing Schwann cell. We have generated mice that
lack a functional Prx gene, and we demonstrate that
their Schwann cells ensheath and myelinate peripheral
nerve axons in an apparently normal manner but that
this sheath destabilizes, and the mice develop a severe
demyelinating neuropathy. These data suggest that the
periaxins play an essential role in the establishment of
a stable Schwann cell-axon unit in the myelinated fibers
of the vertebrate PNS.
In addition to reducing the rates of nerve impulse
transmission, segmental demyelination in human dis¬
ease can be associated with tactile allodynia, the per¬
ception of normally innocuous stimuli, such as touching
or brushing, as painful, and hyperalgesia, a heightened
response to painful stimuli; however, the mechanisms
of neuropathic pain in demyelinating disease are poorly
understood (Rasminsky, 1981). Importantly, we show
that in addition to a marked reduction in their peripheral
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Figure 1. Targeted Disruption of the Prx
Gene
(A) Structure of wild-type and targeted Prx
loci.
(Top) A partial restriction endonuclease map
showing the position of Sacl (S) and Kpnl (K)
sites in the murine Prx gene. A [i-actin pro-
moter-neo gene cassette was inserted be¬
tween the Smal site in exon 6 and the Sacl
site in exon 7. Digestion of DNA with Sacl
identified the targeted allele by the presence
of a 7.9 kb fragment instead of a 9.6 kb when
probed with external probe I, and by a 7.4 kb
instead of 9.1 kb when DNA was digested
with Kpnl and probed with external probe II.
(B) DNA from a control ES clone (C), from a
homologous recombinant ES clone (83), and
from tail clips of 3-week-old littermates ob¬
tained by heterozygous intercrosses was di¬
gested with Kpnl and probed with external
probe II.
(C) Northern blot analysis of RNA (3 pg) from
sciatic nerves of 16-day-old Prx*'*, Prx*'~,
and Prx~'~ mice demonstrates the absence
of the Prx wild-type mRNAs in mice homozy¬
gous for the mutant allele.
(D) Western blot of sciatic nerve homogenate
protein (10 pg) from 1-month-old mice dem¬
onstrates the absence of both L- and S-peri-
axin (147 and 16 kDa, respectively) from ho¬
mozygous mutants.
(E) Prx~'~ mice at 8 months are unable to sup¬
port themselves on their hindlegs.
reflex behaviors associated with allodynia and hyperal¬
gesia. We suggest that these animals will prove to be
valuable in identifying the pathophysiological basis of
neuropathic pain.
Results
Generation and Clinical Phenotype of Prx Null Mice
To inactivate the Prx gene, we deleted exon 6 and part
of exon 7, corresponding to 611-3440 bp of the mouse
cDNA, by homologous recombination in embryonic
stem (ES) cells (Figure 1A); 2 of 130 lines, clones 57 and
83, were heterozygous for insertion at the Prx locus,
and clone 83 was selected for further study (Figure 1B).
Homozygous offspring lacked the 4.6 and 5.2 kb mRNAs
found in the peripheral nerves of Prx+/+ mice (Figure
1C), and neither L- nor S-periaxin polypeptides were
detectable in the peripheral nerves of mutant mice (Fig¬
ure 1D). The genotypes of the progeny of mice hetero¬
zygous for the mutant allele were as expected from
Mendelian laws, which indicated that embryonic devel¬
opment was not compromised by inactivating the Prx
gene. Mice homozygous for the mutant allele appeared
grossly normal for up to 6 weeks, with the exception
thatwhen lifted by the tail, they all displayed a distinctive
clasping of the hindlimbs from about 4 to 6 weeks of
age, and some animals displayed a slight tremor. By 6-9
months of age, there was a pronounced unsteadiness in
the mutants' gait, and they had great difficulty support¬
ing themselves on their hindlimbs, which were often
splayed (Figure IE). Older animals (>6-9 months) lost
weight rapidly, owing to an inability to feed, and their
breathing was labored. As soon as the animals were in
obvious distress, they were euthanized.
Structure of the Schwann Cell-Axon Unit
We next examined the peripheral nerves of periaxin-
deficient mice by light microscopy to determine if the
myelin sheath was affected. At 6 weeks of age, the
sciatic nerves of periaxin null mice contained focal thick¬
enings (tomacula) and infoldings of internodal myelin
(Figure 2B). Nevertheless, Western blotting showed that
the levels of the major myelin proteins, myelin-associ-
ated glycoprotein, P0, and myelin basic protein, were
normal in the sciatic nerves of mutant animals, which
confirmed that at this age there had not been extensive
demyelination (data not shown). A variety of spinal, cra¬
nial, and autonomic nerves also displayed limited abnor¬
malities at this age. However, by 6 months, sensory,
motor, and autonomic (vagus) nerves were extensively
demyelinated, and most internodes in the sciatic nerves
of periaxin null mice contained focal thickenings or in¬
foldings of the sheath (Figure 2D). Profound disruption
of axonal ensheathment and segmental demyelination
was apparent in teased sciatic nerve fibers at this age
(Figures 2E and 2F), and their Schmidt-Lanterman inci¬
sures, which are normally visible as cytoplasm-filled
structures along the length of the internodes, were de¬
ranged (Figures 2G and 2H).
Electron microscopy demonstrated that saphenous
nerves, which are predominantly sensory, were exten¬
sively hypermyelinated but that unmyelinated C fiber
bundles appeared to be morphologically normal, which
is consistent with the absence of Prx gene expression in
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Figure 2. Light Microscopy of Sciatic Nerves
from Prx Null Mice
Resin sections (1 ixm) from the sciatic nerves
of normal (A and C) and mutant (B and D)
mice at 6 weeks (A and B) and at 6 months
(C and D) were compared. The null mutant (B
and D) showed features typical of a progres¬
sive demyelinating neuropathy with evidence
of remyelination, as denoted by onion bulbs
and thinmyelin sheaths (thick and thin arrows,
respectively). Disproportionately thick sheaths
evident at 6 weeks are much more numerous
at 6 months (arrowhead). A low-power view
of wild-type (E) and mutant (F) teased sciatic
nerve fibers from 8-month-old Prx~'~ mice
shows focal thickenings of the myelin sheath
(arrowheads) flanking a demyelinated seg¬
ment. A higher-power view of nerves stained
with TRITC-phalloidin (G and FH) reveals the
loss of Schmidt-Lanterman incisures in the
sheath (arrows); a tomaculum is visible in out¬
line (arrowhead). Scale bar, 10 p.m (A-D); 50
rim (E and F); 25 |j.m (G and Fl).
non-myelin-forming Schwann cells (Schereretal., 1995)
(Figures 3A-3C). Hypermyelination resulted in sheath
infolding (Figure 3B) and axonal compression (Figure
3C). By 8 months, naked or thinly myelinated axons were
common in sciatic nerve fibers, often surrounded by
redundant basal laminae and supernumerary Schwann
cells, which formed onion bulb structures, diagnostic of
attempts to remyelinate demyelinated fibers (Figures
3D). There was little evidence for macrophage infiltra¬
tion, indicating that demyelination was not the result
of a macrophage-mediated inflammatory process. The
damage seemed to be confined to the myelin sheath in
that there was no evidence of axonal degeneration, and
there was no difference in the number of dorsal root gan¬
glion neurons (L5) between wild-type controls (8655 ±
127, n = 3) and periaxin-deficient mice (8668 ± 619,
n = 3). Furthermore, neuronal cell bodies in spinal gray
matter and spinal ganglia showed no evidence of degen¬
erative changes (data not shown). Mice heterozygous
for the null allele (Prx+/~) showed occasional focal thick¬
enings of the myelin sheaths, a feature that did not
increase with age, at least up to 10 months, and no
evidence of demyelination was noted.
The ability of periaxin-deficient mice to remyelinate
was determined after crush lesion. Electron microscopy
of sciatic nerves distal to the lesion site 1 month post
crush revealed that 4-month-old Pnr'~ mice differed
markedly from their wild-type littermates, in spite of their
being able to assemble apparently normal compact my¬
elin in the early developing PNS. In comparison with
the myelinated reinnervated axons of control nerves,
remyelination was retarded in the periaxin null mice,
with many incompletely ensheathed axons and abnor¬
mally thin sheaths (Figures 3E and 3F).
Peripheral Nerve Electrophysiology in Prx~'~ Mice
At 6-8 months, the extensive pathology noted in periph¬
eral nerves was reflected in reduced conduction veloci¬
ties in nerves from control and Pricmice. Both the
peak compound action potential (CAP) and the electro-
myogram from single identified skeletomotoneurons of
the sciatic nerve were reduced by ~60% (Table 1). The
values derived from both techniques were similar, sug¬
gesting that sensory and motor branches were equally
affected in this mixed nerve, a conclusion that was sup¬
ported by morphological examination of the ventral and
dorsal spinal roots. The spike shape of the CAP in mu¬
tants was distorted, which may reflect a degree of ephap-
tic cross-activation caused by extensive demyelination
(Smith and McDonald, 1980) (data not shown).
It was of particular interest to analyze sensory nerves
since they have been reported to be spared in animals
deficient in other PNS myelin proteins (Adlkofer et al.,
1995; Martini et et al., 1995; Anzini et al., 1997). The
conduction velocities of hair follicle mechanoreceptor
afferents in the saphenous nerve were tested by focal
displacement of single identified hairs with von Frey
filaments. Disruption of the myelinated fibers of these
afferents in 6-week-old mutants was reflected in a signif¬
icant reduction in their mean conduction velocities from
7.6 ± 3.3 (5 animals, 52 mechanoreceptors) to 3.9 ± 1.6
ms~1 (6 animals, 42 mechanoreceptors) (p < 0.0001 by
Neuron
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Figure 3. Structure of Schwann Cell-Axon Units in Nerves from Prx Null Mice
Electron microscopy of wild-type (A) and mutant (B and C) saphenous nerves at 6 months. Unmyelinated C fiber bundles appear normal
(arrowhead), but myelinated fibers are grossly hypermyelinated (B and C), with evidence of myelin infolding at a tomaculum (arrow, [B]) and
axonal compression (C). By 8 months, the sciatic nerves of mutant animals (D) display the onion bulb pathology of supernumerary Schwann
cells (arrows) characteristic of a demyelinating neuropathy with attempts at remyelination that results in disproportionately thin myelin sheaths
(arrowhead). In 4-month-old wild-type animals, robust reinnervation and remyelination were observed in sciatic nerves distal to the crush site
1 month post crush (E). In contrast, ensheathment of mutant nerves (F) was highly retarded (arrows), with numerous abnormally thin sheaths
(arrowheads). Scale bars, 2 p.m.
Student's t test). Only 8% of recorded afferents in mutant
animals had conduction velocities >6 ms"', and none
were above 8 msH, in marked contrast to wild-type
animals (Figure 4). The vast majority of these were in
the A fiber conduction velocity range, with a conduction
velocity above 2 ms"1, indicating that they were myelin¬
ated (Koltzenburg et al., 1997); only a minor population,
in each case, displayed conduction velocities character¬
istic of unmyelinated fibers (Figure 4). Similar results
were obtained at 6 months, but the reduction in conduc¬
tion velocities (67%) was more severe (data not shown).
The unmyelinated fibers were also specifically investi¬
gated in 6-week-old animals, and there was no signifi¬
cant difference in the mean conduction velocity in mu¬
tants compared with normal littermates (Prx+,+, 1.46 ±
0.10 ms"1, n = 11 afferent units; Pnr'-, 1.17 ± 0.13
ms"1, n = 15 afferent units; three mice in each case and
p > 0.05 by Student's t test); nor was there a significant
difference between normal and mutant mice in the von
Frey filament response thresholds of the A fibers or the
thermal nociceptive response thresholds of the C fiber
population (Table 2).
A common feature of the saphenous nerves of both
mutant animals and their wild-type littermates at 6
weeks was the presence of a spontaneous low-fre¬
quency discharge (1-2 Hz) in fibers throughout the
Demyelination and Neuropathic Pain Behavior
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Table 1. Nerve Conduction Velocities in Sciatic Nerves










Compound action potential (CAP) and electromyogram (EMG) val¬
ues (ms-1) were measured after electrical excitation of the peripheral
nerve and are mean ± SEM for four animals in each group. Statistical
significance was determined by Student's t test.
range of conduction velocities. However, more mutants
(100%, n = 14) displayed this activity in comparison to
their wild-type counterparts (28%, n = 15). This sponta¬




The spontaneous low-frequency discharge observed in
saphenous fibers prompted us to analyze the response
of the mice in well-characterized models of nociceptive
reflex behavior since it has been suggested that ectopic
activity might contribute to pain following nerve injury
(Rasminsky, 1981; Tal and Eliav, 1996). At 6 weeks of
age, mutant mice displayed a markedly lower threshold
in a reflex test of cutaneous mechanical sensation using
calibrated von Frey hairs applied to the saphenous terri¬
tory of the hindpaw (Table 3). This was in spite of the
fact that we had already shown that the mean threshold
response of hindpaw mechanoreceptors to natural me¬
chanical stimuli, measured electrophysiologically in the
saphenous nerve at 6 weeks, was unchanged (Table 2).
i 0 Wild type
Mutant
0-2 2-4 4-6 6-8 8-10 10-12 12-14
Conduction Velocity (ms-1)
Figure 4. Frequency Range of Conduction Velocities in Saphenous
Nerve Fibers
Nerve conduction velocities were measured from single afferent
fibers in the saphenous nerves of 6-week-old mice. All units with
conduction velocities above 2 ms"1 were tested and found to be
mechanosensitive, and demonstrated a majority of low-threshold,
rapidly adapting units, with very few slowly adapting units. The
locations of peripheral receptive fields for natural mechanostimula-
tion and electrical excitation were identical. Receptive fields were
focal, confined to between one and two hairs, and afferent unitswere
not excited when stimulating electrodeswere slightly displaced from
the natural receptive field.
Table 2. Threshold of the Response of Teased Saphenous
Nerves to Mechanical and Thermal Stimulation with von Frey
Filaments or Noxious Radiant Heat at 6 Weeks of Age
Threshold of Activation







Fibers tested by mechanical stimulation had conduction velocities
above 2 ms"1 (n = 5 in both groups); those tested by noxious thermal
stimulation had conduction velocities below 2 ms"1 (n = 3 in both
groups). Each value is the mean ± SEM, and there was no statisti¬
cally significant difference by Mann-Whitney Rank Sum test.
To determine if this diminished response threshold
was specific to receptors with myelinated afferents, we
also measured the response threshold in a reflex test
of thermal nociceptive sensitivity for which the relevant
afferents are largely unmyelinated C fibers (Hargreaves
et al., 1988; Ahlgren et al., 1997; Koltzenburg et al.,
1997). Prx null mice had significantly lower response
thresholds, which indicated the presence of thermal hy¬
peralgesia, as well as mechanical allodynia (Table 3).
As pointed out earlier, there was no evidence for sensory
neuron loss that might have led to altered reflex be¬
havior.
In contrast to the lowered threshold in the nociceptive
reflex tests, mutant mice at 6 weeks displayed re¬
sponses in the normal range in a mechanical grip test
(Meyer et al., 1979), which indicates a lack of any overt
motor deficit at that age (data not shown).
The mechanical response thresholds (Figure 5) and
nociceptive response latencies (Table 4) were also sig¬
nificantly reduced in 6-month-old mutants when mor¬
phological derangement of myelinated nerves was more
pronounced. In these animals, a role for spinal NMDA
receptors in the mechanical allodynia shown by Prx null
mice was demonstrated by reversal of this behavioral
sensitization following spinal administration of the highly
selective NMDA receptor antagonist 3-([R] 2-carboxy-
piperazin-4-yl)-propyl-1-phosphonic acid ([R]-CPP) (Leh-
mann et al., 1987) (Figure 5). Similarly, a reduction in
thermal nociceptive response latency was reversed in
Prx~'~ mice without affecting the responses of normal
littermates (Table 4).
Table 3. Hindpaw Withdrawal Response to Mechanical













Minimum filament indentation pressure thresholds for repeat paw
withdrawal responses to mechanical stimulation with von Frey fila¬
ments in conscious animals were measured for four animals in each
group. Statistical significance (*P < 0.05) was determined by Mann-
Whitney Rank Sum test. The time taken for hindpaw withdrawal
from an infrared beam was measured for six normal littermates
and seven mutant animals. Statistical significance (**P < 0.05) was
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Figure 5. The Effect of Intrathecal Injection
of (R)-CPP on Mechanosensitive Paw With¬
drawal Threshold
The paw withdrawal threshold was measured
in response to cutaneous mechanical stimu¬
lation with von Frey filaments in Prx*'* (n =
3) and Prx~'~ (n = 8) mice after intrathecal
injection of (R)-CCP (T. 100 pmol in 10 jjlI).
Statistical significance of differences from
wild-type animals (*p s 0.05) was determined
by Mann-Whitney Rank Sum test, and each
value is the mean ± SEM. Intrathecal injection
of the saline vehicle had no significant effect
in either Prx*'* or Prx~'' (n = 5 for both).
Time post injection (min)
Discussion
Several demyelinating neuropathies of genetic origin
have now been modeled in mice by inactivating genes
expressed in myelinating Schwann cells (Suter and
Snipes, 1995; Martini, 1997). Such animals are not only
valuable for examining the biological function of the
proteins encoded by these genes but they also provide
an opportunity to study the pathophysiology of disease.
However, the homozygous periaxin null mouse is unique
in the late onset and the severity of the clinical pheno-
type, which shows parallels with demyelinating periph¬
eral neuropathies of adult onset (Dyck et al., 1993). Fur¬
thermore, sensory deficits have not been a significant
feature of mouse models of peripheral demyelinating
neuropathy thus far even though they are of relevance
to human disease.
Prx Is Required for Stable Myelination in the PNS
This work suggests that the periaxin PDZ domain pro¬
teins have an essential role in myelin-forming Schwann
cells once the sheath has been assembled around the
axon. In Prx null mice, the earliest evidence for morpho¬
logical disruption of the Schwann cell-axon unit is the
focal thickening of the sheath. The ensuing overproduc¬
tion ofmyelin is followed by demyelination and remyelin-
ation. The mechanism by which the thickness of the
myelin sheath is signaled is not known, but it is likely
that it is regulated by the axon (Lemke and Chao, 1988).
It may be significant that the Prx gene itself is regulated
by axonal contact (Scherer et al., 1995).
Many of the other well-characterized proteins ex¬
pressed by differentiating, myelin-forming Schwann
cells are incorporated as structural components of
compact myelin. In contrast, L-periaxin becomes con¬
centrated in the abaxonal plasma membrane of the
Schwann cell, which suggested that it may recruit pro¬
teins to a cortical structure involved in transmembrane
signaling (Gillespie et al., 1994; Scherer et al., 1995;
Dytrych et al., 1998). The periaxins may associate with
the cytoplasmic domains of plasma membrane proteins
involved in adhesion since their expression coincides
with the early events in the establishment of axo-glial
contact and since the translocation of L-periaxin to a
predominantly abaxonal location is a feature of the mat¬
uration of the sheath (Gillespie et al., 1994; Scherer et
al., 1995; Dytrych et al., 1998).
Structure and Electrophysiology of the PNS
in Mutant Animals
At 6 weeks of age, the sciatic nerves of periaxin-deficient
mice are affected relatively mildly compared with mice
lacking the myelin proteins P0 and PMP22, which dis¬
play widespread derangements to the Schwann cell-
axon unit from a much earlier age (Giese et al., 1992;
Adlkoferetal., 1995). Mice lacking P0 also display clasp¬
ing of their hindlimbs, but, at 4-6 weeks, they are much
more clinically affected than are Prx mutants (Giese et
al„ 1992). This foot clasp response is also observed in
mutant mice with neurological disease of purely CNS
origin (Chiesa et al., 1998).
Similar to periaxin null mice, animal models of Char-
cot-Marie-Tooth disease Type X (CMTX) deficient in the
gapjunction protein connexin 32 myelinate normally and
show a late onset pattern of demyelination with attempts
Table 4. Flindpaw Withdrawal Response to Noxious Thermal Stimulation following Intrathecal Administration of the NMDA Receptor
Antagonist (R)-CPP in 6-Month-Old Mice
Treatment
Preinjection Vehicle (R)-CCP Recovery
Wild-type 9.1 ±0.7 (5) 11.9 ±1.6 (6) 10.0 ±1.3 (5) 9.0 ±1.9 (5)
Mutant 6.6 ±0.3* (8) 9.1 ± 1.4* (6) 12.9 ± 1.3 (8) 6.7 ± 0.8* (8)
The effect of intrathecal injection of (R)-CCP (100 pmol in 10 pi) was measured as the mean threshold (latency to paw withdrawal) ± SEM of
values determined between 20 and 50 min following injection and, at recovery, between 100 and 110 min following injection. Statistical
significance from wild-type values with the same treatment ('p ± 0.05) was determined by Student's t test. Number of animals is in brackets.
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to remyelinate (Anzini et al., 1997). However, these ani¬
mals display very mild deficits in nerve conduction; fur¬
thermore, the saphenous nerve, which is predominantly
sensory, shows little evidence of demyelination in
CMTX-deficientmice (Anzini et al., 1997). Mice heterozy¬
gous for the mutant alleles of PO and PMP22 also show
a propensity for sparing sensory versus motor nerves
(Adlkofer et al., 1995; Martini et al., 1995). There was
no evidence for such sparing in Prx mutants since the
profiles of ventral and dorsal roots in cross section were
similar. The reason for the differential susceptibility of
sensory versus motor nerves in other demyelinating
conditions remains unclear.
When deprived of their intimate association with
axons during Wallerian degeneration, myelin-forming
Schwann cells revert to a premyelinating phenotype
(Bunge, 1993; Mirsky and Jessen, 1996). This transition
is accompanied by the removal of myelin debris, the
downregulation of genes that encode myelin proteins, and
the initiation of Schwann cell proliferation (Poduslo
and Windebank, 1985; Lemke and Chao, 1988; Scherer
and Salzer, 1996). Reinnervation is normally accompa¬
nied by remyelination. However, the process of repair
appears to be compromised in the sciatic nerves of
periaxin null mice. Although the reason for this impair¬
ment is not clear, it is of relevance to the cumulative
residual deficits caused by repeated mechanical com¬
pression of peripheral nerves in such diseases as heredi¬
tary neuropathy with liability to pressure palsy (Lynch
and Chance, 1997).
By 6 months of age, conduction velocities in the sci¬
atic and saphenous nerves of mutant animals were re¬
duced to 44% and 33% of the respective normal values.
This was entirely consistent with the extensive demy¬
elination observed in a variety of myelinated nerves
throughout the PNS. The frequent incidence of demy-
elinated axons engulfed by supernumerary Schwann
cells was strikingly similar to the onion bulb pathology
characteristically found in human CMT disease Type IA
(CMTIA) (Dycketal., 1993).
Demyelination, Allodynia, and Hyperalgesia
Damage to sensory nerves is linked to pain and exces¬
sive sensitivity to touch in human peripheral demyelinat¬
ing disease (Devor, 1989; Pentland and Donald, 1994),
and there is good evidence that the mechanical hyper¬
sensitivity observed in tactile allodynia is mediated by
myelinated A fibers (Woolf, 1997; Koltzenburg, 1998). In
a variety of models of central (spinal) sensitization, there
is evidence that peripheral sensitizationmay be a signifi¬
cant contributor to neuropathic pain behavior (Koltzen¬
burg et al., 1994; Woolf and Costigan, 1999). Neverthe¬
less, we could find no evidence for significant changes
in the stimulus-response relationship in either A or C
fibers in Prx~'~ mice with either cutaneous mechanical or
thermal nociceptive stimulation in periaxin null animals;
nevertheless, the spinal cord reflex responsiveness to
this traffic may be affected by sensitization, especially
at central sites. A contributor to central sensitization
may be the presence of spontaneous activity in saphe¬
nous afferents. While repetitive C-afferent stimulation is
normally required to bring about this state, in conditions
of peripheral inflammation, it may be maintained or pro¬
moted by A(3 input (Woolf and Costigan, 1999).
Furthermore, our evidence that NMDA receptor-
dependent events at a central site were essential for
the phenomena of mechanical allodynia and thermal
hyperalgesia behavior to becomemanifest in Pnr'~ mice
indicates that some form of central change, probably
sensitization, is a feature of the phenotype. NMDA re¬
ceptor-dependent central sensitization characteristi¬
cally underpins the mechanical allodynia and thermal
hyperalgesia seen in a variety of other models of chronic
pain states (Mao, 1993; Bennett, 1994; Dickenson and
Sullivan, 1987; Chaplan etal., 1997; Woolf and Costigan,
1999).
Ectopic repetitive firing has been proposed to be the
origin of abnormal sensation in diseases characterized
by segmental demyelination, particularly when there is
no evidence for axonopathic changes (Rasminsky, 1981;
Tal and Eliav, 1996). Demyelinated segments can cer¬
tainly serve as foci for spontaneous multiple spikes or
for those evoked by mechanical stimuli (Smith and Mc¬
Donald, 1980; Calvin et al., 1982; Baker and Bostock,
1992). Nevertheless, the origin of tactile allodynia and
neuropathic pain in human demyelinating disorders is
still poorly understood (Ropper and Shahani, 1984; Car¬
ter et al., 1998). The periaxin-deficient mouse is a prom¬
ising new model in which to address this problem.
Experimental Procedures
Generation and Characterization of PnrMice
The genomic locus was targeted by homologous recombination
using a cassette comprising the human p-actin promoter (Freder-
ickson et al., 1989) and the neomycin resistance (neo) gene flanked
by 4.3 kb and 2.5 kb of strain 129 DNA. The cassette was inserted
between the Smal site in exon 6 and the Sacl site in exon 7 and
subcloned into the plasmid pGEM11Zf. The construct was excised
from the plasmid by digestion with Notl and Sail and electroporated
into the ES cell line CGR8, maintained in the absence of a feeder
layer (Mountford et al., 1994). After selection in G418, the homolo¬
gous recombinants were identified by Southern blotting using
probes external to the construct. The targeted alleles were identified
by the presence of a 7.9 kb fragment instead of a 9.6 kb when DNA
was digested with Sacl and probed with external probe I, and by a
7.4 kb fragment instead of 9.1 kb when DNA was digested with Kpnl
and probed with external probe II (Figure 1A). Two clones, 57 and
83, were injected into C57BL/6 blastocysts, and their progeny were
typed by Southern blotting of tail DNA. Heterozygous offspring were
backcrossed to the parental C57BL/6 strain before intercrossing
at the F6 generations. Control animals were age- and generation-
matched Prx+,+ mice or Prx+/+ littermates. Mice homozygous for
the mutant allele were identified by Southern blotting as described
previously (Dytrych et al., 1998).
RNA and Protein Analysis
RNA was extracted from the sciatic nerves of 16-day-old mice (Ca-
thala et al., 1983), and 3 ng was resolved and probed with a cDNA
fragment comprising bases 1132-1549 of mouse periaxin cDNA as
described previously (Dytrych et al., 1998). L- and S-periaxin pro¬
teins in sciatic nerves from 3-month-old animals were detected with
isoform-specific antibodies in Western blots as described previously
(Dytrych et al., 1998).
Microscopy and Cell Counts
Mice were perfused intravascularly with 2.5% glutaraldehyde and
2% paraformaldehyde in 0.1 M sodium cacodylate buffer (pH 7.3).
Nerves were removed, fixed for 2 hr in the same fixative, postfixed
in 0s04, and embedded in araldite. Ultrathin sections were stained
with uranyl acetate and lead citrate and examined on a Phillips
BioTwin electron microscope. The following nerves were sampled:
sciatic, tibial, lumbosacral and lumbar plexi, cervical and lumbar
Neuron
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nerve roots, saphenous, vagus, and trigeminal. Blocks of cervical
and lumbar spinal cord were also examined. The sciatic nerves of
anesthetized mice were crushed as previously described (Scherer
et al., 1995). For light microscopy, 1 p.m resin sections were stained
with toluidine blue. For teased fiber preparation, sciatic nerves either
were postfixed with 2% OsO< in 0.1 M sodium cacodylate buffer
for 2 hr, dehydrated, infiltrated in Spurr medium, teased in Spurr
embedding medium, and examined by bright-field microscopy or
were teased in 0.1% Triton X-100 in phosphate-buffered saline,
stained with TRITC-phalloidin (Sigma) (0.1 mg/ml) for 1 hr, and exam¬
ined with a Leica TCS4D confocal microscope to visualize microfila¬
ments. For cell counts on dorsal root ganglia, mice were perfused
with neutral buffered formalin, and ganglia were embedded in paraf¬
fin after further immersion fixation in formalin overnight. Sections
(8 jxm) were stained with fast cresyl violet, and neurons with nucleoli
in clear nuclei were counted in every fifth section.
Electrophysiology
Mice were anesthetized with 25% urethane i.p. and maintained at
36°C-37°C with a radiant heat lamp. The saphenous femoral nerve
was exposed in the medial thigh and dissected from its associated
vein and artery. Further dissection under liquid paraffin enabled
the identification of afferent preparations comprising a small number
of units. For fibers with conduction velocities above 2 ms~\ the
mechanosensitivity of individual sensory receptors with high sensi¬
tivity was measured in hairy and hairless skin using calibrated von
Frey hairs. The mechanical threshold was defined as the pressure
required to cause units to fire 50% of the time by direct application
of von Frey filaments to identified receptive fields. The conduction
velocity of single identified afferent fibers was determined using
bipolar electrodes and the peripheral stimulus technique (Iggo,
1958). The cutaneous responsiveness of fibers with conduction ve¬
locities below 2 ms_1 was tested following isolation of few-unit
preparations, and a focal heat stimulator was set to deliver a preset
focal radiant heat stimulus to the receptive field at an intensity
determined by a thermocouple for a preset period of 10-15 s (Sobair
et al., 1997). Interstimulus intervals >10 min were allowed between
applications to mitigate receptor sensitization. The CAP was mea¬
sured over a length of sciatic nerve. The femoral length of the sciatic
nerve was exposed in an isolated solder ring pool that was flooded
with liquid paraffin. Bipolar recording electrodes were positioned
on the sciatic nerve at the level of the femoral head, and bipolar
stimulating electrodes were placed on the sciatic nerve in the pool,
near the knee. A second pair of stimulating electrodes was posi¬
tioned over the skin covering the tibial nerve at the ankle. The peak
of the fastest conducting wave of the CAP was measured, providing
a mean value for the Aa fibers. The electromyogram caused by
activation of a single skeletomotoneuron was measured in the in-
terosseus muscles with a concentric needle electrode using just-
threshold levels of excitation at two locations in the sciatic nerve
(Sharma and Thomas, 1974).
Behavioral Tests and Drug Treatment
The threshold for hindpaw withdrawal in response to graded me¬
chanical stimulation was measured in conscious animals at 6 weeks
of age with von Frey filaments, which provide a calibrated indenta¬
tion pressure against the hairless skin of the hindpaws. The thresh¬
old response in this test was defined as the filament that causes
foot withdrawal five times in every ten applications (Meyer et al.,
1979; Chaplan et al., 1994). The time for hindpaw withdrawal in
response to a quantified noxious thermal stimulus provided by an
infrared beam to the hairless surface of the paws was measured
(Hargreaves et al., 1988). Before determining the effect of an NMDA
receptor antagonist, mice were tested daily over a period of 2 weeks
prior to injection. A minimum of five measurements were made per
animal. Mice were briefly anesthetized with halothane and oxygen
after determining baseline measurements for mechanical allodynia
and thermal hyperalgesia and were injected intrathecally at the L4
level of the spinal cord with 100 pmol of (R)-CPP in saline (10 fxl).
Testing commenced after a 15 min period of recovery from anesthe¬
sia. Mice were then tested every 5 min.
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Chronic neuropathic pain is poorly understood and is usually untreatable by classical analgesics.
Neuropathic pain is characterised by allodynia (perception of innocuous stimuli as painful) and
hyperalgesia (facilitated response to painful stimuli). Pain is a symptom often associated with
human demyelinating conditions such as Charcot-Marie-Tooth disease or multiple sclerosis. Using
a novel mouse model, we have recently provided evidence for the establishment of neuropathic
pain as a result of peripheral demyehnation.
The Prx gene in Schwann cells encodes L- and S-periaxin, two abundant PDZ-domain proteins
thought to have a role in stabilisation ofmyelin in the peripheral nervous system (PNS). Prx-null
mice show progressive demyehnation in peripheral nerves and display an increased behavioural
reflex sensitivity to cutaneous mechanical and noxious thermal stimulation. This sensitisation can
be reversed by intrathecal injection of the NMDA receptor antagonist, [R]-CPP, indicating that
key changes occur within the spinal cord.
In peripheral nerves morphological studies revealed compromised myelination and
electrophysiological investigations indicate the presence of spontaneous action potential discharge;
abnormal activity which may be a consequence of demyelination.
This investigation provides the first direct evidence linking the presence of peripheral
demyehnation to the production of neuropathic pain and present experiments are seeking to
elucidate the mechanisms by which this may occur.
Experiments complied with the Animals (Scientific Procedures) Act 1986
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Focal demyelination of the sciatic or saphenous nerve was induced with lysolecithin
(lysophosphatidylcholine). The behavioural reflex sensitivity of treated mice was assessed using a
thermal stimulus and von Frey filaments. Nerve morphology was investigated using light and
electron microscopy and peripheral nerve recordings were made to assess changes in excitability.
Intrathecal injections of the selective NMDA receptor antagonist, [R]-CPP, were carried out to
explore the role ofNMDA receptor-dependent changes in the spinal cord in the behavioural reflex
sensitivity.
Results
Lysolecithin treatment resulted in 30-40% demyelination of the treated nerve without axon loss.
This was associated with an increased behavioural reflex sensitivity, in both thermal and
mechanical tests, which was reversed by the NMDA receptor antagonist, [R]-CPP. At peak
behavioural change, spontaneous action potential discharge of 2-3 impulses per second was
present.
Conclusions
This study describes the first mouse model of peripheral nerve focal demyelination designed for
the study of neuropathic pain. Changes in the peripheral nerve result in altered nerve excitability,
which may lead to the changes observed in sensory processing in the spinal cord. This model may
be useful for the evaluation of novel therapeutic targets for the treatment of demyelination
associated pain.
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